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The 2-amino-1,3-diaza structural motif is a common feature found in many 
pharmaceutically useful agents. For instance, the structural motif is embedded in the 
structure of 4,6-diamino-1,3,5-triazine. Studies have shown that some of these triazines 
are found to be potent DHFR inhibitors. Such DHFR inhibitors have been noted for their 
therapeutic value as anticancer, antimalarial, antibacterial and anti-protozoal agents. As 
an extension to these studies, it was the intent of this dissertation to explore further if 4,6-
diamino-1,3,5-triazines would also possess other forms of pharmacological activities. 
Therefore, the first objective of this dissertation was to design and synthesize five 
libraries of 4,6-diamino-1,3,5-triazine and its analogues; while the second objective was 
to investigate whether the triazines exhibit inhibitory activity against various 
microorganisms, cancer cells and neuronal sodium channels in addition to the antifolate 
activity. 
 
A small library M-I consisting of seven aromatic 1,3,5-triazines was synthesized by an 
alkoxide-catalyzed condensation of biguanide hydrochlorides with suitably substituted 
carboxylic acid esters at room temperature. Another fourteen 1,2-dihydro-1,3,5-triazines 
in library M-II were prepared based on a two-step reaction: the first step involved the 
preparation of 4,6-diamino-2,2-dimethyl-1-phenyl-1,2-dihydro-1,3,5-triazine (I), then the 
target compounds were derived via a base-catalyzed Dimroth rearrangement of I. In the 
synthesis of library M-III, a two-component reaction was carried out between 
benzylbiguanide and ketones or aldehyde with the use of water scavengers. The synthesis 
of M-IV involved a three-component synthesis that employed cyanoguanidine, O-
 vi
aminophenylalkyl alcohol hydrochloride and various ketones. The fifth library M-V was 
produced using fragment coupling synthesis strategy by alkylation with substituted 
phenoxyalkyl bromide of an N-hydroxytriazines.  
 
In the first two libraries (M-I and M-II), all the compounds were screened for inhibitory 
activity against bovine DHFR, neuronal sodium channels and an array of 
microorganisms. Limited bovine DHFR inhibitory activity was observed in both libraries. 
However, both libraries exhibited moderate to potent neuronal sodium channel blockade 
activity in vitro; among them, M-II-12 showed the best blockade activity with an IC50 
value of 12.57 µM, which was ten times lower than positive control, phenytoin. While 
M-II exhibited limited antibacterial activity, some compounds in M-I library 
demonstrated relatively good antifungal activity against C. albicans and A. niger. The M-
III library was designed based on the same side chain found in TMP. Twenty-three 4,6-
diamino-1,2-dihydro-1,3,5-triazines in M-III were synthesized and screened against S. 
aureus and M. smegmatis for their antibacterial activity. All compounds in this library did 
not exhibit activity against S. aureus that was noteworthy; however, most of them 
possessed unique activity against M. smegmatis. Compound M-III-15 was most active 
within the whole library of M-III providing a zone ratio of 0.98 against M. smegmatis at 
a dose of 100 μg. In the libraries of M-IV and M-V, biological screening against bovine 
DHFR revealed that they were very potent DHFR inhibitors. However, only M-V library 
demonstrated potent antiproliferative activity against the three cancer cell lines MDA-
MB-231, MCF-7 and A549. M-V-20 was the most potent inhibitor found which exhibited 
an IC50 value of 27 nM against the lung cancer cells A549. Further experiments involving 
 vii
the use of hypoxanthine and thymidine as rescue agents confirmed that the inhibition of 
cancer cell growth was mainly due to DHFR inhibition. Therefore, M-V-20 is a novel 
triazaspiroalkane which emerged from this study as having the potential for further 
development into a new drug candidate. 
 
In conclusion, the hypothesis that 4,6-diamino-1,3,5-triazines would possess other forms 
of bioactivity in addition to DHFR inhibition was demonstrated to be partially true.  
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  INTRODUCTION 
 
 1
1 1,3,5-Triazines  
 
The triazines are among the oldest known organic nitrogen-containing heterocycles. They 
can structurally be divided into three types: 1,2,3-triazines (1), 1,2,4-triazines (2) and 
1,3,5-triazines (3). Of these three possible triazine isomers, the 1,2,3-triazines are by far 
the least studied class in comparison with their 1,2,4- and 1,3,5-isomers, because the ring 
system is the least stable of the three. Only a few papers dealing with 1,2,3-triazines have 
been published and the number of known compounds of this type is still small1. It also 
appears that no significant use of 1,2,3-triazines has yet been reported. In contrast to 
1,2,3-triazines, the 1,2,4-triazines are well known. A large number of 1,2,4-triazines have 
demonstrated a spectrum of biological activities and have been used for various 
therapeutic purposes. For example, drug such as lamotrigine (4), which has a 1,2,4-
triazine in its chemical structure, has been used clinically as an antiepileptic drug, and its 
mode of action suggests an involvement of sodium channels blockade.2 1,3,5-Triazines, 
also known as symmetric or s-triazines, having been known for almost 200 years, are 
commonly found in biologically active chemical entities. Baker triazines (1,2-dihydro-
1,3,5-triazines, 5) have been thoroughly investigated and found to be potent dihydrofolate 
reductase inhibitors that exhibit anticancer property3. In this introductory section to the 
dissertation, a mini review on the synthesis and biological evaluation of several types of 
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1.1 Synthesis of 1,3,5-Triazines 
The synthesis of 1,3,5-triazines can be achieved with various different synthetic strategies 
using different starting materials. A complete listing of all possible synthetic routes is 
beyond the scope of this mini review. Therefore, the synthesis of three different subtypes 
of 1,3,5-triazines will be presented and these subtypes include the fully unsaturated 1,3,5-
triazines, dihydro-1,3,5-triazines and fused 1,3,5-triazines. 
 
1.1.1 Synthesis of Fully Unsaturated 1,3,5-Triazines  
1.1.1.1 Synthesis from 1,3,5-Triazines 
Usually, the nucleophilic displacement of chlorine from cyanuric chloride (6) is the first 
method considered for the preparation of fully unsaturated 1,3,5-triazine derivatives. The 
three chloro substituents may be replaced sequentially depending upon the temperature of 
the reaction, and it is this property that makes cyanuric chloride so valuable in the 
synthesis of differently substituted 1,3,5-triazines (Scheme 1).4 This reaction therefore 
























R1,R2, R3 = Aryl, Alkyl
X = O, NH2or RNH
1
 
Scheme 1. Synthesis of 1,3,5-triazines from cyanuric chloride 
Microwave-assisted organic synthesis is a high-speed methodology that offers clear 
benefits, namely a significant enhancement in reaction rates and higher product yields are 
usually observed. Recently, a series of  N2,N4,N6-tris(1H-pyrazolyl)-1,3,5-triazine-2,4,6-
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triamines (7) with symmetrical and asymmetrical substitution pattern, has been prepared 
under microwave irradiation in solvent-free conditions (Scheme 2).6 Higher yields and 
purities are obtained in the microwave-assisted syntheses in comparison to traditional 
methods, in much shorter reaction time of ten minutes. In the synthesis of sterically 
hindered derivatives, the reaction of N4,N6-disubstituted 2-chloro-1,3,5-triazine-4,6-
diamine (8) with hindered amine does not yield the desired trisubstituted triazines 7 under 
conventional heating conditions. However, under microwave irradiation, the same 

































Scheme 2. Synthesis of 1,3,5-triazines using microwave irradiation 
 
With the advent of combinatorial chemistry, several studies on the generation of libraries 
of triazines have been published in the literature. These combinatorial syntheses have 
been conducted in both solid and solution phases, taking advantage of the easy 
manipulation and the low cost of cyanuric chloride. There is an example for a solid phase 
combinatorial synthesis that uses the decreasing reactivity of tri-, di- and 
monochlorotriazine to generate combinatorial libraries of 1,3,5-triazines; the first 
chlorine atom can be selectively substituted by coupling a large excess of 
  INTRODUCTION 
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trichlorotriazine to a support-bound amino acid. On the second and third diversity 
positions, a library composed of 12,000 compounds was generated using 20 amino acids 
and 50 amines as building blocks.7 A solution phase procedure has also been developed 
for the sequential and selective derivatization of cyanuric chloride with functionally 
diverse sets of amines using automated parallel solution phase synthesis. This procedure 
produces large combinatorial arrays in a 96-well plate with the formation of a single 
compound in each well in high purity.8  
Alongside the synthesis starting from 6, aryl functionalized 1,3,5-triazines can be 
prepared from other 1,3,5-triazinyl-halides. A catalytic cross-coupling methodology, 
Suzuki reaction, which involves the palladium catalyzed cross-coupling of heteroaryl-
halides with aryl boronic acids, has been reported.9  The high yielding synthesis of 1,3,5-
triazines 10 was carried out via palladium-catalyzed Suzuki cross-coupling reactions of 
commercial available 6-chloro-2,4-diaminotriazine (9) and aryl boronic acids (Scheme 
3).9 Clearly, it offers an advantageous way over traditional synthesis which involves the 
condensation of aryl-nitrile and biguanide, to allow a rapid and convenient synthesis of a 


















Scheme 3. Synthesis of 1,3,5-triazines from Suzuki reaction 
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When the approach directly starting from a 1,3,5-triazine is not applicable, construction 
of the 1,3,5-triazine rings from various subunits by the formation of carbon-nitrogen 
bonds as introduced in the following section is the alternative way.  
 
1.1.1.2 Synthesis from Cyclization of Six-atom Urea Derivatives 
Six-atom fragment derivatives can be cyclized to generate a new carbon-nitrogen bond 
thereby forming 1,3,5-triazine heterocycles. These six-atom fragment derivatives are 
normally carrying the urea or thiourea structures, which can be used to introduce ketone 
or thio-keto groups on the ring of the 1,3,5-triazines. Another strategy involving the 
inclusion of these ketone or thio-keto groups on the 1,3,5-triazine ring is that they can be 
conveniently converted into dichloro-triazine structure. Further nucleophilic substitutions 
on the dichloro-triazines block can subsequently be carried out to introduce molecular 
diversity in the triazine nucleus. Mylari et al. applied this strategy to synthesize a series 
of R-2-hydroxyethyl-triazines in their design of novel sorbitol dehydrogenase 
inhibitors.57 (R)-2-Benzyloxy-N-ureidocarbonyl-propionamide (11) was cyclized under 
basic condition to form 1,3,5-triazine-dione 12, which was then heated with phosphorous 
oxychloride to obtain the dichloro-1,3,5-triazine 13. Further substitution and 
dechlorination on 13 gave the target compound 14 (Scheme 4). This synthetic strategy 
starting from different substituted biuret provides another method to introduce alkyl or 
aryl group as the third substitution in tri-substituted 1,3,5-triazines.   
 


























11 12 13 14  
 
Scheme 4. Synthesis of 1,3,5-triazines from biuret 
 
 
1.1.1.3 Synthesis from Five-atom Biguanides 
Biguanide (15) is normally the first choice as a starting material to build up 2,4-diamino-
1,3,5-triazines. Biguanide react with a variety of carboxylic acid derivatives in basic or 
neutral conditions to produce a wide range of 6-aryl or alkyl substituted-2,4-diamino-
1,3,5-triazines 16 (Scheme 5), and yields are usually good. The reaction is believed to 
involve the formation of acyl biguanide intermediate followed by cyclization to form the 
1,3,5-triazines. Quirke, in his book series, has given a concise account of the main feature 






















Scheme 5. Synthesis of 2,4-diamino-1,3,5-triazines from biguanide 
A similar reaction between biguanides and one-atom fragment moiety carbodiimides in 
the present of DMF provides a new general route to the synthesis of melamines. 
Biguanides 17 react with carbodiimides to form melamine derivatives 18 in 60-70% 
yields (Scheme 6).10 The reaction is thought to involve primary addition of the reactants, 
followed by the cyclization of the resulting intermediate triguanide to the heterocyclic 
end products 18 upon the loss of ammonia gas. 





































Scheme 6. Synthesis of melamines from the reaction of biguanides and carbodiimides 
Biguanide derivative 19 that  also contains a five-atom fragment has been used to 
produce 1,3,5-triazines carrying a methoxy group, after reacting with carboxylic 
derivatives.11 The triazines 20 can undergo ether-ether exchange reaction to introduce 

















Scheme 7. Synthesis of methoxy substituted 1,3,5-triazines from biguanide derivative 
Using thiocarbamic substituted biguanide derivative 22 as a starting material, targeted 4-
amino-6-p-tolylamino-5H-1,3,5-triazin-2-one 23 was synthesized by the treatment of 
PhCH2Cl and 22 with the elimination of benzyl mercaptan (Scheme 8).12 Thus, the use of 
arylbiguanide analogue provides a convenient means of the preparation of 1,3,5-





















Scheme 8. Synthesis of 1,3,5-triazinones from biguanide derivatives 
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1.1.1.4 Synthesis from Dicyandiamide (Cyanoguanidine) 
Dicyandiamide (cyanoguanidine, 24) along with biguanides constitutes the two major 
sources for the construction of the 2,4-diamino-1,3,5-triazine structures. The synthetic 
mechanism of dicyandiamide bears some resemblance to the syntheses from biguanides.  
Nitriles is the most commonly used two-atom fragment to condense with 24 in the 
synthesis of 6-substituted-2,4-diamino-1,3,5-triazines 25. The condensation is catalyzed 
by potassium hydroxide and subjected to temperature between 82oC and 150oC for 1.5-
44h which is dependent on the nitriles used (Scheme 9).13 Shie et al. have developed a 
new methodology using more commercially available aldehydes as starting materials to 
one-pot tandemly synthesize 1,3,5-triazines.14 In this reaction, nitriles are the 
intermediates converted from aldehydes using iodine as an oxidant in the present of 
ammonia water. As shown in Scheme 10, benzonitrile, which was produced in situ from 
the reaction of benzaldehyde (26) with I2/aq NH3, was treated with cyanoguanidine (1.1 
equiv) and KOH (2.2 equiv) at refluxing temperature for 24 h to obtain 2,6-diamino-4-















R = Me, Et, Ph
24 25  

















Scheme 10. Tandem synthesis of 1,3,5-triazines starting from aldehydes via nitrile intermediates 
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Alongside the reaction with nitrile derivatives, cyanoguanidine can also react with amide 
derivatives to build up 2,4-diamino-1,3,5-triazines. This method provides an effective 
route to the formation of 6-heterocyclic substituted 2,4-diamino-1,3,5-triazine, as shown 
in Scheme 11. Starting from 1,2,4-triazolo[4,3-b]pyridazine-3-carboxamide (28), a 6-
heterocyclic substituted-2,4-diamino-1,3,5-triazine 29 was synthesized in the present of 

























Scheme 11. Synthesis of 2,4-diamino-1,3,5-triazines from the reation of cyanoguanidine and amide  
 
There are few examples of the 1,3,5-triazine synthesis starting from cyanoguanidine in 
which the 2,4-diamino pattern is not formed. Dichloro-1,3,5-triazines (32) can be 
synthesized from the cyclocondensation reaction between cyanoguanidine (24) and 
chloromethyleneiminium salts 31 (Scheme 12).16 The salts 31 are prepared in situ from 
the reaction of N-methylacetamide (30) and POCl3, PCl5 or COCl2. There is an obvious 
synthetic advantage in this, since 1,3,5-triazines with similar substitution patterns are not 
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1.1.1.5 Synthesis from Amidines and Guanidine Derivatives. 
Amidines are important three-atom synthons which have the propensity to react with 
various three-atom fragments to generate 1,3,5-triazines. As illustrated in Scheme 13, the 
synthesis of aryl- and alkyl-substituted 1,3,5-triazines 33 may readily be achieved by the 
condensation of N-cyanoamidines (34) with chloromethyleneiminium salts (35).17 
Dichloromethylenedimethyliminium chloride reacts with 34 under similar conditions to 
give dimethylaminotriazines, and it may also act as a precursor of chloromethylene- 
iminium salts bearing aryl, aryloxy and arylthio substituents. Using dimethylformamide 

















Scheme 13. Synthesis of 1,3,5-triazines from chloromethyleneiminium salts with N-cyanoamidines 
 
In another report, as in Scheme 14, addition reaction of ethyl 2-chloro-3,3-dicyano-
acrylate with pyrrolidino nitrile gives 49-63% intermediate 36. In the presence of 
triethylamine, 36 then reacts with the bisnucleophilic amidine H2NPhC=NH to give 
























Scheme 14. Synthesis of 1,3,5-triazines from bisnucleophilic amidine 
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Guanidines are also important three-atom fragments in the synthesis of 1,3,5-triazines. 
The reaction of the N-aroylthioimidates 39 with guanidine (38) in EtOH gives 1,3,5-
triazines 40 in 60-93% yield.18 It provides one of the few methods to synthesize 








38 39 40  
Scheme 15. Synthesis of 1,3,5-triazines from guanidines 
 
1.1.1.6 Synthesis from Nitriles, Isocyanates, Imidates and Carbodiimides 
Trimerization of nitriles, isocyanates, isothiocyanates, imidates as well as carbodiimides 
can lead to the formation of symmetrical 2,4,6-trisubstituted-1,3,5-triazines.4 Normally, 
extreme condition such as high pressure, high temperature or strong acids, bases are 
required in this trimerization. Catalysts have been introduced in many cases to carry out 
these transformations with an increase in yields under milder reaction condition.13 
Recently, a series of lanthanide-imido complexes benzylimido-lutetium complex 
[{Cp’Lu(m3-NCH2Ph)}4] (41) have been found extremely useful in the cyclotrimerization 
of nitriles, which make the reaction undergo at room temperature to give 42 in 80-85% 
yield (Scheme 16).19 The combination of C-N bond-formation, hydrogen-transfer, and C-









Scheme 16. Synthesis of symmetrical 2,4,6-trisubstituted-1,3,5-triazines via trimerization 
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Trimerization of isocyanate provides a method to the synthesis 1,3,5-triazin-2,4,6 
(1H,3H,5H)-trione. A strong base 2,8,9-trimethyl-2,5,8,9-tetraaza-1-phosphabicyclo 
[3.3.3]undecane (43) has been used as a catalyst, which catalyzed the trimerization of Ph 
isocyanate to give 1,3,5-triphenyl-1,3,5-triazin-2,4,6(1H,3H,5H)-trione (44) in 97% 












Scheme 17. Synthesis 1,3,5-triazin-2,4,6-trione via trimerization of isocyanate 
 
1.1.2 Synthesis of Dihydro-1,3,5-Triazines 
Because of the high degree of symmetry of 1,3,5-triazines, only two dihydroisomers are 
possible: 1,2-dihydro-1,3,5-triazines and 1,4-dihydro-1,3,5-triazines. It should be noted 
that the majority of known dihydro-1,3,5-triazines bear at least two aryl or 
polyfluoroalkyl groups, or substituents which probably stabilize the compounds. The 
simple dihydro-1,3,5-triazines containing only alkyl substituents or just hydrogen, are at 
present unknown.  
 
1.1.2.1 Synthesis from 1,3,5-Triazines 
Starting from the 1,3,5-triazines, few syntheses of dihydro-1,3,5-triazines have been 
reported compared with other strategies. Although many versatile synthetic approaches 
are available, most of them are yet to be tried. The known reactions involve preparation 
of 2,4,6-triphenyl-1,2-dihydro-1,3,5 triazine from the reductions on 2,4,6-triphenyl-1,3,5-
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triazines (42) using lithium aluminum hydride or by treatment with potassium in THF 




















Scheme 18. Synthesis of dihydro-1,3,5-triazines from the reductions on 2,4,6-triphenyl-1,3,5-triazines 
The organolithium chemistry of triazine derivatives has received more attention recently. 
Wakefield and coworkers have shown that triphenyldihydrotriazines are formed by 
reacting 2,4,6-triphenyl-1,3,5-triazine with a lithium reagent and the chemistry of 
reactions have been explored.23 Boesveld et al. have reported a series of addition products 
mono substituted 1,4-dihydro-1,3,5-triazines 46 which is synthesized from the treatment 
of  1,3,5-triazine 45 with an alkyllithium LiR [R=Me, n-Bu, t-Bu, Ph, CH2TMS, 
CH(TMS)2 or Si(TMS)3(THF)3] upon hydrolysis (Scheme 19).24 Experiments also 
showed that the 1,4-dihydrotriazine 46 in toluene was in equilibrium with its 1,2-dihydro 
















45 46  
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1.1.2.2 Synthesis from Biguanide 
Various biguanides have been reported to react with aldehyde or ketone to give the 
corresponding 1,2-dihydro-1,3,5-triazines (47). The reaction is acid catalyzed and has 















Scheme 20. Synthesis of 1,2-dihydro-1,3,5-triazines from biguanides 
It is a well-known art in organic synthesis that in situ removal of water from a 
condensation reaction very often would provide a better result since the reaction 
equilibrium would shift to the product side. An efficient synthesis of 1-aryl-4,6-diamino-
1,2-dihydro-1,3,5-triazines 48 using triethyl-orthoacetate as a water scavenger has also 
been reported in good yield from an acid-catalyzed reaction between corresponding 
arylbiguanide hydrochlorides and carbonyl compounds (Scheme 21).26 The method has 
been recently used in the synthesis of solution-phase combinatorial library of 4,6-
diamino-1,2-dihydro-1,3,5-triazine as new leads against A16V+S108T mutant 























Scheme 21. Synthesis of 1,2-dihydro-1,3,5-triazines using triethyl-orthoacetate as a water scavenger 
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In addition to forming 1,2-dihydro-1,3,5-triazines, the reactions of biguanide analogues 
amidinothioureas with aldehyde or acetone were found to form 6-amino-4-mercapto-1,2-

















Scheme 22. Synthesis of 4-mercapto-1,2-dihydro-1,3,5-triazines from amidinothioureas  
 
 
1.1.2.3 Synthesis from Dicyandiamide (Cyanoguanidine) 
Dicyandiamide can be used as a starting material to prepare 1,2-dihydro-1,3,5-triazines. It 
can react with molecular equivalent of the aryl amine or its acid salt plus one equivalent 
of acid and a ketone or an aldehyde with the loss of one molecule of water to give the 
1,2-dihydro-1,3,5-triazine nucleus 50. This procedure has been named by E. J. Modest as 





















Scheme 23. Three-component synthesis of 4,6-diamino-1,2-dihydro-1,3,5-triazines 
The `one-pot' three-component synthesis produces relatively clean hydrochloride salts of 
dihydrophenyltriazines, which can readily be separated from the reaction mixture as 
crystalline precipitate. This unique feature in the synthesis served as a basis for adapting 
the method for the combinatorial mixture synthesis of dihydrophenyltriazine antifolate 
compounds (Scheme 24). A total of three libraries 51 were synthesized using this method 
and were used to screen for DHFR inhibitory activity.30 


























Scheme 24. Combinatorial synthesis of 4,6-diamino-1,2-dihydro-1,3,5-triazines 
 
1.1.2.4 Synthesis from Amidines or Their Derivatives 
The synthesis from amidines or their derivatives normally produces dihydro-1,3,5-
triazines without amino groups substituted on the triazine rings. Aryl aldehydes, Shiff’s 
bases are the most commonly used fragments to build up dihydro-1,3,5-triazines with 
amidines. Condensation of benzaldehyde with benzamidine gives 2,4,6-triphenyl-1,2-
dihydro-1,3,5-triazine (52) (Scheme 25).31 N-Substituted 1,2-dihydro-1,3,5-triazine 53 
can also be prepared using this method.32 In this reaction, the N-benzylbenzamidine has 
































Scheme 26. Synthesis of 1,2-dihydro-1,3,5-triazines from benzaldehyde and N-benzyl benzamidine 
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An unusual reaction of N-haloamidines with enamines derived from aldehydes forms 1,4-
dihydro-1,3,5-triazines 54 (Scheme 27).33 It provides a different third substitution which 





















Scheme 27. Synthesis of  1,4-dihydro-1,3,5-triazines from the reaction of N-haloamidines with enamines 
Amidines derivative, O-methylisourea 55, has been employed in the preparation of 
dihydro-1,3,5-triazines. A three-component condenzation of isopropyl propionimidate 56 
with O-methylisourea tosylate in the presence of acetone gives 39.4% of 1,2-dihydro-
1,3,5-triazine 57 (Scheme 28).34  The scope of the reaction is, however, very limited. 
Moderate yields of dihydro-1,3,5-triazines were obtained only with aliphatic methyl 














Scheme 28. Synthesis of 1,2-dihydro-1,3,5-triazines from O-methylisourea 
 
 
1.1.2.5 Synthesis from Nitriles 
One of the first known synthetic preparations of 1,2-dihydro-1,3,5-triazines involves 
trimerization of benzonitriles in the presence of alkali metals or organometallic reagents. 
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In 1896, Lottermoser reported that in the presence of sodium, benzonitrile in refluxing 
benzene produced a mixture of 2,2,4,6-tetraphenyl-1,2-dihydro-1,3,5-triazines, sodium 
cyanide and 2,4,6-triphenyl-1,3,5-triazines.35 Cook et al. obtained 2,2,4,6-tetraphenyl-
1,2-dihydro-1,3,5-triazines as the sole product36 and succeeded in preparing a series of 












Scheme 29. Synthesis of 1,2-dihydro-1,3,5-triazines from the trimerization of benzonitriles 
Japanese patents have claimed to produce 1,2-dihydro-1,3,5-triazines by high pressure 
reactions between aromatic or heteroaromatic nitriles and formaldehyde, acetaldehyde or 
ketones in the presence of ammonia.38 
 
1.1.3 Synthesis of Fused 1,3,5-Triazines 
Most of the syntheses of fused triazines have been based on the use of amino substituted 
nitrogen heterocyclic systems. These compounds can react with the other reagents to give 
the desired product by the formation of two carbon-nitrogen bonds. For example, 2-
trihalomethyl-4H-isoxazolo[2,3-a]-1,3,5-triazin-4-ones (59) have been synthesized by 
cyclization of 3-amino-5-methylisoxazole with N-(1-chloro-2,2,2-trihaloethylidene)-O-
methyl-urethanes (Scheme 30).39 The pyrazolo-[1,5-a]-1,3,5-triazines 60 have been 
prepared in a convergent fashion by the coupling of 3-aminopyrazole with aroyl 
thioimidates (Scheme 31).40 Starting from 2,4-diamino-6-phenyl-1,3,5-triazine, the 
synthesis of 7-substituted-2-phenylimidazo[1,2-a]-1,3,5-triazine-4-yl-amines (61) also 
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employs similar strategy by cyclization of 2,4-diamino-1,3,5-triazine in refluxing ethanol 























































Scheme 32. Synthesis of fused 1,3,5-triazine 61 by cyclization of 1,3,5-triazine with 2-chloroacetone 
There are many examples of synthesis of fused 1,3,5-triazines from 5+1 atom cyclization. 
The basic synthetic strategy is similar to the syntheses of 1,3,5-triazines from biguanides, 
but in this case the five-atom component incorporates a heterocyclic substituent. The 
examples in the following equations illustrate the approach. N1-(5-Aryl-1,3,4-oxadiazolo-
2-yl)-ureas on cyclocondensation with CS2/KOH afforded 2-aryl-1,3,4-oxadiazole[3,2-a]-
1,3,5-triazine-5,7-(6H) dithione nucleobases (62) (Scheme 33).42 2-Amino-1,3,5-
triazino[1,2-a]benzimidazoles (63a, 63b) were obtained by a ring annelation from 2-
guanidinobenzimidazoles (Scheme 34).43 Pharmaceutical oxadiazolo-1,3,5-triazine 
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derivatives 64 which showed antihypertensive and vasodilating activity, have been 
prepared by cyclocondensation of 2,4-diamino-6-(diallylamino)-1,3,5-triazin-3-oxide 



























































Scheme 35. Synthesis of oxadiazolo-1,3,5-triazine 64 from 1,3,5-triazin-3-oxide and COCl2 
The synthesis of fused 1,3,5-triazines can also be achieved by the formation of one 
carbon-nitrogen bond. 2-Triphenylphosphanimino-4-azidotetrazolo[5,1-a]-1,3,5-triazine 
(65) has been obtained by reaction of 2,4,6-triazido-1,3,5-triazine with 1 equivalent of 
triphenylphosphine (Scheme 36).45 4-Diamino-6-hydrazone-1,3,5-triazines can be 
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cyclized to 1,2,4-triazolo[4,3-a]-1,3,5-triazines 66 with Pb(OAc)4 in CH2Cl2. The product 
1,2,4-triazolo[4,3-a]-1,3,5-triazines 66 can be rearranged to 1,2,4-triazolo[1,5-a]-1,3,5-
triazines 67 in MeOH-NaOH (Scheme 37).46 N-Carbethoxy-N’-(6’-chloropyridazinyl-3’) 
thiourea which is upon heating in the presence of sodium ethoxide afforded the 































































Scheme 38. . Synthesis of fused 1,3,5-triazine 68 via a ring annelation 
 
 
1.2 Pharmaceutical Applications and Important Compounds  
1.2.1 Fully Unsaturated 1,3,5-Triazines 
Since the 1970s, several studies have been carried out on the antitumor activity of 2,4,6-
tris(N,N-dialkylamino)-1,3,5-triazines. One of these analogues, hexamethylmelamine 
(HMM, 69) is effective against lung, breast, and ovarian cancers but causes severe nausea 
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and vomiting. Some structural analogues of HMM were prepared and tested.48 These 
studies pointed out that compounds such as 2,4,6-tris(N-methyl-N-
hydroxymethylamino)-1,3,5-triazine (trimelamol, 70) and 2,4-bis(N-hydroxymethyl-N-
methylamino)-6-N-methylamino-1,3,5-triazines (71), containing hydroxymethyl 
functionalized amino moieties, showed the highest cytotoxicity. Almitrine (72), which is 
used to treat respiratory problems, was used as a lead compound to develop triazine 
derivatives as potent modulator of multidrug resistance in cancer therapy.49 Its analogue 
73 (S9788) was selected as the best candidate for the development and the phase I 
clinical trial was finished.50 Irsogladine (74) was used clinically as an antigastric ulcer 
agent. However, it inhibited cell proliferation and tubular morphogenesis of vascular 
endothelial cells. In vivo studies demonstrated that p.o. administration of irsogladine 
significantly inhibited tumor growth of human glioma cells in mice. These in vivo and in 
vitro assays demonstrate that irsogladine may be a unique and potent inhibitor of tumor 
angiogenesis.51 Another diaminotriazine 75 have been established as suitable lead 
compound for the possible development of new antitumor triazine derivatives based on 
anti-metastatic effects and antiangiogenic action.52 Recently, a novel scaffold, composed 
of a 2-hydroxy-4,6-diamino-1,3,5-triazine nucleus, has been disclosed as a potent 
inhibitor of the VEGF-R2 (flk-1/KDR) tyrosine kinase in vitro and has demonstrated 
antiangiogenic properties in vivo. The most potent triazine 76 has selectivity comparable 
to other reported small molecule inhibitors in preclinical development.53 There are 
something in common among these anticancer triazines: these anticancer triazines have 
more than one free or substituted amino groups on the triazine rings; they also have 
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another aromatic or heterocyclic ring direct or indirect linking with the triazine ring 





























































Figure 1. Chemical structures of anticancer triazines 
 
Although 1,3,5-triazines are well known in the context of anticancer drugs, they are also 
found in several other fields of medicinal chemistry. These structures have been found to 
act as VLA-4 integrin antagonists and anti-inflammatory agents,54 inhibitors of Erm 
methyltransferases,55 estrogen receptor modulators,56 inhibitors of sorbitol dehydrogenase, 
57 hypolipidemic agents,58 potential antitrypanosomal drugs,59 antimalarial agents60 and 
antimicrobial agents61. Some of these important compounds were listed in Figure 2.    


























































































Figure 2. 1,3,5-triazines of various biological activity 
 
 
1.2.2 The Pharmaceutical Applications of Dihydro-1,3,5-Triazines 
4,6-Diamino-2,2-dimethyl-1,2-dihydro-1,3,5-triazine derivatives (Baker triazines) are 
becoming increasingly important as pharmaceuticals. Many of these compounds are 
inhibitors of dihydrofolate reductase, and some have shown activity against leukemia. 
Baker triazine antifol (77) had been undergoing clinical trials as a drug in cancer 
chemotherapy.62,63 Recently, a series of 4,6-diamino-1,2-dihydro-1-aryl-2-(1-adamantyl)-
1,3,5-triazines 78 was patented as potent Toxoplasma gondii dihydrofolate reductase 
inhibitors with IC50= 2×10-4M to 9.7×10-8 M.64  



















1-Adamantyl-1,3,5-triazines (78)  
An extensive range of 1-aryl substituted 4,6-diamino-2,2-dimethyl-1,2-dihydro-1,3,5-
triazine have also shown potent antimalarial activity (e.g. cycloguanil (79)). The 
emergence of resistant strains of Plasmodium falciparum has restricted the widespread 
clinical use of cycloguanil.65 N-oxydihydrotriazines such as clociguanil (80), which do 
not show cross resistance with cycloguanil against triazine resistant strains of P. berghei 
and are also active against P. falciparum, have been developed.66 N-oxydihydrotriazines 
(arylmethoxy-, aryloxy-, and arylalkoxy-dihydrotriazines) were thoroughly investigated 
as antimalarial agents but triazine research has been replaced by works on quinoline- and 
phenanthrenemethanols. However, interest in N-oxydihydrotriazines as potential 
















 Clociguanil, 80  
 
Some bis-oxydihydrotriazine derivatives have appeared in the literature as active agents 
against African trypanosomes Trypanosoma brucei rhodesiense67 and Trypanosoma 
congolense.68 A series of bis-dihydrotriazine derivatives was found to be curative of 
experimental Trypanosoma evansi infections in mice, rats, buffalo, and cattle.69 One of 




hexanediol dihydrochloride (SIPI 1029, T-46, 81) has been explored as a lead for new 













SIPI 1029, T-46, 81
1  
 
1.2.3 The Pharmaceutical Applications of Fused 1,3,5-Triazines 
Many therapeutic agents have fused 1,3,5-triazines in their chemical structures. In 1980s, 
7-methyl-pyrazolo[1,5-a]-1,3,5-triazine-2,4-diamine (LA 2851, Dametralast) was 
developed as a new bronchodilator and anti-allergic compound.71 Recently, research 
interests on pyrazolo[1,5-a]-1,3,5-triazines 82 have been focused on the blockade activity 
against corticotropin-releasing factor (CRF) receptors.72,73 
A series of imidazo[1,2-a]-1,3,5-triazines have been reported as A1 adenosine receptor 
(A1AR) antagonists. Prompted by pharmacophore and docking based models, a number 
of N-alkyl and N-acyl-(7-substituted-2-phenylimidazo[1,2-a][1,3,5]triazin-4-yl)amines 
(ITAs, 83) were synthesized and screened. Among the ITAs investigated, 1-[(7-methyl-2-
phenylimidazo[1,2-a]-1,3,5-triazin-4-yl)amino]acetone 83 exhibited the best combination 
of affinity at the A1AR (Ki = 12 nM) and selectivity over the A2AAR and A3AR subtypes 
(Ki values > 10000 nM).40  
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Some other pharmaceutical uses of fused 1,3,5-triazine have also been reported. Several 


















As stated, the literature on the synthesis and applications of 1,3,5-triazines is vast, and it 
is beyond the scope of this brief review to include all aspects. Therefore, only an 
introduction and recent representative examples have been included. 1,3,5-Triazines (or 
s-triazines) continue to draw considerable interest in recent years due to their applications 
in various fields. Their exciting range of biological activity maintains ongoing interest in 
the area of medicinal chemistry. Antifolate is the area of an intense study, and 4,6-
diamino-1,2-dihydro-1,3,5-triazines interfere with folic acid and metabolism triggered an 
enormous amount of research on the antifolate activity of this class of compounds. The 
investigations concerning this class of compounds and their antifolate activity are the 
major parts of this dissertation. The following chapter will discuss the DHFR enzymes 
and their important inhibitors. 
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2 Dihydrofolate Reductase (DHFR) Inhibitors 
2.1 Biochemistry of Dihydrofolate Reductase  
The folates (pteroylglutamates), based on the structure of folic acid, belong to a family of 
vitamins (Figure 3) and are essential components for cell growth and proliferation. 
Members of this family differ from each other in several ways, namely, redox state of the 
pyrazine ring (X), the substitution at N5 and N10 positions (Y), and in the presence of 
additional glutamate residues attached to the γ-carboxyl group of the single glutamate 




































CH3 at N5, 5-methyl
CHO at N5 or N10, 5-or 10-formyl
CHNH at N5, 5-formimino-
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Figure 3. Structures of the folate family 75, 118 
Among members of this family, only tetrahydrofolates (THF) carry one-carbon units and 
these one-carbon forms are physiologically interconvertible, with the exception of 5-
methyl units, the formation of which is considered irreversible. These one-carbon units 
are utilized in a number of one-carbon transfer reactions of synthetic and catabolic 
pathways (Scheme 39).76 































Scheme 39. Folate cofactor-dependent reactions and interconversion pathways76, with the indication of    
how drugs such as MTX, TMP and PYR may interfere with the scheme of events 
 
One of these pathways involves the continuous synthesis of thymidylate (dTMP). dTMP 
is produced by the reductive methylation of 2’-deoxyuridylate (dUMP) catalyzed by 
thymidine synthase (TS) in the presence of N5,N10-methylene tetrahydrofolate, which is 
converted from THF by serine hydroxymethyl transferase (SHMT). In the pathways, 
N5,N10-methylene tetrahydrofolate not only supplies the one-carbon unit to the 5-position 
of the uracil ring of dUMP, but also serves as a reductant supplying a hydrogen from C6 
of the reduced pyrazine ring of THF, yielding DHF to complete the cycle. In this cycle, 
THF must be regenerated via the DHFR-catalyzed reaction in order to maintain the 
intracellular pool of one-carbon derivatives for dTMP, purine nucleotide and amino acid 
biosynthesis. Blocking the formation of THF by inhibition of DHFR or inhibition of TS 
can shut off the supply of dTMP necessary for DNA synthesis. In the cell, it leads to what 
is called thymineless death. Thus, folate metabolism becomes an attractive target for the 
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design of chemotherapeutic agents as it plays a key role in the biosynthesis of nucleic 
acid precursors. As certain microbial organisms also utilize folate cofactors to mediate 
one-carbon metabolism, the antagonism of folate metabolism was thus identified as the 
starting point for the design of therapeutic agents against proliferative disorders such as 
cancer77-80 and a variety of microbial diseases.81-84 
Among the enzymes involved in the metabolism of folic acid, dihydrofolate reductase 
[DHFR; 5,6,7,8-tetrahydrofolate-NADP+ oxidoreductase (E.C.1.5.1.3)] is by far the most 
extensively studied enzyme. DHFR is an essential and ubiquitous enzyme found in most 
living organism. Its inhibition has profound impact on the biosynthesis of biomolecules 
that are essential for cell proliferation. It catalyzes the reduction of dihydrofolate (DHF) 
to THF, using NADPH as a cofactor (Scheme 40).85 Therefore, the inhibition of DHFR 
can result in the depletion of the intracellular THF pool and prevents biosynthesis of 
thymidine, and as a consequence, DNA biosynthesis, ultimately, RNA and protein 
synthesis are adversely affected. In addition, inhibition of DHFR probably will lead to a 
buildup in the level of dUMP and hence to a biosynthetic precursor, deoxyuridine 
triphosphate.86 High levels of deoxyuridine triphosphate lead to incorporation of uracil 
into DNA to levels beyond which the DNA repair enzymes (uracil-DNA-glycosylase) 
can cope with, and eventually leading to cell death.  





Scheme 40. DHFR catalyzed conversion of dihydrofolate to tetrahydrofolate 
The wealth of knowledge on the inhibitors of this enzyme was acquired relatively early in 
the 1950s and 1960s. Many well known anticancer, antibacterial and antimalarial drugs 
are potent inhibitors of DHFR. Methotrexate (MTX, 84) an anticancer drug, was 
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developed shortly after the elucidation of the folic acid structure, and before DHFR was a 
known entity.87 It soon became an important chemotherapeutic agent, and has maintained 
this status until today. MTX differs from folic acid only in the bioisosteric replacement of 
the 4-oxo group by an amino group, and the presence of a methyl group at the N10 
nitrogen. Pyrimethamine (PYR, 85), developed shortly thereafter, was found to be very 
active as an antimalarial agent, with reasonably low toxicity to mammalian cells.88 
Trimethoprim (TMP, 86) was also discovered in the 1950s, has potent broad spectrum 




























With the advent in protein crystallography, extensive studies were conducted to elucidate 
the 3-D structures of DHFRs derived from different species, namely human, protozoa, 
fungi, and bacteria sources. This has led to an explosion of information relating to how 
numerous ligands and cofactors bind to various DHFR active centers. To date, there are 
over 100 coordinates of 3-D structures of this enzyme with substrate, cofactor, and a wide 
variety of inhibitors are deposited in the Brookhaven Protein Data Bank. It is essential to 
determine the 3-D structures of several DHFRs from different species to determine their 
common features and also to try to learn the basis for inhibitor selectivity on antifolate 
drug developments. The following sections deal with structural results to date on the 
DHFRs.  
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2.2 Structure and Ligand Interactions   
By the 1960s, it has become evident that this enzyme, DHFRs, although performing the 
same function in many species, differ structurally from species to species.91 DHFRs 
derived from vertebrate and bacteria are known to differ in a number of physical and 
chemical properties. Vertebrate DHFRs have molecular weights of approximately 22,000, 
as compared to 18,000 for bacterial DHFRs. In terms of amino acid sequence, vertebrate 
DHFRs differ remarkably from bacterial DHFRs; vertebrate DHFRs contain about 30 
more amino acid residues than bacterial enzymes, and possess much higher amino acid 
homology to each other (about 75%-90%), and low amino acid homology compared to 
bacterial DHFRs (of 20-30%).92 However, the overall backbone folding in these various 
types of DHFR is very similar. The molecule is folded into eight-stranded β sheets, 
consisting of seven parallel strands plus a single antiparallel strand leading to the 
carboxyl terminus. Four α helices pack up against this β sheet while the remaining 
residues are involved in loops, connecting elements of secondary structure. The active 
sites of vertebrate and bacterial DHFRs are also very similar and some of the amino acids 
are conserved. The core of the active site is hydrophobic but at either end of this core, a 
polar region with hydrogen bonding sites is present. When the substrate or inhibitor binds 
to DHFR, a ternary complex forms between the substrate/inhibitor, DHFR and NADPH. 
The following section will discuss these complexes based on different species of DHFR. 
 
2.2.1 Escherichia coli DHFR 
The first three dimensional structure elucidated for DHFR was the binary complex of E. 
coli DHFR with MTX.93 The structure was subsequently refined at higher resolution 
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(Figure 4).94 The main feature of the protein is the eight-stranded β sheets beginning at 
the amino terminus and ending as an antiparallel strand at the carboxyl end. Four helical 
regions are inserted into the loops connecting successive β strands. A cis Gly-Gly peptide 
bond is present at residues 95 and 96, which appears to be invariant with this enzyme. A 
15 Å cavity cuts across one face of the enzyme and into this cavity is where MTX is 
bound. 
 
                                   Figure 4. Binary complex of E. coli DHFR and MTX94 
The pteridine ring of MTX is bonded via a salt bridge, through its N-1 and 2-amino group 
to Asp 27, which is invariant in bacterial species and replaced by Glu in the vertebrate 
enzymes as well as in Saccaromyces cerevisiae DHFR.97 NMR studies with the MTX and 
TMP complexes indicate that both inhibitors are in protonated state interacting with 
active site carboxylic anion when bound to bacterial DHFR (Aspartate) or bovine DHFR 
(Glutamate).95-96 The data also suggest that the preferential binding of TMP to bacterial 
DHFR does not arise from any differences in the ionic interaction between the protonated 
inhibitor and the active-site carboxyl of the enzyme from different sources. Evidence 
consistent with this view has also been obtained from X-ray crystallographic studies 
which indicated that inhibitor side chain binding is critical for selectivity.94 The 2-amino 
group is further H-bonded through water molecule to Thr 113. The 4-amino group is H-
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bonded to the backbone of the carbonyl functional group of Ile 5 and Ile 94. Several van 
der Waals contacts are present between the pteridine and enzyme side chains. The p-
aminobenzoyl moiety lies in a hydrophobic pocket comprising the side chains of Leu 28, 
Phe 31, Ile 50, Leu 54 and Ile 94. The glutamate porton interacts through α-carboxyl 
group with Arg 57. There is no direct hydrogen bond from the γ-carboxyl function which 
interacts only with several water molecule that are in turn hydrogen bonded to Lys 32 and 
α-carboxyl and amide groups of MTX. 
The structure of binary complex of TMP with E. coli DHFR was reported in 1982,97 and 
later refined to 2.3 Å.98 The pyrimidine ring occupies the same locus as the corresponding 
ring of MTX, and has the same H-bonding interactions. The aromatic ring is found in the 
hydrophobic pocket described for the benzene ring of MTX. One edge of this ring and 
part of one face lies exposed to solvent. The pyrimidine and benzene rings nearly 
perpendicular to each other.  
 
2.2.2 Chicken Liver DHFR 
The 3-D structure of chicken liver DHFR has been solved in ternary complex with a 
number of ligands plus NADPH at 2.2 Å resolution.92a,100 The chicken liver protein 
(Figure 5) has 189 residues, compared with 159 for E. coli DHFR. However, these extra 
protein segments are accommodated without undue interference in the overall fold 
although the width of the active site cleft of chicken liver DHFR is about 1.5Å wider than 
in E. coli DHFR. Two hydrophobic cavities are found in the active site region in the TMP 
ternary complex with NADPH, whereas the bacterial enzymes have room for only one. 




Figure 5. Chicken liver DHFR 3D-Structure92b  
The two rings of TMP now lie almost as an open book, rather than being nearly 
perpendicular to each other. The pyrimidine ring of TMP is inserted more deeply in the 
active site cleft than is a phenyldihydrotriazine (87) ligand. The 4-Amino group of TMP 
can only form one hydrogen bond with the carbonyl group of Ile7 in the backbone, as it 












However, the phenyldihydrotriazine is hydrogen bonded to both Ile7 and Val115 
(equivalent to Ile5 and 94 in E. coli DHFR). The phenyldihydrotriazine binds at the far 
interior end of a large cleft that bounded is at the bottom by two strands of β sheet (βA 
and βF) and on the sides by helices αB and αC (Figure 6). It interacts with chicken liver 
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DHFR in approximately the same manner as the pyrimidine DHFR inhibitor.100 Each 
phenyldihydrotriazine behaves like puckered pyrimidine, where 5-carbon has been 
replaced by a substituted nitrogen atom. The other nitrogen attached to the side of the 
gem-dimethyl groups is the protonated center which interacts with Glu 30, along with the 
adjacent amino group. In addition, the 4-amino group donates a second hydrogen bond to 
a highly ordered and structurally invariant bound water molecule. Additional hydrogen 
bonds occur between the inhibitor’s 6-amino group and the carbonyl oxygens of Ile-7 and 
Val-115. In addition to the several polar interactions, numerous van der Waals contacts 
occur as well. DHFR has two potential binding sites for inhibitor side chains (upper and 
lower clefts). Phenyldihydrotriazines have favorable van der Waals interactions with the 
upper cleft. The phenyl ring attached to N1 is also of the right length to fit into the upper 
cleft without disrupting hydrogen bonding between the enzyme and the 
phenyldihydrotriazine moiety. This greatly enhances the binding affinity of the inhibitor 
to the enzyme. For steric reasons, the phenyl and dihydrotriazine rings lie perpendicular 
to each other. The torsion angle was found to be 70o at the optimal binding conformation. 
This result is consistent with the binding conformation of MTX where the pteridine ring 
is perpendicular to the aromatic side chain. Two analogues of phenyldihydrotriazines101 
with long chains in the meta-position were crystallized with chicken liver DHFR. These 
chains were bound in a narrow channel leading from the extreme upper portion of the 
active site cleft to the protein surface.100 This channel is located near Arg 70 which is 
equivalent to Arg 57 in E. coli DHFR. A series of 5-phenylpyrimidines containing meta-
carboxyalkoxy chains in the benzene ring was investigated to see whether binding might 
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be enhanced by the interaction with Arg 70.102 The expected increase in binding was, 
however, not observed. 
 
 




2.2.3 Murine L1210 DHFR 
The X-ray structures of the ternary complex of L1210 DHFR with TMP or MTX and 
NADPH were solved.103, 104 These are the first structures reported for a mammalian 
DHFR. The binding of TMP to the L1210 enzyme is essentially the same as that reported 
for chicken liver DHFR. MTX binding with vertebrate DHFR was of interest, since this 
complex was not obtained with chicken liver DHFR. The pteridine binding position was 
found to be similar to that found in the bacterial DHFRs, despite the residual differences 
between the active site regions. The 4-amino group of the pteridine in MTX is known to 
be H-bonded to the main chain carbonyl oxygen atoms of both Ile 7 and Val 115. The 
benzoyl group of MTX was found to be rotated by about 60o compared to its orientation 
in bacterial DHFR. This in turn altered the other contacts between the ligand and the 
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enzyme. The binding of glutamate moiety of MTX was less clearly defined in this 
structure than was the pteridine or benzoyl portions of the inhibitor. 
 
2.2.4 Human DHFR  
 
Figure 7. Crystal structure of recombinant human DHFR with Folate105 
The crystal structure of recombinant human DHFR with folic acid bound to the active site 
has been elucidated at 2 Å resolution (Figure 7).105 Binary complexes with MTX and 
with TMP have also been investigated and solved at 3.5 Å resolution. The results show 
clearly that the pteridine rings of folic acid and MTX have inverse orientations in the 
enzyme relative to the p-aminobenzoylglutamate portions of the molecule, as postulated 
early by Bolin et al.94 The 2-amino and 3-NH functional groups of folate are hydrogen 
bonded to Glu 30, which in turn is hydrogen bonded to Thr 136. The 4-oxo group is 
found to be hydrogen bonded by way of a water molecule to the invariant Trp 24. The 
binding of the pteridine ring of MTX is as described for the bacterial and L1210 enzyme. 
TMP is bound in the orientation described for chicken liver DHFR. However, one 
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important difference between the human and chicken liver enzymes is that the cleft for 
human DHFR is not significantly wider than for chicken DHFR enzyme, a factor which 
Matthew et al.100 considered important with chicken liver DHFR relative to specificity.  
 
2.2.5 Mycobacterium tuberculosis DHFR 
Crystal structures of ternary complexes of M. tuberculosis DHFR with NADPH and 
different inhibitors have been determined, together with the binary complex of M. 
tuberculosis DHFR and NADPH, with the resolutions ranging from 1.7-2.0 Å.106 In the 
ternary complexes, the three DHFR inhibitors used were MTX, the TMP and Br-





















Structural comparison of these complexes with human dihydrofolate reductase indicates 
that the overall protein folds are similar, despite only 26% sequence identity, but that the 
environments of both NADPH and of the inhibitors contain interesting differences 
between the enzymes from host and the pathogen. Especially, residues Ala101 and 
Leu102 near position N6 of NADPH are distinctly more hydrophobic in the M. 
tuberculosis than in the human enzyme. Another striking difference occurs in a region 
near atoms N1 and N8 of methotrexate, which is also near atom N1 of trimethoprim, and 
near the N1 and two methyl groups of Br-WR99210. A glycerol molecule binds here in a 
pocket of the M. tuberculosis DHFR:MTX complex, while this pocket is essentially filled 
with hydrophobic side-chains in the human enzyme. These differences between the 
  INTRODUCTION 
 
 40
enzymes from the pathogen and host provide opportunities for designing new selective 
inhibitors of M. tuberculosis DHFR. 
 
Figure 8. Crystal structure of ternary complex of M. tuberculosis, NADPH and Br-WR99210106 
 
2.2.6 Lactobacillus casei DHFR and Neisseria gonorrhoeae DHFR 
The structure of the ternary complex of L. casei DHFR with MTX and NADPH was 
reported in 197899 and was later refined to 1.7 Å in 1982.94 The overall binding pattern of 
MTX was practically identical to that from E. coli DHFR, despite the many differences in 
side chain. In the binding area for the Glu moiety of MTX, the α-carboxy group 
interacted with Arg 57, but the γ-carboxy group now interacted with His 28, a residue not 
present in E. coli DHFR. Comparison of the structure of the DHFR-TMP-NADPH 
ternary complex with binary complexes of related ligands such as methotrexate and 
trimetrexate suggest that there will not be large conformational differences between the 
binary and ternary complexes. Thus in order to detect any differences between the 
structures it is important to obtain structures of high quality.107  
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There is no X-ray structure of Neisseria gonorrhoeae DHFR available. However, a model 
has been constructed from an analysis of substituents effect on the binding sites. The 
major difference is that N. gonorrhoeae DHFR contains an active site that has Phe 
replaced Leu-28 of E. coli DHFR, thus creating a more hydrophobic pocket.108  
 
From the above descriptions, it can be seen that several important points must be noted in 
the design of potent inhibitors of DHFR. 
♦ There must be a protonated N in the heterocyclic ring of the inhibitor for 
the charge-mediated hydrogen bond formation to occur when the inhibitor 
binds to the enzyme. There is also partial delocalization of positive charge 
onto the amino group next to the protonated N, which leads to the second 
hydrogen bond formation. 
♦ There must be at least one amino group in the heterocyclic ring of the 
inhibitor. The second amino group, which is para to the protonated N, is 
favourable for more extensive hydrogen bond formation. Its presence can 
also promote the protonation of the heterocyclic N as it enhances the 
basicity of this N. This, in turn, leads to more efficient binding of the 
inhibitor to DHFR. However, the presence of the second amino group is 
advantageous but not crucial. In the absence of this group, folic acid can 
also bind to DHFR, although the binding affinity is not as great as 
inhibitors with the second amino group. 
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♦ The substituents at the C2 position of the triazine ring (in phenyl 
dihydrotriazines) or the C6 position of the pyrimidine ring (in substituted 
pyrimidines) is important for the selectivity of the inhibitor to the enzyme. 
♦ Hydrophobic or bulky substituents (e.g. substituted phenyl ring) attached 
to the heterocycle is favorable for interactions with DHFR. There are 
hydrophobic binding regions in DHFR that can accommodate large 
substituents next to the heterocyclic ring.  
♦ The optimal binding conformation for DHFR inhibitors is one in which 
the heterocyclic ring is perpendicular to the hydrophobic side chain. This 
conformation is required for optimal polar interactions to take place 
between the heterocyclic ring and DHFR as well as non-polar interactions 
between the hydrophobic side chain and the enzyme. 
 
2.3 DHFR Inhibitors as Antimetabolites 
Of great importance in medicine is the crucial role played by antimetabolites in the 
treatment of a large number of diseases. Antibacterial, antiviral and anticancer agents are 
among numerous examples of antimetabolites. Antimetabolites are structural analogues 
of normal biochemical compounds which compete with the natural substrate for the 
active site of enzyme and block the formation of undesirable metabolic products in the 
body. Folic acid antagonists, sulfa drugs, structural analogues of amino acids, analogues 
of purine and pyrimidine, inhibitors of polyamine biosynthesis are among the most used 
antimetabolites in modern chemotherapy. DHFR is a unique enzyme for antimetabolites 
development in that inhibitory effects on this single target, DHFR, can impact 
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macromolecular biosynthesis and cytotoxicity at a number of metabolic steps involving 
folate-dependent biosynthetic reactions.  
The wealth of the knowledge acquired on the DHFR inhibitors resulted relatively early in 
the 1950s and 1960s in the well known anticancer, antibacterial and antimalarial drugs. 
During the past decades, intense research activity has come from both private companies 
and academic institutions, aim at discovery new effective DHFR antimetabolites. The 
following section will focus on the achievements in this area. 
 
2.3.1 DHFR Inhibitors as Cancer Chemotherapeutic Agents  
The term chemotherapy refers to a wide range of drugs used in the treatment of various 
cancers. These drugs generally work by killing dividing cells. Since cancer cells have lost 
many of the regulatory functions present in normal cells, they continue to attempt to 
divide when other cells do not. This feature makes cancerous cells susceptible to a wide 
range of cellular poisons. The chemotherapeutic agents work to cause cell death in a 
variety of ways. Most of these agents, no matter which are naturally occurring 
compounds from plants or are man-made chemicals, inhibit cell division by various 
mechanisms. The anticancer chemotherapeutic agents may be categorized in the 
following three groups:  1) Antimetabolites. Drugs that interfere with the formation of 
key biomolecules within the cell including nucleotides, ultimately interfere with DNA 
replication and therefore cell division. 2) Genotoxic drugs: Drugs that damage DNA. By 
causing DNA damage, these agents interfere with DNA replication, and cell division. 3) 
Spindle inhibitors: These agents prevent proper cell division by interfering with the 
cytoskeletal components that enable one cell to divide into two. Although cancer 
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chemotherapy is entering a new era of research based, in large part, on the study of 
oncogene and their protein products, the increases in survival or improvement in the 
quality of life for most cancer patients during the next decade will likely be accomplished 
by these traditional chemotherapeutic agents. It is critical and insightful to look at current 
chemotherapeutic agents and to investigate what rational extensions can be made to 
improve their chemotherapeutic effects. The DHFR inhibitors have been the recipient of 
just such a re-examination. No other traditional area of cancer chemotherapy has 
generated more interest or enthusiasm for renewed potential. This enthusiasm is sparked 
by new strategies for circumventing some forms of resistance and toxicity and by 
recognition of other related enzymatic targets. The following section will describe the 
status and applications of several important DHFR inhibitors in use or in clinically 
development as chemotherapy agents.  
The first antifolate of significance, aminopterin (4-amino-4-deoxy-pteroylglutamic acid, 
AMT, 90), was synthesized in 1949.87 Its only structural change from the folic acid is the 
replacement of the 4-oxo moiety of folic acid by a 4-NH2 group in AMT. This single 
structural change was sufficient to change an essential vitamin (folic acid) into a highly 
toxic drug. AMT was the first drug reported to induce remissions in children with acute 
leukemia.109 Although AMT is a more potent antifolate than MTX, its use was superseded 
by MTX in the early 1950s because of its toxicity profile unpredictable.110 Comparatively, 
AMT offers some advantages such as greater accumulation and metabolism by leukemic 
lymphoblasts in vitro 111 and more complete oral bioavailability;112 however, its 
unpredictable toxicity disfavored its use over MTX.113 Very recently, there has been 
renewed interest in the clinical use of AMT, especially, in pediatric acute lymphoblastic 
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leukemia.114 With the knowledge of antifolates gained in the last 50 years, changes in 













Methotrexate (4-amino-4-deoxy-10-N-methyl-pteroylglutamic acid, MTX, 84) was 
introduced into clinical service in the early 1950s and has remained the only antifolate in 
widespread use until the present time, despite numerous attempts to replace or 
complement it. MTX is commonly used to treat leukemia, osteosarcoma, breast cancer, 
and head and neck cancer.115 It is also used clinically in a variety of other pathogenic 
conditions, including rheumatoid arthritis, psoriasis, and graft-versus-host disease; in 
these cases lower doses of MTX are used and the effect is generally attributed to an 
immunosuppression phenomenon. 
MTX enters cells through an active carrier transport mechanism used by reduced folate 
carrier (RFC) or by binding to folate receptor and entering through an endocytic pathway. 
Once inside the cell, MTX is polyglutamylated, i.e., additional up to five glutamates are 
added via linkage to the gamma-carboxyl group of glutamate.116 MTX polyglutamates 
(MTXGn) are retained for longer periods in cells compared to MTX, thus the level of 
MTXGn achieved in tumor cells after MTX administration is an important determinant of 
cytotoxicity. MTX and MTXGn was found to nearly stoichiometrically inhibit the 
enzyme DHFR in vitro,117 although binding is reversible in intact cells.118 The primary 
mechanism by which DHFR inhibition causes cytotoxicity is the resulting inhibition of 
synthesis of dTMP and purine precursors for DNA synthesis. The inhibition of these 
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pathways probably occurs through three mechanism:118 (1) indirect inhibition through 
partial or full depletion of the cytosolic tetrahydrofolylpolyglutamate (H4PteGlun) pool 
thus limiting cofactor availability (2) direct inhibition of dTMP and/or the purine 
biosynthetic transformylases including GAR and AICAR by accumulated H2PteGlun (3) 
direct inhibition of dTMP and/or the purine biosynthetic transformylases by MTXGn. 
Decreased synthesis of dTTP, dATP, and dGTP due to the above effects may lead to 
rapid inhibition of DNA synthesis. Following inhibition of DNA synthesis, single and 
double strand breaks begin to accumulate in genomic DNA. These breaks occur because 
the progress of DNA synthesis is halted and/or because DNA repair processes continue to 
remove damaged or mismatched bases from DNA but cannot properly repair the resulting 
a basic sites because of deoxyribonucleotide triphosphate (dNTP) deficiency. Cell death 






















Clinically, MTX is perhaps unique among the other anticancer drugs in that an antidote 
leucovorin (6R,S-5-formyltetrahydrofolate, LV, 91) can be given after high-dose MTX 
therapy to reduce its toxicity.119 Although the exact mechanism of selective rescue is 
debatable, it is likely due to the competition of LV for transport and polyglutamylation. 
In addition, the competition for binding at DHFR by LV metabolites and, by supplying 
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one-carbon units on a tetrahydrofolate that can bypass the requirement for DHFR may 
also be the contributing factors to the resume therapy. These processes occur more 
efficiently in normal tissue than in tumors and thus normal cells are preferentially rescued.  
Despite its frequent utility, several problems are associated with the clinical use of MTX, 
such as: (1) high levels of toxicity to bone marrow and gastrointestinal mucosa120, (2) 
resistance to the drug accompanied by an elevation of levels of the target enzyme, 
DHFR121, and (3) the decrease in the transport of the drug. 122 The most common reason 
for the intrinsic resistance is a defect in the membrane transport of MTX.123 MTX also 
fails to penetrate the blood-brain barrier efficiently and thus cannot be used systemically 
to treat CNS relapse or brain tumors. 
Even though MTX is efficacious, its side effects and the evidence of resistance have 
limited its widespread use. Therefore, considerable effort has been invested in attempting 
to design more therapeutically selective antifolates or antifolates with a wider tumor 
spectrum in the hope that a new drug can be developed. Initially, the design was based on 
the burgeoning knowledge of folate-dependent pathways and the determinants of the 
mechanism of action of MTX. These determinants include transport, the tight-binding 
inhibition of its target DHFR and metabolism of MTX to MTXGlun. These early studies 
led to the development of other antifolate DHFR inhibitors of two types: (1) “classical” 
analogues that use the same cellular transport systems as MTX and are also metabolized 
to Glun; and (2) “nonclassical” (i.e., lipophilic) analogues that do not require transport 
systems and that are not metabolized to Glun. The latter property may be useful since 
deficient active transport of classical analogues like MTX may limit their tumor spectrum 
(i.e., be a cause of natural resistance). With few exceptions, these DHFR inhibitors 
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contain a 2,4-diamino heterocycle since this has generally been shown to be critical for 
stoichiometric binding to DHFR. So many analogues have been made, and the distinction 
between these two classes, once very clear, has now become somewhat blurred. Several 
of the most widely studied classical and nonclassical DHFR inhibitors are presented 
below.  
 
2.3.1.1 New Classical Antifolates 
A class of rationally designed derivatives of MTX, the 10-deaza-aminopterins (10-DAM, 
92), has demonstrated substantially greater antitumor effects than methotrexate,124 as well 
as excellent clinical activity in non-small cell lung cancer.125 The improved activity 
appears to be caused by more effective internalization by the one carbon, reduced folate 
carrier (RFC-1), and its subsequent accumulation in tumor cells through the formation of 
polyglutamylated metabolites. Its 10-ethyl analogues 10-EDAM (edatrexate, 92a) was 
promoted into a number of clinical trials.126 However, 10-EDAM did not show any clear 
advantage either in response or in toxicity over MTX. Another new analogue 10-
propargyl-10-deazaaminopterin (PDX, 92b) with the addition of a propargyl moiety at 
the carbon 10 position,127 yielded the best agent with regard to uptake into cells by the 
RFC-1 transporter and retention in the cell by polyglutamylation128. PDX was about 5 
times more potent than MTX as an inhibitor of growth in L1210 cells, but was only one-
third as potent as an inhibitor of DHFR from L1210. The analog was transported inward 
very effectively in L1210 cells showing a 10-fold advantage over MTX.127 It 
subsequently demonstrated dramatic antitumor activity in mouse xenograft models of 
human breast and lung cancers.128 The broad applicability of this new antifolate with 
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limited toxicity and proven efficacy in NSCLC encourage further development of this 
compound. Several trials are now underway combining PDX with other 


















2.3.1.2 New Non-classical Antifolates 
 
2,4-Diaminoquinazoline Derivatives 
Bertino et al tested 17 nonclassical 2,4-diamino-6-(anilino)methyl-quinazoline antifolates 
as inhibitors of DHFR from L1210 leukemia cells and from human leukemia cells in 
1979, which is part of a large rescreening effort of compounds originally developed as 
potential antimalarial agents.129 Several potent inhibitors of this enzyme displayed 
activity comparable to that of MTX. In general, the potency of DHFR inhibition was 
correlated to the inhibition of cell growth in vitro against L1210 cells. One of this 
compounds, the trimetrexate (TMTX, 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino) 
methyl] quinazoline, 93), was further evaluated. Cross inhibition studies revealed that 
TMTX did not use the RFC system for uptake; this was consistent with its nonclassical 
lipophilic structure.130-131 Since TMTX does not contain a pABGlu moiety in the side 
chain, it is not an FPGS substrate; it also does not inhibit FPGS. TMTX is essentially as 
potent an inhibitor of human DHFR as is MTX.132 Once inside the cell, the mechanism of 
action of TMTX is similar to that of MTX and leads to a block in early S-phase of the 
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cell cycle.133 TMTX was chosen for further development because of its potent inhibition 
of DHFR and its slightly greater potency relative to MTX in inhibiting the growth of a 
range of murine tumor models both in vitro and in vivo and TMTX could overcome some 
types of natural MTX resistance and thus extend the tumor range of antifolates.133-134 An 
interesting sidelight is that TMTX has found some use as a treatment for the opportunistic 
infections of AIDS patients, in particular for Pneumocystis carinii.135 TMTX (Neutrexin) 
has been approved for the treatment of P. carinii. pneumonia in 1993. Due to its inherent 
















The 4,6-diamino-1,2-dihydro-1,3,5-triazines were developed initially as antimalarial 
agents. This class of compounds was found to inhibit the plasmodial DHFR and was also 
studied clinically against cancer in the 1950s. However, it appeared to have a less 
satisfactory therapeutic index than MTX and was believed to offer little advantage at that 
time.136 In the 1960s, Baker focused his work on the diaminopyrimidines and the 4,6-
diamino-1,2-dihydro-1,3,5-triazines.137 The primary reason for the selection of these 
inhibitors was the fact that they could penetrate cell walls by passive diffusion and 
therefore could tolerate the gross structural changes necessary for the design of an ideal 
inhibitor. Numerous active-site-directed reversible and irreversible inhibitors of DHFR 
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were synthesized and evaluated.138 Several active-site-directed irreversible inhibitors and 
some reversible inhibitors were considerably more effective than MTX.139 However, 



























Further efforts were made to optimize the physicochemical properties of the inhibitors, 
led to triazinate (TZT, 94). TZT has a good balance of hydrophilicity and lipophilicity 
that enable them to be water soluble and yet able to diffuse across the cell membrane.140 
Triazinate was found to be the most effective compound against the Walker 256 and the 
Dunning leukemia of all the nonclassical antiloate synthesized. It also generated 
substantial excitement as a potential antitumor agent in man because of its capacity to 
penetrate the blood-brain-barrier. However, its development was halted when it was 
found to be associated with neurological and cutaneous toxicity.  Another triazinate folate 
antagonist, 3-chloro-4-(4-(2-chloro-4-(4,6-diamino-2,2-dimethyl-1,3,5-triazin-1-(2H)-
yl)phenyl) butyl)benzene sulfonyl fluoride (NSC-127755, DTBSF, 95) was also 
investigated for antitumor activity.141 It was found to be an irreversible inhibitor of DHFR, 
and its mechanism of action was determined to be an alkylation of the enzyme through 
the sulphonyl group.142 It was highly active against transplantable colon carcinomas and 
the Dunning murine ovarian tumor M5076. Recently, Antoniadou-vyza et al. patented a 
new series of 4,6-diamino-1,2-dihydro 1,3,5-triazines 96 that carried an adamantyl group 
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at 2-position of the triazine ring. These compounds act as inhibitors of cell proliferation. 
The activity is attributed to the inhibition of DHFR. It has been claimed that they exhibit 
anticancer, antimicrobial, antiparasitic activity.143    
  
2,4-Diaminopyrimidines 
2,4-Diaminopyrimidines were developed as potential therapeutic agents for the treatment 
of leukemia. 2,4-Diamino-5-(3’,5’-dichlorophenyl)-6-methylpyrimidine (DDMP, 
metoprine, 97) was found to be one of the most effective pyrimidine analogues in 
inhibiting tumor growth.144 But the outcomes from clinical trials suggested that metoprine 
was not as effective as MTX used for the same medication; the clinical interest was thus 
abandoned.145 However, as more information about the mechanism of action, enzyme 
selectivity, and drug resistance became available, the potential of the use of 
diaminopyrimidines as antitumor agents became more evident and this class of antifolates 















In the 1980s, interest was centered on 2,4-diamino-6-(2,5-dimethoxybenzyl)-5-
methylpyrido[2,3-d]pyrimidine (piritrexim, PTX, 98), which was reported to be as 
effective as MTX as an inhibitor of mammalian DHFR.146 PTX is lipophilic, not 
dependent on the RFC for transport, cannot form polyglutamate derivatives and is a 
potent (IC50 = 5 nM) mammalian DHFR inhibitor.146 In addition to being a good DHFR 
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inhibitor, the mechanism of action of PTX may be somewhat different from that of 
TMTX (or MTX) since metabolite protection in murine cells requires adenosine and 
cytidine in addition to thymidine and hypoxanthine. PTX has at least three major 
advantages over TMTX in that it is orally active (bioavailability > 75% 147), rapidly 
cleared, and does not inhibit histamine metabolism. In clinical studies, PTX has been 
principally developed as an oral lipophilic antifolate.148 The most common dose-limiting 
toxicity is myelosuppression, with mucositis occurring somewhat less often. Several 
phase II clinical trials have been done so far149, however, whether PTX has any 
therapeutic advantage over more established antifolates such as MTX or TMTX must still 
be proven. 
 
2.3.2 DHFR Inhibitors as Antibacterial Agents 
The success of trimethoprim (TMP) as an antibacterial agent which surprisingly showed a 
30,000-fold greater affinity for bacterial than for mammalian DHFR attracted many 
competitive programs in this field.150 Dozens of publications appeared, and literally 
hundreds of compounds were synthesized, tested for antibacterial activity, and in many 
instances tested for activity against isolated bacterial DHFR.151 However, none of those 
compounds to date has produced anything to cast doubt on the wisdom of the original 
selections. In recent years, only limited efforts have been directed towards the study of 
DHFR inhibitors for common bacteria. Kuyper et al. designed a series of TMP analogues 
to mimic the conformation of the drug, TMP, as observed in its complex with bacterial 
DHFR.152 Of the analogues prepared, 2-amino-4-methyl-5-(3,4,5-trimethoxyphenyl)-7H-
pyrrolo[2,3-d]pyrimidine showed good inhibitory activity against four bacterial DHFR 
enzymes with potency similar to TMP However, it is significantly less selectivity than the 
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reference compound. Efforts aimed at the identification of selective and potent DHFR 
inhibitors for Gram-positive bacteria, particularly S. aureus, yielded iclaprim (ICL, 99), 
which is more active than TMP against both wild-type and TMP-resistant S. aureus 
strain.153 In 2003, ICL successfully completed phase II clinical trials for complicated skin 
and skin structure infections in hospitalized patients. The development of even more 
potent and selective inhibitors failed, largely because of the high level of binding to 










Mycobacterium tuberculosis and particularly the multi-resistant strains pose emerging 
threats to public health in many countries, and new drugs are urgently needed. No DHFR 
inhibitor is currently used for tuberculosis treatment. The triazine DHFR inhibitor 
WR99210 (89) has been shown to exhibit reasonable in vitro activity against M. 
tuberculosis, as well as against other mycobacteria.155 The selectivity of WR99210, 
however, is not sufficient for use as an antimicrobial agent because it shows poor 
gastrointestinal tolerance. The three-dimensional structure of the M. tuberculosis DHFR 
complexed with several inhibitors has been solved, and the enzyme has been 
characterized.106 Although the general fold of the protein is essentially the same as that of 
the human enzyme, a number of differences was detected, which could be exploited for 
inhibitor design.   
  INTRODUCTION 
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Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium, are three of the 
pathogenic organisms most often responsible for opportunistic morbidity and mortality in 
people with AIDS and other immune disorders.156 Therapeutic intervention is limited by 
the dearth of safe and effective antiparasitic and antifungal agents. Low doses of co-
trimoxazole are used for the treatment and prophylaxis of Pneumocystis pneumonia.156 
An alternative treatment with PTX, TMTX, or both,157 both potent inhibitors of the target 
enzyme but lacking selectivity for the mammalian DHFR, requires concomitant and 
expensive rescue therapy with LV. Thus, the goal of the research efforts in this area is the 
design and synthesis of antifolates for use against one or more of the abovementioned 
organisms and selective enough not to require LV rescue. A number of pyrimidines, 
phenyl dihydrotriazines, purines, and quinazolines were synthesized as potential 
inhibitors of P. carinii DHFR and T. gondii DHFR and rat liver DHFR. Two groups, 
namely, those of Andre Rosowsky158and Aleem Gangjee159 have made major 
contribution to the development in this area.  
 
2.3.3 DHFR Inhibitors as Antimalarials and Other Antiprotozoal Agents 
Malaria each year kills about 2 million children and debilitates over 500 million 
individuals worldwide, and its incidence continues to increase.160 Although the need for 
antimalarial agents is acute, in recent years very few new antifolates have been designed, 
synthesized, and tested against Plasmodium spp., the causative agent of malaria. The 
research in this field has been concentrated almost exclusively in academia, because most, 
if not all, big pharmaceutical companies terminated their engagement in tropical diseases 
in the past decade. 
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An inspiration and a fresh start for the design and discovery of novel folate inhibitors was 
provided by the publication of the 3-D structure of Pl. falciparum DHFR-TS, the target 
for the clinically established antimalarial drugs PYR and cycloguanil. The structure 
reveals insights to the nature of inhibitor WR99210 binds as a complex with NADPH and 
2’-deoxyuridylate in drug resistance and autologous gene repression, all of which 
influence species-specific drug sensitivity.161 
PS-15 (100) is a prodrug of WR99210. It is metabolized in vivo to the active form by 
microsomal mixed-function oxidases. Both compounds are active against Pl. falciparum 
and P. carinii infections in vivo and are active against M. avium complex in vitro.162 
Recently twenty-two novel analogues of PYR and twenty-four of cycloguanil (CYC) 
represented in 101 and 102 respectively have been synthesized and evaluated for 
inhibitory activity against the Pl. falciparum DHFR that carries triple and quadruple 
mutations which are responsible for antifolate resistance.163 The inhibitors were designed 
to avoid steric clashes in the active site of the mutant enzymes. The action of the 
compounds demonstrates the feasibility of developing antifolates against mutated targets 
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Leishmaniasis, African trypanosomiasis (sleeping sickness) and Chagas’ disease are 
major causes of mortality and cause much economic hardship, particularly in the 
developing world. In addition, Leishmaniasis is increasingly posing as a complication 
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with AIDS patients. The World Health Organization estimates that millions of people are 
infected, or are at risk, from these diseases. The enzyme DHFR has not been fully 
investigated in the parasitic protozoans Leishmania and Trypanosoma. The structure of 
the enzyme and the enzyme specificity is significantly different from that of the human 
enzyme suggesting the possibility of designing selective drugs. However, DHFR 
inhibitors that are currently used in the clinics are not suitable for the treatment of the 
diseases caused by Leishmania and Trypanosoma. Hence, there is need for development 
of new and selective inhibitors, which are active in vivo. 
In summary, DHFR inhibitors seemed to be useful in the treatment of a variety of disease 
conditions as discussed before. This is because DHFR is present in human as well as 
bacteria and certain parasites. This area has been the subject of intense investigation. No 
other traditional area of cancer chemotherapy has generated more interest or enthusiasm 
for renewed potential. Advances in X-ray crystallographic techniques have made the co-
crystallization of the inhibitor with DHFR possible and this facilitated the design of 
antifolates tremendously. DHFR is also an important target in the design of antibacterial 
and antiprotozoal agents. Hence, it is a challenge to develop a novel and potent antifolate. 
The synthesis and testing of a few series of antifolates against mammalian DHFR, 
bacterials and various cancer cell lines will be reported in the later part of this dissertation. 
 
2.4 Antifolates Used as Antiepileptic Sodium Channel Blockers 
Often molecules are discovered or synthesized for one indication and then turn out to be 
useful for others. This serendipity did bring many drugs to the market, such as tamoxifen 
(birth control vs cancer), viagra (hypertension vs erectile dysfunction), salvarsan 
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(sleeping sickness vs syphilis) and interferon-α (hairy cell leukemia vs hepatitis). It is a 
well known strategy in the search for new lead compounds that a rational drug design is 
based on the knowledge of the molecular cause of the pathological dysfunction.168 Before 
starting a costly HTS campaign, it can represent an appealing alternative. Once the initial 
screening has provided a hit, it will be used as the starting point for a drug discovery 
program. By use of traditional medicinal chemistry as well as parallel synthesis, the 
initial “side activity” is transformed into the main activity, and conversely, the initial 
main activity is strongly reduced or abolished. This strategy leads with a high probability 
to safe, bioavailable, original, and patentable analogues.164 
Example that relate to the antifolate area is the design of a triazine derivative lamotrigine 
(4) as an anticonvulsant drug. In 1960, Noell et al. demonstrated that convulsions in rats 
could be provoked by the intraventricular injection of minimal doses of folic acid, and by 
LV, MTX and AMT.165 Spector reported an inhibitory action of methotrexate on the 
frequency of leptazol-induced seizures in rats. This effect was nullified by the 
pretreatment with folic acid.166 It indicated that not only folic acid, but also its derivatives 
could be important in epileptogenesis. On the other hand, it is possible that epileptogenic 
effect of sodium folate derives from one of its constituents such as pterin, para-amino-
benzoic acid (PABA) or glutamic acids, although glutamic acid in particular has 
depolarizing and convulsant properties.167 Although the mechanism of the epileptogenic 
effects of sodium folate is still unknown, the observation that folates induce seizures in 
animals prompted a screen of putative antifolates as anticonvulsant agents. Lamotrigine, 
a phenyl-1,2,4-triazine, emerged from this screening process. Lamotrigine has proven to 
be a promising new treatment of partial and generalized tonic-clonic seizure.168 In 
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addition, it may also have utility in the management of Lennox-Gastaut syndrome as well 
as primary generalized epilepsy with absence attacks. 
Despite the original rational for its design as antifolate analogues of pyrimidine, 
lamotrigine has only weak antifolate activity, and this is almost surely not the mechanism 
of its anticonvulsant action. However, its spectrum of activity in both animal seizure 
models and human epilepsies is similar to that of the prototypic antiepileptic sodium 
channel blockers phenytoin and carbamazepine, suggesting that sodium channels may be 
the molecular target of this new anticonvulsant.169 Sodium channels play an important 
role in the neuronal network by transmitting electrical impulses rapidly throughout cells 
and cell networks, thereby coordinating higher processes ranging from locomotion to 
cognition. These channels are large transmembrane proteins, which are able to switch 
between different states to enable selective permeability for sodium ions. For this process 
an action potential is needed to depolarize the membrane, and hence these channels are 
voltage-gated.170 The antiepileptic drug phenytoin was a milestone in the recognition of 
the potential of neuronal sodium channels blocker in CNS-related disorders. It became 
apparent that voltage-gated sodium channels could be targeted, either selectively or in 
combination with other cellular processes, for the treatment of stroke, epilepsy, and 
several types of neuropathic pain.  
As said by Sir James Black, winner of the 1988 Nobel prize in Physiology and Medicine  
“The most fruitful basis for the discovery of a new drug is to start with an old drug.” A 
series of triazines antifolate like compounds based on this serendipitous strategy will be 
reported in the next part of the dissertation for their sodium channel blockade activity and 
potential in vivo properties.  
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2.5 Pharmacological Evaluations 
The molecular designing of drugs for specific purposes (such as enzyme inhibition, anti- 
cancer efficacy, etc.) which is based on knowledge of molecular properties and also on 
information cataloged on analogue molecules need to be validated using pharmacological 
evaluations. The pharmacological evaluations involve in vitro and in vivo researches. In 
vitro research aims to describe and understand the effect of an experimental variable on a 
subset of an organism's components. In vivo research differentiates whole organism 
research from in vitro research. In vivo research is more suited to observe an overall 
effect than in vitro research, which is better suited to deduce mechanisms of action. 
Triazines have been evaluated for a variety of biological activity. In this study, a range of 
pharmacological assays were used and will be reported in this dissertation. Thus, the next 
section will introduce these  the important in vitro and in vivo experiment carried out in 
the study.    
 
2.5.1 DHFR Inhibitory Activity by Enzyme Kinetics Assay 
Dihydrofolate reductase catalyzes the reversible reduction of DHF to THF by NADPH as 
shown in Scheme 40. At neutral pH, the reaction normally proceeds in the forward 
direction and the production of THF is strongly favoured.171 This makes the practical 
assay of DHFR activity possible. The most commonly used assay method is the UV 
spectrophotometric assay developed by Osborn and Huennekens in 1958.172 This assay is 
based on the decrease in UV absorbance at 340 nm, which is a result of the oxidation of 
NADPH and the reduction of DHF. NADPH absorbs maximally at 340 nm, but NADP+ 
does not. When DHF, DHFR and NADPH are incubated together under physiological 
  INTRODUCTION 
 
 61
pH, DHF is reduced to THF and NADPH is oxidized to NADP+. The absorbance at 340 
nm will decrease as the NADPH is oxidized to NADP+ and the rate of decrease in 
absorbance is equivalent to the rate of DHFR activity. 
In the presence of an inhibitor, the decrease in absorbance at 340 nm occurs at a slower 
rate. Competitive DHFR inhibitors compete with the substrate (DHF) for the enzyme. 
Those with very strong affinity for the enzyme will cause a tremendous drop in DHFR 
activity, which is reflected as a reduction in the rate of absorbance decrease over time. By 
comparing the different rates in the presence and absence of DHFR inhibitors, the 
binding affinity of various inhibitors can be determined. 
The potency of inhibitors can also be determined using this spectrophotometric assay. 
Different concentrations of the inhibitor can be used in the assay and the concentration 
which causes 50% inhibition of DHFR activity (IC50) can be found from a plot of the 
percentage of inhibition versus concentration of inhibitor. Potent DHFR inhibitors will 
have low IC50 values. 
This enzyme assay can be utilized in another way to investigate the exact nature of the 
enzyme inhibitor. A standard double-reciprocal plot of 1/velocity of enzyme against 
1/substrate concentration (Lineweaver-Burk Plot) at various levels of the inhibitor can 
reveal whether the inhibition is competitive, uncompetitive, non-competitive or mixed.173-
175  Hence, this spectrophotometric assay is a very versatile assay and it can be used to 
investigate the binding affinity, potency and nature of the enzyme inhibitor. It can also be 
used to determine the activity of DHFR. 
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2.5.2. Antiproliferative Assay 
The evaluation of antineoplastic agents on human tumor cell lines in culture often relies 
on traditional assays of cell growth such as physical cell count, autoradiography, 3H-
thymidine incorporation, cell protein measurements or clonogenic growth assays.176-181 
Although these methods can yield unique information on different aspects of cell 
proliferation, they are time consuming and labor intensive and generally involve 
cumbersome preparative and analytical steps. In many areas of biomedical research, 
including preclinical anticancer drug development programs, there is consequently a need 
for more simplified and rapid methods, allowing large number of small samples to be 
analyzed accurately at a minimum cost of time and labor. 
Larsson and Nygren developed a fluorometric method for the determination of cellular 
growth and cytotoxicity of human tumor cell lines in 96-well microculture plates in 
1989.182 This method is commonly known as Fluorometric Microculture Cytotoxicity 
Assay (FMCA), which is rapid, reliable, sensitive and inexpensive and does not involve 
the use of radioisotopes. In this assay, fluorescein diacetate (FDA) was used as the 
fluorogenic substrate. The non-fluorescent FDA rapidly enters intact cells and is 
hydrolyzed to its fluorescent derivative fluorescein which is retained intracellularly for 
some time by cells with intact plasma membranes.183 The amount of FDA flurescence 
produced and retained by the culture from this dye can be measured at 485 nm and 535 
nm and it is linearly related to the number of intact cells. 
The FMCA has been found to be suitable for drug sensitivity testing of hematological as 
well as solid tumor cells.184-185 The in vitro results correlate favorably with the clinical 
outcome in patients with leukemia or non-Hodgkin’s lymphoma (NHL) and other solid 
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tumors.186-187 The feasibility of using this assay for drug screening had been tested in 
more than one hundred human cancer cell lines and it was found to be a rapid, sensitive, 
reproducible and convenient assay. Hence, FCMA is adapted for the routine screening of 
drugs, including antifolates, for potential antiproliferative activity.     
 
2.5.3. Antibacterial Assay 
The mechanistic strategy underlying the action of antibacterial agents involves the 
exploitation biochemical differences between an infecting organism and the host to 
achieve selective eradication of the infecting organism. These differences enable an 
antibiotic to target the infecting organism and impair one of its critical biochemical 
processes without harming the host. For example, TMP and PYR inhibit the conversion 
of DHF to THF by bacterial forms of DHFR. The human form of DHFR is relatively 
insensitive to the inhibition by these drugs.  
For any given clinical situation, some antibiotics will be effective and reliable, while 
others will be ineffective or unreliable. It is misleading to classify antibiotics as being 
either strong or weak because the relative effectiveness of different antibiotics varies with 
the clinical situation. Therefore, the notion of antibiotic strength has little meaning.188 
Rather than the strength, or even the potency of an antibiotic, it is more important to 
consider four other parameters of antibiotic effect.189 
First, among these measures, is the determination of the test compound’s spectrum of 
activity. The action of antibiotics are classified as being narrow spectrum or broad 
spectrum depending on the number of different bacterial species against which they 
exhibit useful activity. A broad-spectrum antibiotic is not necessarily advantageous, 
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because narrow-spectrum agents are often just as effective and sometimes even more 
effective at killing bacteria than broad-spectrum agents. So for the primary screen, the 
choice of organisms would broadly include Staphylococcus aureus, Escherichia coli, 
Pseudomonas aeruginosa and Microbacterium smagmetis. It is useful to test for activity 
against fungi at this stage, using for example Candida albicans and Aspergillus niger.  
A second important measure of antibiotic effect is bacterial sensitivity. Sensitivity is 
measured by assessing the ability of a bacterial strain to replicate following antibiotic 
exposure. Permanent loss of replicative ability implies that an antibiotic is bactericidal, 
while temporary loss with the resumption of growth and replication following removal of 
the antibiotic implies that it is bacteriostatic. A distinction is made between the minimum 
concentration of an antibiotic needed to inhibit growth (the minimum inhibitory 
concentration or MIC), and the minimum concentration needed to kill an organism (the 
minimum bactericidal concentration or MBC). However, it is usually not clear how 
quantitative differences in antibiotic concentration are mechanistically linker to 
qualitative differences in result (bacteriostatic vs bactericidal). The broth dilution 
approach may be used to determine either an MIC or MBC. To determine the MIC of an 
antibiotic against an organism, the organism is simply inoculated into tubes of culture 
broth containing various concentrations of antibiotic. The lowest antibiotic concentration 
that inhibits growth is the MIC. To determine the MBC, the organism is inoculated into 
tubes of culture broth containing various concentrations of antibiotic as in a MIC 
determination. After a period of time, samples from each tube are removed and 
inoculated into antibiotic-free media. The lowest antibiotic concentration that prevents 
subsequent growth in the antibiotic-free media is the MBC. The other method for 
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determine the bacterial sensitivity is agar diffusion or disk diffusion tests. The test is 
performed by overlaying a thin agar slab with live organism, and then overlaying a paper 
disk that contains a known amount of antibiotic. The antibiotic slowly diffuses out of the 
disk, eventually distributing evenly throughout the agar. As antibiotic diffuses out of the 
disk, however, regions in the agar close to the disk experience a relatively high peak 
concentration of antibiotic; regions further from disk experience progressively lower peak 
concentration. For regions in the agar in which the integrated antibiotic concentration 
over time is above a characteristic threshold, the growth of organisms on the agar will be 
inhibited, and this will be visible as a clear “zone of inhibition” around the disk. The 
lower the susceptibility of an organism to the antibiotic, the larger the zone of growth 
inhibition. The simplicity and low cost of this method makes it advantageous over broth 
dilution methods for the primary screening.  
A third important measure of antibiotic effect is therapeutic index. This is the ratio of the 
minimum concentration likely to produce an adverse effect to the minimum concentration 
needed to produce the desired effect. 
A fourth measure of antibiotic effect is the ability to penetrate and reach the infecting 
organism. Antibiotics are unique among pharmacological agents in that their site of 
action may be in any body compartment, or simultaneously in multiple compartments. 
Delivery of antibiotic to the site of infection is often the most difficult challenge of 
antibiotic therapy. 
Therefore, in the evaluation of antifolate as antibiotic agents, the four measures must be 
considered. However, in the primary stage of development, the antifolate compounds in 
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this dissertation will be focused on the first two measures: the spectrum and sensitivity. 
The detailed methods will be discussed in the experimental section. 
 
2.5.4. Sodium Channel Blockade Assay 
The sodium channel blockade assays have been applied to identify compounds that may 
have the potential to interfere with the functions of sodium channels.  The assays range 
from the low-throughput (but high information content) techniques such as 
electrophysiology to the high-throughput, lower-information-content assays such as the 
simple ligand binding experiments.170 Typically this measurement may involve an initial 
binding assay where the target site of action is known and a suitably labeled ligand is 
available, or a flux assay where any means of modulating ion flux through the target 
channel is of interest. These primary assays may be followed perhaps by patch-clamp 
electrophysiology to provide direct evidence of a functional effect at the required target. 
The former two techniques have formed the core of drug discovery efforts in the sodium 
channels investigation for many years. 
While the three-dimensional structure of sodium channels has not been solved, models 
have been derived to explain how the sodium channels may be embedded in the 
membrane (Figure 9). Thus the R-subunit has a modular architecture of four homologous 
domains (DI-DIV) each consisting of six transmembrane segments (S1-S6). The regions 
between the S5 and S6 segments (the P segment) in all four domains of the protein should 
fold to form part of the extracellular entrance of the channel with the S6 segments lining 
the ion-conducting pore. There is a marked asymmetry in the contribution of each domain 
to the permeation pathway, and the S5 and S6 regions from DIII and DIV have been 
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shown to play a particularly prominent role in the determination of sodium ion selectivity. 
In particular this model, which places the S6 segments facing the pore of the channel and 
the S5 segments facing the lipid portion of the membrane, predicts a binding site for local 
anaesthetics and anticonvulsants on DIV S6. 
 
 
Figure 9. Model of sodium channels embedded in membrane.170 
Binding studies have revealed the presence of multiple neurotoxin binding sites on the 
sodium channels, as well as additional (or overlapping) sites for drug classes such as 
anticonvulsants, local anesthetics, and the pyrethroid class of insecticides. The voltage-
sensitive sodium channels in nerve and neuroblastoma cells have three separate receptor 
sites for neurotoxins associated with protein components of the channels.190 The 
inhibitors tetrodotoxin and saxitoxin are known to bind at receptor site 1 and inhibit ion 
flux through the sodium channels. Grayanotoxin and the alkaloids veratridine, 
batrachotoxin, and aconitine are believed to act at receptor site 2 to cause persistent 
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activation of sodium channels. The polypeptides scorpion toxin and sea anemone toxin 
bind at receptor site 3. These toxins slow the sodium channels inactivation and enhance 
persistent activation of sodium channels by toxins acting at site 2 through an allosteric 
mechanism. Neurotoxins acting at these three receptor sites have been valuable probes 
for the structure and functions of the sodium channels. Radioactive derivatives of 
saxitoxin, tetrodotoxin, scorpion toxin, and sea anemone toxin have been prepared and 
used in direct binding studies to examine the properties of receptor sites 1 and 3. Direct 
binding studies of receptor site 2 have proven difficult because the ligands acting at that 
site are hydrophobic and have relatively low affinity.191 Brown et al. have described the 
preparation of a radiolabeled congener of batrachotoxin, batrachotoxinin A-20-a-
benzoate, shown that this derivative retains full biological activity, and studied its binding 
to lysed and washed membrane preparations from mouse brain.196 Specific binding of 
[3H]BTX-B was observed but, because of the low affinity and high lipid solubility of the 
toxin, specific binding was less than 10% of total binding.192 One approach to circumvent 
these difficulties is to take advantage of the positively cooperative interaction between 
batrachotoxin and scorpion toxin to enhance the affinity of [3H]BTX-B binding and 
thereby increase the ratio of specific to nonspecific binding. In the presence of scorpion 
toxin, binding of [3H]BTX-B is enhanced 10- to 20-fold so that approximately 75% of the 
toxin binding is specific.190 Under these conditions, interaction of ligands with neurotoxin 
receptor site 2 can be accurately and conveniently examined. Since the drug binding site 
has partial overlap with and is allosterically linked to neurotoxin site 2, drug binding 
causes release of specifically bound [3H]BTX-B. While this assay does not directly 
provide information regarding modifications of the functions of the sodium channels, it 
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remain to be extremely useful for the preliminary evaluation of binding for newly 
synthesized ligands.193   
 
2.5.5. in vivo Anticonvulsant Experiment  
The role of sodium channels in epilepsy, ischemia, pain, drug dependency, and many 
other areas is well documented. In 1975, the epilepsy branch of the national institute of 
neurological and communicative disorders and stroke (NINCDS) established an 
anticonvulsant drug screening project that is still ongoing. Since 1975, several thousand 
chemical compounds have been tested for anticonvulsant activity and neurotoxicity.194 
The strategy of testing involves the determination of the anticonvulsant activity using a 
battery of tests. These tests detect, on one hand, the anticonvulsant activity resulting from 
the prevention of seizure spread (MES test and strychnine test) and, on the other hand, 
the anticonvulsant activity related to the elevation of seizure threshold (sc Met test, 
bicuculline test and picrotoxin test). In addition, a battery of toxicity tests is performed, 
designed to determine the minimal median neurotoxic dose, the 24-hour median lethal 
dose, and the profile of the overt toxic manifestations. The sequence of the testing 
consists of the determination of the anticonvulsant activity in laboratory animals in 
electrically induced seizures and chemical induced seizures followed by determination of 
the acute toxicity. 
Maximal Electroshock Seizure (MES) test (Electrically Induced Seizures)195 
In this test, animals are stimulated at determined time of peak effect, through auricular 
electrodes by a 60-cycle alternating current applied for 0.2 or 0.3 second. The current 
used in mice is normally a 45 mA. And in rats, a 150 mA current is usually applied. The 
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characteristics of electroshock seizure are a tonic limb flexion of 1 to 2 seconds followed 
by a tonic limb extension of roughly 10-12 seconds, and finally generalized clonic 
movements for 12 seconds. The total duration of the seizure is approximately 25 seconds. 
Only abolition of the hindlimb tonic extensor spasm is recorded as the measure of 
anticonvulsant potency. The tonic component is considered abolished if the hindleg 
extension does not exceed at a 90o angle with the plane of the body. Following drug 
administration, the animals are challenged at intervals of ½, 1, 2 and 4 hours. The 
intervals at which the greatest percentage of animals is protected by the approximate 
ED50 dose are recorded as the time of peak effect. Abolition of the tonic-extensor 
components of the electroshock seizures indicates that the compound has the ability to 
prevent seizure spread and helps to select drugs likely to be effective in generalized 
seizures and complex partial seizures.  
Subcutaneous Metrazole Seizure Threshold (sc Met) test (Chemical Induced 
Seizures)195 
A dose of pentylenetetrazole (Metrazole) at 85 mg/kg subcutaneously in mice causes 
seizures in more than 97% of animals. This is called the convulsive dose 97, or CD97. In 
rats, the CD97 is 70 mg/kg. This test measures the ability of anticonvulsant drugs to 
provide complete protection against seizures induced by subcutaneous injection of a CD97 
of pentylenetetrazole. A threshold convulsion is defined as one episode of clonic spasms 
that persists for at least 5 seconds. The ability of the compound to elevate the 
pentylenetetrazole seizure threshold is determined by the absence of clonic seizures 
during a 30 min period. In this test, succinimides and oxazolidinediones are particularly 
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effective. Because these drugs are effective in the treatment of absences, the assumption 
is the sc Met tests indicate drugs likely to be active against absences. 
Determination of Acute Toxicity196 
Acute toxicity induced by a chemical compound in laboratory animals is usually 
characterized by some type of neurologic abnormality. In mice, the endpoint for the 
toxicity is measured by the rotorod test and the righting reflex. In rotorod test, a normal 
mouse maintains its equilibrium for a long time when placed on a rod that rotates at a 
accelerating speed from 4 to 40 rpm over 5 min. Neurologic deficit is exhibited by the 
mouse that it fails to maintain its equilibrium for a minute on this rotating rod in each of 
three trials. For the righting test, if a mouse is placed on its back, the animal will quickly 
right itself and assume a normal posture. Neurologic deficit is indicated by the animal’s 
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3 RATIONALE AND OBJECTIVES 
MTX is a very potent DHFR inhibitor which has been used clinically for more than 40 
years in the treatment of certain types of leukemia, lymphoma and solid tumors, as well 
as rheumatoid arthritis and psoriasis.115 In vitro research has showed that it inhibits 
mammalian DHFR almost stoichiometrically and its inhibition of cancer cell growth is 
known to occur in the nanomolar concentration range.117 MTX seems to be an ideal 
anticancer agent, however, several problems are associated with the clinical use of 
MTX,120-122 such as: (1) high level of toxicity to bone marrow and gastrointestinal 
mucosa is common; (2) resistance to the drug is accompanied by an elevation of the level 
of the target enzyme, DHFR and (3) the decrease in the transport of the drug across the 
cell membrane. Drug resistance has been partially overcome by the use of a combination 
of different drugs with different mechanisms of action. However, this is not ideal as the 
patient is subjected to more adverse effects from the other drugs and taking more drugs at 
the same time can lead to non-compliance to the drug therapy. Cost is also a concern 
when more drugs are prescribed to treat a single disease. Although MTX is a very potent 
inhibitor of mammalian DHFR, it is not selective in its action. Normal cells are killed 
simultaneously when cancer cells are being attacked by the drug. To overcome this, a 
rescue agent, LV is given to the patient to rescue the normal cells.119 By doing this, some 
of the cancer cells are also given a chance to revive. Hence, using LV to salvage normal 
cells is not an ideal solution to the toxicity problem. A more potent, selective and less 
toxic drug must be designed to replace MTX as an anticancer agent.  
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1,3,5-Triazines have been identified as non-classical antifolates, since it has been found 
that this class of compounds interferes with folic acid metabolism and has shown promise 
in cancer chemotherapy. This came about as a result of work that generated a non-
classical antifolate known as Baker’s Triazinate (94) in the 1960s.137 This compound was 
found to be a very potent anticancer agent in rats as well as human. The discovery of this 
compound set off an avalanche of research and interest in the design of triazine 
antifolates for cancer chemotherapy. Baker’s Triazinate belongs to a class of compounds 
known as phenyldihydrotriazines. This class of compounds was found to be more active 
against mammalian DHFR as compared to bacterial or parasitic DHFR. Baker’s triazinate 
is more lipophilic than MTX and it has the potential to cross the blood-brain barrier for 
the treatment of brain tumor. It was also found to be useful in other types of solid tumors 
due to its ability to enter mammalian cells by passive diffusion without active transport. 
This property of Baker’s triazinate, that the antifolates do not require reduced folate 
carrier (RFC) for cell entry, stimulated researchers to synthesize different kind of 
lipophilic antifolates which may circumvent the acquired-resistance of cancer cell due to 
the defective transport of MTX. Rosowsky et. al. found that a human cancer cell line 
which was transport resistant to MTX retained its sensitivity to lipophilic derivatives of 
MTX.197 A quantitative structure-activity relationship (QSAR) study conducted by Coats 
et. al. also proved that MTX-resistant cells were resistant to highly hydrophilic inhibitors 
like MTX but not to the lipophilic inhibitors.198 Finally, the work of Allega and his 
colleagues in developing TMTX as an agent for treatment of P. carinii pneumonia 
deserves mention as an elegant example of biochemical modulation.199 The combination 
of TMTX and LV is very active and nontoxic for the treatment of P. carinii infections in 
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AIDS patients. The basis of this selectivity is that the fungus does not transport reduced 
folates, but the lipophilic molecule TMTX is able to enter cells of both fungus and the 
host; the TMTX treatment is then followed by LV, which rescues the host cells but not 
those of the P. carinii cells. This strategy has been applied on selectively target leukemic 
cells that developed resistance to MTX on the basis of transport using lipophilic TMTX 
with LV.200 These reports prompted the present study, which aimed to design lipophilic 
antifolates based on the 4,6-diamino-1,2-dihydro-1,3,5 triazines structure with the hope 
of overcoming the drug resistant problem faced by MTX. 
 X-ray crystallographic studies of enzyme DHFR and inhibitor complexes have been 
identified as important tools for the design of antifolates. Crystallographic studies of 
ternary complexes formed with six 4,6-diamino-1,2-dihydro-1-phenyl-1,3,5-triazines and 
chicken liver DHFR were carried out by Matthews et al.100 As shown in this study, the 
parent phenyldihydrotriazine (87) itself governs the overall mode of binding at the active 
site of DHFR. The triazine heterocycle, which has a pKa of nearly 11 when bound to 
DHFR, interacts with the side chain of Glu-30 by way of charge-mediated hydrogen 
bonds at N3 and the 4-amino group. In addition, the 4-amino group donates a second 
hydrogen bond to a highly ordered and structurally invariant bound water molecule. 
Additional hydrogen bonds exist between the inhibitor's 6-amino group and the carbonyl 
oxygens of Ile-7 and Val-115. This arrangement of hydrogen bonds makes protonated N3 
and 4,6-diamino groups very important determinants for the vertebrate DHFR inhibitory 
activity of 1,3,5-triazines. In addition to the several polar interactions between 
phenyldihydrotriazine and dihydrofolate reductase, numerous van der Waals contacts 
occur as well. The N1 phenyl substituents are found to locate at the left of the binding 
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cleft. The torsion angle involves rotation about the N1-C single bond is about 70o, where 
the perpendicular confirmation would have a torsion angle of 90o. The finding suggests it 
presents some hindrance tension in the binding of phenyl ring and the enzyme. Releasing 
this tension by replacing the phenyl ring using other small hydrophobic group may 
improve the fitness between the enzyme and triazine molecules.  The idea was 
corroborated by the SAR studies in triazines. In the study, using either n-butyl or phenyl 
group attached to the N1 position of the triazine ring would produce good anticancer 
agents as the active site of the mammalian DHFR could accommodate hydrophobic 
groups at that position.201 In another study, triazine molecule Br-WR99210 (88) with an 
alkyloxy group linking to the N1 position, instead of phenyl ring linking to the triazine 
ring, is also an active inhibitor of DHFR.106 Crystallographic study explored on the 
ternary complexes of Br-WR99210, M. tuberculosis DHFR or human DHFR with their 
cofactor NADPH showed that the triazine ring adopts a pseudo chair confirmation with 
C2 moving out of the plane of the ring.106 The two amino groups form four hydrogen 
bonds with protein residues Ile5, Asp27, Ile94 and Tyr100, which is similar to the 
binding between triazines with chicken liver DHFR. The 4-bromo phenyl ring adopts a 
similar position orientation and occupies a similar position to the phenyl ring of MTX in 
the MTX-containing ternary complex.  
WR99210 (89) is a potent inhibitor of Pl. falciparum proliferation in culture; in contrast, 
human fibroblast HT1080 cells are known to tolerate this compound.202 The large 
difference in sensitivity to WR99210 is not due to differential affinity for DHFR. Enzyme 
kinetic assays revealed a mere 10-fold difference in binding of WR99210 between 
Plasmodium DHFR-TS and human DHFR.203 WR99210 selectivity does not arise from 
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host-parasite differences in drug uptake, metabolism, or export. And host-parasite 
differences in the regulation and expression of DHFR and TS may play a role in drug 
selectivity. In the design of anticancer agent, we hypothesized that relatively nonspecific 
DHFR can selectively inhibit pathogen functions such as cancer because of the 
differences between cancer cells and normal cells. 
WR99210 has been developed for about ten years, and almost all the attentions have been 
focused on the antimalarial applications. Since this compound also showed potent activity 
against mammalian DHFR, this compound has the potential to be developed into an 
anticancer agent. However, limited research based on this structure has been done in the 
anticancer area. This class of compounds, thus, was chosen to be the center of focus for 
the present study. The crystallographic structures of ternary complex of Br-WR99210, 
DHFR and NADPH showed distinct differences between M. tuberculosis and human 
DHFR near the N1 and two methyl groups of this triazine. This difference may be present 
in other species between pathogen DHFR and human DHFR. Currently at the C2 
dimethyl group position, there is a complete lack of structure-activity studies in the 
literature to date, because with the traditional Baker’s triazines’ SAR, groups larger than 
dimethyl groups at C2-position of triazine ring would decrease the inhibitory activity. 
However, recently study showed that a very bulky group at C2 position, such as a 
adamantyl group as in compound 96, exhibited very potent inhibitory activity against 
mammalian DHFR.143 In addition, lipophilicity plays an important role in the design of 
nonclassical antifolates as anticancer agents. QSAR studies performed by Corwin Hansch 
showed that excessive lipophilicity led to low anticancer activity.204 Therefore, 
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substituents with moderate lipophilicity must be considered to ensure good anticancer 
activity.  
A phenyloxy-alkoxy-dihydrotriazine consisting of a diaminodihydrotriazine, a linker and 
phenyl ring was developed in this dissertation (Figure 10). Introducing different 
substituents in the phenyl ring, at the C2 position of the triazine ring and different linker 
produces new molecules of diverse lipophilicity and spatial orientations. In this study, an 
array of substituted phenol was chosen to achieve this objective. These phenols, based on 
the Craig’s plot, having substituents of varying lipophilicity and electronic properties, 
were substituted at 4’ position of the phenol molecules. The C2 position of the triazine 
ring was altered by using ketones of various sizes. The linker was varied with different 
length. After the synthesis, the compounds were screened against bovine DHFR to 
investigate the extent of inhibition of DHFR and against various human cancer cell lines 














Figure 10. Chemical structure of phenyloxyalkoxydihydrotriazines 
Since triazines have been evaluated for a variety of biological activity either related or 
unrelated to DHFR, several series of triazines have been designed in this study to 
investigate their antibacterial activity as well. One of the strategies is to develop 
antibacterial agent targeted on bacterial DHFR. TMP is a potent inhibitor of bacterial 
DHFR and has broad spectrum antibacterial activity, but is well tolerated in the 
mammalian host.150 On the basis of the preceding crystallographic analysis, there are two 
potential binding sites, the upper and lower clefts for inhibitor side chains for each 
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species of DHFR. Both clefts are larger in the vertebrate DHFRs than in the bacterial 
DHFRs. However, unlike a benzylpyrimidine which is the backbone of TMP, 1-
phenyldihydrotriazines has no side chain torsional freedom in relation to the triazine rings 
except for simple rotation about the single bond connecting to the two rings. Thus, for N-
phenyltriazine binding to E. coli DHFR which has a smaller cleft, the decreased binding 
may be happened because of the repositioning of the triazine ring itself. So in our study, 
several new series of triazines with a range of side chain length has been designed to 
avoid such a tension and screened against certain bacterial, with the hope that such leads 
can make us find a new potent antibacterial agents.  
 As we introduced in Section 2.4., the side activity of some antifolates may have values in 
the design of new sodium channel blockers. Lamotrigine has been found due to this 
serendipity discovery process.168 Lamotrigine structure is built up by a phenyl ring 
directly linked to a diamino-diazacycle structure motif. In our study, some of the above 
designed 1,3,5-triazines for anticancer and antibacterial purposes, which have 2,4-
diamino-diazacycle motif and a phenyl ring, may have potential to be developed as a 
neuronal sodium channel blockers. 
 
Therefore, the objectives of this dissertation, which was three-fold, may be summarized 
as follows: 
(1) To design and synthesize three libraries of triazines, namely: 2-amino-4-(substituted 
phenylamino)-1,3,5-triazines (M-I),   4-amino-6-(substituted anilino)-1,2-dihydro-2,2-
dimethyl-1,3,5-triazines (M-II), and 4,6-diamino-1-benzyl-1,2-dihydro-2,2-disubstituted-
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1,3,5-triazines (M-III) and to investigate their DHFR inhibitory activity against bovine 
DHFR, and their antimicrobial activity. 
(2) To screen libraries M-I, M-II for sodium channel blockade activity. Selected 
compounds from these libraries would be screened for anticonvulsant activity using 
animal models. 
(3) To design and synthesize a series of lipophilic antifolate triazine derivatives 4,6-
diamino-1-phenylalkoxy-1,2-dihydro-1,3,5-triazines (M-IV) and 4,6-diamino-1-((4’-
substituted phenyloxy)alkyloxy)-1,2-dihydro-1,3,5-triazines (M-V) using WR99210 as a 
lead compound and explore the structure and activity relationship (SAR) against bovine 
DHFR of these compounds bearing a range of side chains at the N1-position of the 
triazine moiety and bearing different substitution groups at C2-position and to further 
screen these compounds which possess potent inhibitory activity against bovine DHFR 












































The mammalian DHFR inhibitory activity was determined using bovine DHFR which is 
commercially available. For the screening for antibacterial activity, the evaluation of 
antibacterial activity was restricted to typical Gram positive pathogens: S. aureus, 
B.subtilis; Gram negative pathogens: K. aerogenes, P. aeruginosa, E. coli, and 
Mycobacterium pathogen in particular, M. smegmatis which is taxonomically related to 
M. tuberculosis. In the study of anticonvulsant activity of triazines, in vitro and in vivo 
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experiments were used. It was recognized that several mechanisms were involved in the 
design and screening of anticonvulsant agents. The present in vitro study examined one 
of the important mechanisms: sodium channel blockade activity using radioligand 
binding assay ([3H] BTX-B). And further in vivo study of the anticonvulsant activity used 
the standard screening protocol using MES and sc Met test together with sedative test 
(Rotorod test) on experimental mice to evaluate those compounds. In order to discover 
more selective anticancer drug, four typical cell lines were chosen for the anticancer 
research: human breast cancer cell line MCF-7, MDA-MB-231, Lung Carcinoma A549, 
and normal human cell line fetal lung fibroblasts MRC-5. The antiproliferative activity 
and the selectivity over the normal cell were determined using FMCA. The study should 
provide new leads for anticancer antifolates and potential alternatives to MTX for cancer 
chemotherapy. The antifolates with weaker activity against the mammalian DHFR could 
be leads for further development of new chemical entities for the treatment of the 
epilepsy and infectious diseases caused by a wide spectrum of bacterial pathogens 
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RESULTS and DISCUSSION 
4. 2-Amino-4-(Substituted Phenylamino)-1,3,5-Triazine (M-I) 
Aromatic 1,3,5-triazines have a long history in their agricultural applications where they 
were used as fungicides, insecticides and herbicides. However, only limited success in 
their pharmaceutical uses has been reported.  To date, on-going efforts are being made in 
exploiting the potential of developing the aromatic 1,3,5-triazines into therapeutic agents. 
The 2-amino-1,3,5-triazine structure has attracted increasing attention because of its close 

































Figure 11. 2-Amino-1,3-diaza structural motif and their pharmaceutical examples 
 
The 2-amino-1,3-diaza structural motif is common in several pharmaceutically useful 
agents, such as TMP (bacterial DHFR inhibitor), Baker’s triazines (mammalian DHFR 
inhibitors) and lamotrigine (anticonvulsant agent and sodium channel blocker) (Figure 
11). In the structures of these pharmaceutical agents a hydrophobic unit (a phenyl ring) is 
also present and is linked to the common 2-amino-1,3-diaza structural motif. Stevens et 
al has examined compounds that have both units and found that the 4,6-diamino-2-
phenyl-1,3,5-triazines were inactive against mouse L1210 lymphoid leukemia as well as 
the DHFR derived from either E. coli or the L1210 cells.217 However, phenyl substitution 
on the other positions of the triazine ring containing the 2-amino-1,3-diaza structural 
motif has not been studied for the same pharmaceutical activities. Therefore, it has 
prompted us to examine the pharmacological activity of 2-amino-4-(substituted 
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phenylamino)-1,3,5-triazines (M-I) as shown in Figure 12. Thus, the aim of this study 
was two-fold, firstly, to synthesize a series of M-I triazines, and secondly, to screen for 
inhibitory activity of these compounds against bovine DHFR, neuronal sodium channels 
and a standard array of microorganisms. The bioassays were selected because our lab has 
been using them on a regular basis. These bioassays will indicate whether the test 
compounds have potential antibacterial, anticonvulsant or anticancer properties. From 
literature, phenyl substitution is usually halogen or electro-withdrawing groups. Thus in 
this exploratory study, anilines that contain halogens Cl and Br were selected to produce 
the 3’ or 4’-monosubstituted phenyl triazines. In addition, the strong electro-withdrawing 










Figure 12. Chemical structure of 2-amino-4-(substituted phenylamino)-1,3,5-triazines (M-I) 
 
4.1. Chemistry 
The synthesis of 2,4,6-trisubstituted-1,3,5-triazines has been reviewed in the introduction 
chapter of this dissertation. There are a variety of methods available in the synthesis of 
M-I. Among these methods, the synthesis starting from biguanide was one of the most 
convenient ways to produce this type of triazines. Biguanide and its derivatives would 
react with a range of carboxylic acid derivatives including lactones, amides, orthoesters, 
esters, acid anhydrides and acid chlorides to give various 6-substituted-2,4-diamino-
1,3,5-triazines.4 The syntheses proceeded in basic or neutral conditions, and yields were 
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usually good. The reaction probably occurred via the acylation of the biguanide followed 
by cyclization. 
In this exploratory study, a small library of seven compounds was synthesized using this 
procedure whereby a methoxide-catalyzed condensation of the intermediate biguanide 
hydrochlorides was carried out with suitably substituted carboxylic acid esters at room 
temperature. The synthetic route utilized for the preparation of 2-amino-4-(substituted 















. R1CH2 (or Ph)COOEt(Me)
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Scheme 41. The synthesis of 2-amino-4-(substituted phenylamino)-1,3,5-triazines (M-I) 
The reaction proceeded well at room temperature, but at elevated temperature a 
Williamson type side reaction was observed between 6-chloromethyl M-I and sodium 
methoxide. The intermediate phenylbiguanides (R = 4’-Cl, 4’-Br, 3’-Cl, 3’-NO2, 3’-Br; 
R2 = CH3, CH2Cl or Ph) were synthesized using the methods reported by Modest and 
yields of 65-73% were observed.25 Esters of benzoic acid, acetic acid and chloroacetic 
acid were used to form the triazines ring with the biguanides. TLC and biguanide test 
monitored the progress of the reaction and the yields of the final target products ranged 
between 36.9% and 60.1%. The physicochemical constants of the seven 2-amino-4-








Table 1. Chemical structures and physicochemical data of 2-amino-4-(substituted phenylamino)-6-
substituted-1,3,5-triazines (M-I) 
Elemental Analysis 





C H N C H N 
M-I-01 4’-Cl CH3 193-194 58.5 50.96 4.28 29.72 50.66 4.14 29.77 
M-I-02 4’-Cl CH2Cl 174-176 43.5 44.46 3.36 25.93 44.56 3.23 25.88 
M-I-03 4’-Cl Ph 151-152 36.9 60.51 4.06 23.52 60.14 4.12 23.67 
M-I-04 3’-Cl CH3 151-152 44.5 50.96 4.28 29.72 50.88 4.45 29.47 
M-I-05 3’-NO2 CH2Cl 196-198 52.1 42.79 3.23 29.94 42.65 2.98 29.89 
M-I-06 3’-Br CH3 163-164 60.1 42.88 3.60 25.00 43.01 3.87 25.11 
M-I-07 3’-Br CH2Cl 123-124 42.0 38.18 2.88 22.26 38.47 2.56 22.19 
 
4.2. Pharmacological Evaluations 
4.2.1. Antifolate Activity of Compounds M-I against Bovine DHFR 
Evaluation of the compounds for the DHFR inhibitory activity was performed using 
enzyme inhibition assay. This assay is an UV spectrophotometric assay which measures 
the change in UV absorbance at 340 nm over time. DHFR catalyzes the NADPH-
dependent reduction of DHF to THF. NADPH is oxidized to NADP+ in the process. 
NADPH absorbs maximally at 340 nm whereas NADP+ does not. Therefore, the rate of 
decrease in absorbance at 340 nm over time is an indication of the rate of enzyme 
reaction. In the presence of a DHFR inhibitor, this decrease in absorbance will occur at a 
slower rate and if there is 100% inhibition of DHFR activity, no reduction in absorbance 
will be observed. 
During the enzymatic assay, DHFR was allowed to equilibrate with NADPH in 
phosphate buffer at 37oC. A fixed amount of DHF was then added and the UV 
absorbance at 340 nm was measured over a period of 5 minutes. If an inhibitor was 
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present, the enzyme would be allowed to incubate with the inhibitor at 37oC before the 
addition of DHF. Different concentrations of the inhibitor were used and the percentage 
of DHFR inhibition at each concentration was calculated. A graph of the percentage of 
inhibition against the logarithmic concentrations of the inhibitor was then plotted. The 
concentration of the inhibitor which inhibited 50% of DHFR activity (IC50) was 
determined from the graph. 
All seven 2-amino-4-(substituted phenylamino)-6-substituted-1,3,5-triazines (M-I) were 
tested using DHFR derived from bovine liver. However, none of this type of compounds 
inhibited the bovine DHFR (IC50 values > 100 µM). These negative results were 
consistent with the study on other aromatic 1,3,5-triazines as carried out by Stevens et 
al,217 suggesting that the protonated nitrogen atom as in 1,2-dihydro-1,3,5-triazine is very 
important for the interaction between triazine moiety and bovine DHFR enzyme. When 
this 1,2-dihydro-1,3,5-triazines motif was replaced with aromatic 1,3,5-triazine as in M-I, 
the nitrogen could not be protonated at physiological pH = 7.4 condition, which might 
have led to the disappearance of inhibitory activity against the bovine DHFR.  
 
4.2.2. Antimicrobial Activity of M-I 
Since the bacterial DHFR is not commercially available, the antimicrobial activity of M-I 
was carried out directly using various intact microbial cells. The selection of the 
microbial cells for this screening included 6 bacteria and 2 fungi. The bacterial cells were 
Staphylococcus aureus, Bacillus subtilis, Mycobacterium smegmatis, Pseudomonas 
aeruginosa, Klebsiella aerogenes, Escherichia coli, and two fungi are Candida albicans 
and Aspergillus niger. Among them, Staphylococci aureus and Bacillus subtilis are 
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Gram-positive bacteria; Mycobacterium smegmatis is widely used as a model system for 
pathogenic Mycobacteria; Pseudomonas aeruginosa, Klebsiella aerogenes and 
Escherichia coli are Gram-negative bacteria. Agar diffusion method using paper disc was 
used for the screening of antimicrobial activity. Various standard antibiotic discs (oxoid) 
were used as references for the respective susceptible microorganisms. The diameters 
(mm) of the inhibition zones on the agar were measured and the diameters of paper discs 
were subtracted. Zone ratio (ZR) was used to express the comparative efficiency as a 
compensation for interassay fluctuations; and the zone ratio was calculated from the 
following formula: 
ZR =
Mean zones of inhibition of test compounds
Mean zones of inhibition of stardard antibiotic discs  
Compounds (M-I-01 ~ M-I-07) were screened at the loading dose of 100 µg per disc for 
antimicrobial activity against 8 different microorganisms. The antimicrobial results are 
shown in the Table 2  
Table 2. Antimicrobial activity of M-I presented as ratios of zone of inhibition 
“-” = No activity 
a: 100 µg per disc; b: standard drugs for the calculation: S.aureus: Cephaloridine 30 μg, P.aeruginosa: 
Carbenicillin 100 μg, M.smegmatis: Streptomycin 10 μg, B.subtilis: Tetracycline 30 μg, K.aerogenes: 
Neomycin 30 μg, E.coli: Ampicillin 10 μg, C.albicans and A.niger: Chlorhexidine 400 μg.  
Zone Ratiob 
Compd.a R R1 S. 
aureus M.smegmatis P.aeruginosa K.aerogenes C.albicans A.niger 
M-I-01 4’-Cl CH3 0.07 0.50 0.84 - - - 
M-I-02 4’-Cl CH2Cl 0.25 0.07 - - - - 
M-I-03 4’-Cl Ph - 0.19 - - - - 
M-I-04 3’-Cl CH3 0.18 0.36 - 0.32 0.40 2.33 
M-I-05 3’-NO2 CH2Cl 0.10 - - - - - 
M-I-06 3’-Br CH3 0.41 0.37 - 0.40 0.83 5.78 
M-I-07 3’-Br CH2Cl 0.44 0.62 - 0.42 1.15 6.82 
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Compounds in this series demonstrated various degrees of inhibition against all the tested 
microorganisms except E. coli and B. subtilis, which were insensitive to all the 
compounds tested at 100 µg as no significant zones of inhibition were observed. In 
general, potency and spectrum of 1,3,5-triazines with substituents at 3’-position of the 6-
phenyl ring were better than those of 4’-substituted compounds, as illustrated by 
analogues M-I-04, M-I-06 M-I-07, which showed broader spectrum and high inhibitory 
activity against  S. aureus, M. smegmatis, K. aerogenes and two fungi compared to that of 
M-I-01~M-I-03. However, among this series, M-I-01 demonstrated unique activity 
against P. aeruginosa. Simultaneous substitution of Cl on 6-Me position as in M-I-02 led 
to a loss of activity against P. aeruginosa. This result suggested that the position C2 of 
triazine ring may not be too large to retain the activity against P. aeruginosa. The 
suggestion was further proven by the replacement of the 6-methyl group in M-I-03 with a 
phenyl group which led the loss of activity against P. aeruginosa even against S. aureus. 
Of all the 3’-substituted phenylamino compounds, 3’-NO2 substituted triazine M-I-05 
exhibited the poorest antibacterial activities across the spectrum. In contrast to M-I-05, 
three triazines M-I-04, M-I-06 and M-I-07 exhibited potent activity against the two fungi, 
C. albicans and A. niger. Especially against A. niger, all three compounds demonstrated 
more than two times the zone of inhibition at 100 µM as compared to the standard drug 
chlorhexidine at 400 µM.  
Since M-I-01, M-I-04, M-I-06 and M-I-07 showed reasonably good antibacterial and 
antifungal activities according to the preliminary paper disc study, an assay for 
determining the critical concentration (CC) of these compounds was carried out against 
various microorganisms. The critical concentration was the lowest “absolute 
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concentration” in µg per mL giving minimum inhibition of the growth of microorganism. 
In this assay, the square of zone size, d2 (d = (diameter of zone size-diameter of cup)/2), 
was plotted on the graph against the logarithm of concentration to obtain the critical 
concentration. After extrapolated to d2 = 0, the critical concentration was calculated by 
taking the antilogarithm of the value. The value of the critical concentrations determined 
is usually 2-4 times greater than the MIC as determined by the broth dilution method. 
Table 3. Critical concentrations of four newly synthesized 1,3,5-triazines 
ND: Not Determined 
Critical Concentration (µg/ml) 
Compd. R R1 S. aureus M.smegmatis P.aeruginosa K.aerogenes C.albicans A.niger 
M-I-01 4’-Cl CH3 - 340.9 443 - - - 
M-I-04 3’-Cl CH3 69.1 176.7 - 392.5 - 766 
M-I-06 3’-Br CH3 52.0 169.3 - 363.0 1426 533 
M-I-07 3’-Br CH2Cl 47.3 186.6 - 86.4 277 295 
Cephapirin   0.16 ND ND ND ND ND 
Carbenicillin   ND ND 132 ND ND ND 
Gentamicin   ND ND ND 3.4 ND ND 
Rifampicin   ND 49.5 ND ND ND ND 
Chlorhexidin   ND ND ND ND 419 1305 
 
Table 3 contains data on the critical concentration determination of the four compounds.  
A similar trend of potency and spectrum, as in the preliminary screening, was observed. 
M-I-01 did not show advantages over the positive standard carbenicillin against P. 
aeruginosa.  Bacteria S. aureus, M. smegmatis, K. aerogenes were not sensitive to M-I-
04, M-I-06 and M-I-07, compared with their standard controls. However, three 
compounds exhibited very potent activity against the fungi. Compound M-I-04 with 
chloro substituted on the 3’ position of phenyl ring showed no activity to C. albicans; but 
replacing of the chloro group into a bromo group, as in M-I-06, made the compound 
active against C. albicans. This change also reduced the critical concentration against A. 
niger from 766 µg/ml of M-I-04 into 533 µg/ml of M-I-06, and both concentrations were 
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much lower than positive control, chlorhexidine (1305 µg/ml). Among the compounds in 
the whole series, M-I-07, those with a 3’-bromo substitution on the phenyl ring and a 
chloromethylene group in the 6-position of the 1,3,5-triazine ring, exhibited the best 
activity not only against C. albicans and A. niger, but also against K. aerogenes. The 
inhibitory potency of M-I-07 against M. smegmatis was also comparable to M-I-06 and 
M-I-04. 
This preliminary report on the antimicrobial activity of this type of aromatic 1,3,5-
triazine M-I is believed to be the first. Obviously, the antimicrobial activity may not 
relate to the antifolate activity. The exact mechanism for their antimicrobial activity is 
unclear. Based on this study, future exploration may need to be done on this series, 
especially for their antifungal activity. On the other hand, aromatic 1,3,5-triazines have 
been found in many applications in agriculture as fungicides, insecticides and herbicides. 
These applications are represented by Anilazine (fungicide), Menazon (insecticide), and 
the range of herbicides of which Simazine and Atrazine are the most important. They are 
old and well-established products but only the two herbicides are still of importance 
today. So this type of compounds may have the potential to be developed into new 
generation of antifungal agents.   
 
4.2.3.  Sodium Channel Blockade Activity of Compounds M-I 
The pharmacophoric similarity between M-I and lamotrigine prompted us to screen M-I 
against neuronal sodium channels in an attempt to explore whether aromatic 1,3,5-
triazines (M-I) would possess potent sodium channel blockade activity. The competition 
of all 6 compounds with the binding of [3H] batrachotoxinin-A-20α-benzoate ([3H] BTX-
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B) to neurotoxin site 2 of the voltage-dependent sodium channels from rat brain 
synaptosomes were studied and compared with the displacement properties of phenytoin 
tested in the same experimental model. Because of solubility problem, M-I-03 was 
excluded in this screening. As shown in Table 4, sodium channel binding activities were 
expressed as IC50 values, the concentration (μM) of inhibiting 50% of the specific 
binding of [3H] BTX-B.  
Table 4. Sodium channel blockade activity of M-I 
Compd.  R R1 
BTX, IC50 (SEM) 
(µM) 
M-I-01 4’-Cl CH3 273.8 (13.8) 
M-I-02 4’-Cl CH2Cl 168.1 (13.3) 
M-I-04 3’-Cl CH3 245.5 (15.5) 
M-I-05 3’-NO2 CH2Cl 189.9 (18.0) 
M-I-06 3’-Br CH3 198.2 (17.2) 
M-I-07 3’-Br CH2Cl 171.9 (5.1) 
phenytoin   126.4 (7.0) 
 
All compounds exhibited moderate inhibitory activity against sodium channel and no one 
showed activity better than the positive control phenytoin. Compound M-I-01, having 4’-
chloro substitution on the phenyl ring, demonstrated weaker sodium channel blockade 
activity than triazines M-I-04 and M-I-06, which have a 3’-halogen atom on the phenyl 
ring. Further modifying of the substitution on the 6-methyl group, improved activity 
could be observed on M-I-02, M-I-05 and M-I-07. This result suggested that 6-position 
of the 1,3,5-triazine ring is an important determinant factor on their sodium channel 
blockade activity. Thus, further exploration may vary the 6-position of triazine ring to 
increase the sodium channel blockade activity.  
 
 




In summary, the seven 2-amino-4-(substituted phenylamino)-6-substituted-1,3,5-triazines 
(M-I) were synthesized in reasonably good yield. Several compounds in this series 
showed good activity against some microbial species, especially compound M-I-07 
which exhibited potent antifungal activity against C. albicans and A. niger. All the 
compounds synthesized in the series also possess some extent of sodium channel 
blockade activity. This study validated that the 2-amino-1,3-diaza structural motif found 
in the synthesized aromatic 1,3,5-triazines (M-I) did demonstrate antimicrobial and 
sodium channel blockade activity. Though only weak activities were observed, it 
nevertheless provided valuable lead compounds for further development. It is noteworthy 
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5. 4-Amino-6-(Substituted Anilino)-1,2-Dihydro-2,2-Dimethyl-1,3,5-Triazine (M-II) 
Compared to the aromatic 1,3,5-triazines (M-I), the 1,2-dihydro-1,3,5-triazines have been 
more extensively studied due to their favorable inhibitory activity against DHFR. In 
particular, the potent antimalarial agent chloroguanil belongs to this class of DHFR 
inhibitor, known as the 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-phenyl-1,3,5-triazines 
(I). It has been reported that the DHFR inhibitory activity diminished substantially, when 
I rearranged to M-II through Dimroth rearrangement.205 It can be seen that M-II is 
structurally very similar to M-I and therefore we hypothesized that M-II, like M-I may 
also exhibit antimicrobial activity as well as sodium channel blockade activity (Figure 
13). Since 1950s there has been no further study on the biological activity of M-II, this 


























Figure 13. Chemical structures of I, M-I and M-II 
Therefore, the objective of this study was to synthesize a series of M-II derivatives and 
explore whether they would demonstrate neuronal sodium channel blockade activity, 
anticonvulsant activity, bovine DHFR inhibitory activity and antimicrobial properties. In 
this study, an array of 14 anilines was chosen to generate a small library of M-II 
derivatives. These anilines were substituted at different positions in the phenyl ring by 
substituents of varying hydrophobicity constant. In addition, several anilines had 
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electron-donating groups on them and others had electron-withdrawing groups. As such, 
the library of M-II derivatives was designed to possess different physicochemical 




The strategy for the synthesis of this series of compounds (M-II) was based on a two-step 
reaction. The first step involved the preparation of 4,6-diamino-2,2-dimethyl-1-phenyl-
1,2-dihydro-1,3,5-triazine (I). This synthesis was carried out according to the reported 
three-component method. The target compounds (M-II-1~M-II-14) were derived via a 
base-catalyzed Dimroth rearrangement of I.    
 
5.1.1. The Synthesis of Triazines I 
The synthesis of I was carried out according to a “three-component” method as reported 
by Modest in 1956.29 The reaction was executed by refluxing in an acid, which was used 
as the catalyst. The mechanism of this reaction was believed to occur in two steps. The 
first step involved a nucleophilic attack of the lone pair electrons on the N atom of the 
substituted aniline on the cyano-carbon of cyanoguanidine to form arylbiguanide as an 
intermediate. The intermediate would then undergo a Mannich-like condensation reaction 
with the ketone/aldehyde, where the lone pair electrons on N1 and N4 of the 
arylbiguanide would attack the electron-poor carbonyl carbon of the ketone/aldehyde 
from both the top and the bottom face. If a non-symmetrical ketone or aldehyde was used, 
a pair of enantiomers would be formed. Towards the end of this process, a molecule of 
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water was lost from the oxygen atom of the ketone/aldehyde and hydrogen atoms from 
N1 and N4 of the arylbiguanide intermediate.  
In this study, acetone contributed to the dimethyl substitution on the position C2 of the 
1,2-dihydro-1,3,5-triazine ring, and it also served as the solvent for the reaction. 
Hydrochloric acid was used as a catalyst in the reaction. 14 anilines with different mono 
substitutions (R = methyl, methoxy, chloro, bromo and nitro) at 2’, 3’ or 4’ positions of 
the phenyl ring were used for synthesis. However, 2’-NO2 and 4’-NO2 anilines did not 
react with acetone under reflux, which was the typical condition to generate triazines I. 
The difficulties might be due to the fact that the electron-withdrawing NO2 group at 2’ or 
4’ position of aniline reduced the basicity of the nitrogen atom, which disfavored the 
nucleophilic attack of the lone pair electrons of the substituted aniline on the cyano-
carbon of cyanoguanidine. 1-(4’-Nitrophenyl)-1,2-dihydro-1,3,5-triazines I was 
synthesized successfully by Modest at room temperature with the accompaniment of 
some biguanide by-product. However, this compound was reported to be light-sensitive 
and was easily decomposed in aqueous or alcoholic solution.29 This unstable 
physicochemical property discouraged the effort in attempting to further optimize the 
conditions for the synthesis of this compound for the biological evaluation. Thus, an 
array of 14 compounds (I-1~I-14) were synthesized under a 24-hour reflux, yielding 
48.2-67.5 % of the 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-phenyl-1,3,5-triazines I upon 
recrystallization (Scheme 42). 
 



















R = Me, MeO, Cl, Br, 3-NO2
1
 
Scheme 42, One-pot Three-component Synthesis of 1-phenyl-1,2-dihydro-1,3,5-triazines I 
 
5.1.2. The Synthesis of Target Compounds M-II via a Dimroth Rearrangement 
The Dimroth rearrangement refers to an isomerization process involving the translocation 
of a substituent from the ring nitrogen atom (or endocyclic heteroatom) to a substituent 
amino group (or exocyclic heteroatom).207 The Dimroth rearrangement is believed to be 
catalyzed by alkali, acid, heat, or light. While electron-withdrawing groups will facilitate 
the ring-opening process, the pH of the solution will affect the rate of rearrangement.208 It 
was reported that Dimroth rearrangement could occur in I under different conditions. 
Rearrangement was evident when I was treated with heat and alkali; or its free base was 
heated; or an aqueous solution of the free base of I was exposed to an alkaline for a 
prolonged period of time at room temperature; or when I was melted.29, 209 This process 
involved the conversion of an internally strained structure of I to a less strained molecule 
4-amino-6-anilino-1,2-dihydro-2,2-dimethyl-1,3,5-triazine (M-II) in a lower energy state. 
Hence, the process was thermodynamically favorable to proceed toward the M-II side.  
The synthesis of the target compounds M-II is outlined in Scheme 43. Adding 10M 
sodium hydroxide dropwise into a solution of I⋅HCl in 50% aqueous methanol, until pH 
14 (determined by pH paper) was reached or when maximum precipitation occurred, 
followed by refluxing the reaction mixture produced acceptable yields 28.4-91.7 % of the 
rearranged 6-anilino-1,2-dihydro-1,3,5-triazine isomers M-II. The rearrangement of the 
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compounds having a methyl or methoxy group on the phenyl ring proceeded with lower 
yields than those of the corresponding nitro analog M-II-14, where the electron-
withdrawing nitro group could have stabilized the transient dipolar acyclic species as 
intermediates. The influence of the aryl substitution on the Dimroth rearrangement 
observed in this study was in substantial agreement with the work reported by Stevens.209 
Compounds of I and M-II were readily distinguished by differences in melting points, 
UV spectra and TLC characteristics. For example, I can be differentiated from M-II by 
its characteristic ultraviolet absorption spectrum, and the differences of their UV 















Scheme 43. Synthesis of 4-amino-6-(substituted anilino)-1,2-dihydro-2,2-dimethyl-1,3,5-triazine (M-II) 
 
As shown in the Table 5, in general, all compounds in I exhibited an absorption maxima 
at around 240 nm, but the maximum absorption of the corresponding M-II was shifted to 
a longer wavelength (ranging from 243 to 256.8 nm). However, the 6-(2’-substituted 
anilino)-1,2-dihydro-1,3,5-triazines M-II (02, 05, 08 and 11) did not show much 
differences from their isomers I in their UV absorption maxima. This phenomenon could 
be due to the extended conjugation between triazine ring and phenyl ring in M-II being 
disturbed by the steric strain by the 2’-substitutions. For the 6-(2’-substituted anilino)-
1,2-dihydro-1,3,5-triazines M-II (02, 05, 08 and 11), 1HNMR spectroscopy provided a 
useful means to differentiate the product from its triazine isomers I. The restricted 
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rotation by 2’-substitution of the pivotal inter-ring C-N1 bond caused the two methyl 
groups in the triazine ring to be diastereotopic and appeared as a doublet with peaks of 
equal intensity in a 1H NMR spectrum. These peaks were replaced by a singlet in the 
Dimroth Rearranged products due to the release of restriction of rotation. For example, 
the 1H NMR spectrum of I and M-II-02 run in DMSO-d6 showed the different signals on 
the protons of 2,2-dimethyl groups. 2,2-Dimethyl groups in I-02 were found as two single 
peaks at around 1.2 ppm and 1.5 ppm, respectively, while 2,2-dimethyl groups in M-II-
02 occurred as a single peak at 1.3 ppm. Hence, for this class of Dimroth rearranged 
dihydrotriazines, the use of both UV and NMR spectroscopy provided evidence for the 
formation of the rearranged product formed. Thus, the chemical structures and 
physicochemical data of the newly synthesized 4-amino-6-(substituted-anilino)-1,2-
dihydro-2,2-dimethyl-1,3,5-triazine (M-II-01~M-II-14) were summarized and  are 
shown in Table 6. 
Table 5, Ultraviolet absorption differences between I and M-II 
Compd R λmax of I λmax of M-II △ λmax 
01 H 241.2 250.6 9.4 
02 2’-CH3 240.6 243.2 2.6 
03 3’-CH3 241.4 250.0 8.6 
04 4’-CH3 241.2 249.4 8.2 
05 2’-OCH3 246.4 246.6 0.2 
06 3’-OCH3 240.4 251.8 11.4 
07 4’-OCH3 241.2 247.6 6.4 
08 2’-Cl 245.6 245.2 -0.4 
09 3’-Cl 241.2 252.2 11.0 
10 4’-Cl 240.4 255.0 14.6 
11 2’-Br 239.0 244.8 5.8 
12 3’-Br 238.8 254.4 15.6 
13 4’-Br 239.7 256.6 16.9 
14 3’-NO2 241.0 256.8 15.8 
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Table 6. Physicochemical data of the newly synthesized M-II and yields 
Elemental Analysis 





C H N C H N 
M-II-01 H 85.0 178-180 60.81 6.96 32.23 60.99 6.86 31.98 
M-II-02 2’-CH3 59.4 200-203 62.31 7.41 30.28 62.76 7.21 29.90 
M-II-03 3’-CH3 69.5 178-180 62.31 7.41 30.28 62.00 7.32 30.05 
M-II-04 4’-CH3 59.9 110-112 62.31 7.41 30.28 62.45 7.44 30.56 
M-II-05 2’-OCH3 28.4 210-212 57.04 7.02 27.71 57.00 6.83 27.42 
M-II-06 3’-OCH3 60.3 170-171 57.04 7.02 27.71 57.12 7.18 27.25 
M-II-07 4’-OCH3 61.7 115-116 58.28 6.93 28.32 58.02 7.00 28.30 
M-II-08 2’-Cl 83.0 196-198 52.49 5.61 27.82 52.25 5.54 28.01 
M-II-09 3’-Cl 80.4 175-176 52.49 5.61 27.82 52.33 5.05 27.42 
M-II-10 4’-Cl 84.0 132-134 52.49 5.61 27.82 52.45 5.55 28.00 
M-II-11 2’-Br 72.5 176-178 44.61 4.76 23.65 44.52 4.33 23.43 
M-II-12 3’-Br 84.7 180-182 44.61 4.76 23.65 44.53 4.78 23.26 
M-II-13 4’-Br 87.0 175-176 44.61 4.76 23.65 44.61 4.72 23.33 
M-II-14 3’-NO2 91.7 138-139 50.38 5.38 32.04 50.24 5.22 32.34 
 
5.2. Pharmacological Evaluations 
5.2.1. Antifolate Activity of Compounds M-II against Bovine DHFR  
The 14 compounds of M-II series having various substitutions in the phenyl ring were 
tested on the bovine DHFR and their inhibitory activities were compared with the activity 
of the parent isomers I (Table 7). All the 14 compounds were deemed to have no DHFR 
inhibitory activity (IC50 values > 50 µM), except M-II-07 and M-II-12 exhibited very 
limited DHFR inhibitory activity. However, their parent isomers I, especially 1-(3’- or 
4’-substitutedphenyl)-1,2-dihydro-1,3,5-triaiznes were found to be very potent inhibitors 
against bovine DHFR with the IC50 values ranging from 0.060 to 0.29 µM.  
 
 
  RESULTS AND DISCUSSION 
 
 99


















NF: Not Found 
IC50 (µM) 
Compd.  R R1 R2 
M-II I211-213 
01 H CH3 CH3 >100 0.47 
02 2’-CH3 CH3 CH3 >100 23.99 
03 3’-CH3 CH3 CH3 >100 0.079 
04 4’-CH3 CH3 CH3 >100 0.085 
05 2’-OCH3 CH3 CH3 >100 275.42 
06 3’-OCH3 CH3 CH3 >100 0.29 
07 4’-OCH3 CH3 CH3 73.0 0.12 
08 2’-Cl CH3 CH3 >100 13.80 
09 3’-Cl CH3 CH3 >100 0.079 
10 4’-Cl CH3 CH3 >100 NF 
11 2’-Br CH3 CH3 >100 NF 
12 3’-Br CH3 CH3 51.2 0.060 
13 4’-Br CH3 CH3 >100 0.095 
14 3’-NO2 CH3 CH3 >100 0.263 
 
These dramatic differences in the bovine DHFR inhibitory activity between two groups 
suggested that 6-amino group may also involve in the interaction with active site of the 
enzyme to ensure the binding activity. In the present study, when the 6-amino group was 
substituted by a bulky phenyl group, the interaction between the backbone carbonyl 
oxygen atoms of amino acids of the enzyme and lone pair of the 6-amino group of 
triazines may have been blocked, leading to the loss of the binding affinity. In addition, 
another interaction between the phenyl ring in triazines I and the cleft of the active site 
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was also dismissed by the translocation of the phenyl ring in M-II. The loss of binding 
activity was in agreement with previous computer graphic superposition study of 4-
amino-6-(3’-cyanoanilino)-1,2-dihydro-2,2-dimethyl-1,3,5-triazine and MTX by 
Welsh,210 which showed that the two methyl groups at C2 position of M-II overlapped 
with a free amino group in MTX, thus destroying the essential salt-bridge typically 
observed between MTX and DHFR.210 This blockade action may directly lead to the loss 
of the DHFR inhibitory activity of M-IIs. However, the loss of the DHFR inhibitory 
activity against bovine DHFR did not necessarily infer the loss of antifolate activity 
against the bacterial DHFR, since TMP was also a weak inhibitor against mammalian 
DHFR but a potent inhibitor against bacterial DHFR. So the antimicrobial property of 
this series of compounds M-IIs was evaluated using common microbes.  
    
5.2.2. Antimicrobial Activity of M-II 
Since bacterial DHFR is not commercially available, the antimicrobial activity of M-II 
was carried out directly using various microbial cells. The antibacterial results are 
presented in Table 8. In this screening, all the 14 compounds did not show inhibition 
against Gram-positive P. aeruginosa and the two fungi using the test compounds of 100 
µg per disc. M. smegmatis and K. aerogenes were slightly more sensitive to some of the 
compounds screened. Substitutions on the phenyl ring in M-IIs seemed to affect the 
inhibitory activity against some bacteria. The 2’-substituted compounds were devoid of 
antibacterial activity in all the tested bacteria. The 4’ and 3’ substituted compounds, with 
electron-withdrawing groups (Cl, Br, NO2), except for M-II-10, showed better inhibitory 
activity than the compounds with electron-donating groups. Especially compounds M-II-
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9, M-II-12 and M-II-13 (ZR = 0.56) demonstrated more than half of inhibitory activity 
against K. aerogenes compared with the positive control neomycin at 30 µg per disc.   
Table 8. Sensitivity test of compounds M-II against microbial cells 
a: 100 µg per disc; b: standard drugs for the calculation: S.aureus: Cephaloridine 30 μg, 
P.aeruginosa: Carbenicillin 100 μg, M.smegmatis: Streptomycin 10 μg, B.subtilis: Tetracycline 
30 μg, K.aerogenes: Neomycin 30 μg, E.coli: Ampicillin 10 μg, C.albicans and A.niger: 
Chlorhexidine 400 μg.  
Zone Ratiob 
Compda  R S.aureus B.subtilis M.smegmatis K.aerogenes E.coli 
M-II-1 H - - - - - 
M-II-2 2’-CH3 - - - - - 
M-II-3 3’-CH3 - - - - - 
M-II-4 4’-CH3 0.15 - - - - 
M-II-5 2’-OCH3 - - - - - 
M-II-6 3’-OCH3 - - - - - 
M-II-7 4’-OCH3 - - - - - 
M-II-8 2’-Cl - - - - - 
M-II-9 3’-Cl 0.15 - 0.3 0.56 - 
M-II-10 4’-Cl - - - - - 
M-II-11 2’-Br - - - - - 
M-II-12 3’-Br - 0.24 0.25 0.56 0.09 
M-II-13 4’-Br - 0.25 0.28 0.56 - 
M-II-14 3’-NO2 - - 0.23 - - 
 
Although the inhibitory activity against bacterial DHFR cannot be determined so far, the 
limited antimicrobial activity of the compounds indirectly suggests that these compounds 
may not inhibit bacterial DHFR as well. TMP also exhibited weak DHFR inhibitory 
activity against vertebrate DHFR, and the loss of a hydrogen bond between TMP’s 4-
amino group and the carbonyl of Val 115 may lead to weak affinity to the vertebrate 
DHFR.100 However, the unsubstituted diamino groups of TMP could play a crucial role in 
binding with the bacterial DHFR.98 In our study, the 6-amino group of M-IIs, which was 
supposed to bind in the same way to the DHFR as 4-amino group of TMP, was blocked 
by a bulky phenyl substitution. The blockade effects at 6-amino position may interrupt 
the interaction between the bacterial enzyme and the triazines motif, since the cleft in the 
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active site of bacterial DHFR was smaller than the vertebrate DHFR.100 This study 
suggested that the 2,4-diamino heterocycle motif is indeed very important to ensure the 
inhibitory activity against vertebrate and bacterial DHFRs, and substitutions on the amino 
groups may lead to the loss of the inhibitory activity against DHFR. 
 
5.2.3. Sodium Channel Blockade Activity of Compound M-IIs 
The competition of all 14 compounds with the binding of [3H] batrachotoxinin-A-20α-
benzoate ([3H] BTX-B) to neurotoxin site 2 of the voltage-dependent sodium channel 
from rat brain synaptosomes was studied, and compared with the displacement properties 
of phenytoin tested in the same experimental model. As shown in Table 9, sodium 
channel binding activities were expressed as IC50 values, the concentration (μM) that 
inhibited 50% of the specific binding of [3H] BTX-B. All the compounds from M-II-1 to 
M-II-14 demonstrated blockade activity against neuronal sodium channel to various 
extents. The activity varied with different substitutions on the phenyl ring as well as the 
different substituted ring positions. In general, potency of unsubstituted compound M-II-
1 was increased by substitutions at 3’ or 4’ position of the phenyl ring. 4-Amino-6-(3’-
substituted anilino)-1,2-dihydro-2,2-dimethyl-1,3,5-triazines showed better activity than 
the 4-amino-6-(4’-substituted anilino)-1,2-dihydro-2,2-dimethyl-1,3,5-triazines. 
Substitutions at 2’-position of phenyl ring generally led to a decrease of activity as 
compared to substitution on the other positions, indicating that potential steric effects 
could be involved. The polarity of the substituents also had much influence on the 
blockade activity. Electron withdrawing groups on 6-N-phenyl ring as illustrated by M-
II-(9-14) showed the highest sodium channel blockade activity with IC50 values ranging 
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from 12.57 μM to 24.70 μM, with the exception of the 2’-substituted compounds (M-II-8 
and M-II-11). 4-amino-6-(3’-bromoanilino)-1,2-dihydro-2,2-dimethyl-1,3,5-triazines 
(M-II-12) displayed better activity (12.57 μM) than 3’-nitro and 3’-chloro substituted 
compounds and the activity was about ten times higher than the control, phenytoin (126.4 
μM), suggesting that high lipophilic substituents are favored to the sodium channel 
blockade potency. However, the electron donating groups on the 6-N-phenyl ring were 
not tolerated well and demonstrated relatively weaker activity ranging from 71.51 μM to 
581.73 μM, especially the 2’-substituted phenylamino triazines.  
Table 9. Data on the sodium channel blockade activity of M-IIs  
3[H] BTX  Compds  R IC50, μM (SEM) 
M-II-1 H 258.63 (15.44) 
M-II-2 2’-CH3 581.73 (34.67) 
M-II-3 3’-CH3 185.94 (5.91) 
M-II-4 4’-CH3 71.51 (1.52) 
M-II-5 2’-OCH3 343.13 (38.70) 
M-II-6 3’-OCH3 76.17 (1.60) 
M-II-7 4’-OCH3 207.23 (2.32) 
M-II-8 2’-Cl 85.54 (6.25) 
M-II-9 3’-Cl 16.51 (0.19) 
M-II10 4’-Cl 24.70 (0.76) 
M-II-11 2’-Br 57.45 (1.97) 
M-II-12 3’-Br 12.57 (0.75) 
M-II-13 4’-Br 18.39 (1.23) 
M-II-14 3’-NO2 23.08 (0.27) 
Phenytoin  126.4 (7.0) 
 
Since then, a new series of triazines, 4-amino-6-(substituted anilino)-1,2-dihydro-2,2-
dimethyl-1,3,5-triazines M-II, have been identified as potent neuronal sodium channel 
blockers. Compared the compounds between M-I-01 and M-II-10, between M-I-04 and 
M-II-09 and between M-I-06 with M-II-12, the sodium channel blockade activity of 
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aromatic M-I was more than ten times lower than that of the corresponding M-II. 
Triazines M-I and M-II have similar substitution arrangement, except at C2 position of 
the triazines (Figure 14). The puckered configuration in M-II with C2 moving out of the 
planar ring may be an active site interaction point. Aromatic planar structure as in M-I 
would lead to the decreased activity. In terms of protein-binding energetics, the 1,2-
dihydro-1,3,5-triazine ring may possess an advantage over the more structurally rigid 
aromatic triazine ring. Specifically, the flexibility of the triazine ring geometry in M-II 
may render this family of sodium channel blockers more adaptable in satisfying the steric 
requirements and hydrogen-bonding directionalities imposed by the active site of sodium 
channel. The results shown in M-II prove again that the 2 position of the 1,3,5-triazines 














M-II M-I  
Figure 14. Chemical structures of M-I and M-II 
Lamotrigine, phenytoin, carbamazepine are antiepileptic agents that target the sodium 
channel. The pharmacophore of these anticonvulsant sodium channel activity is believed 
to comprise at least one aryl unit, one or two electron donor atoms, and/or an NH group 
in a special spatial arrangement.214 Compared to these structures, similar units could be 
found in M-II as illustrated in Figure 15. It was hypothesized that M-II, as sodium 
channel blockers would possess anticonvulsant activity in vivo. 





























HDAU=Hydrogen Donor/Acceptor Unit, HP=Hydrophobic Unit, ED=Electron Donor
EDED ED ED
Carbamazepin Phenytoin Lamotrigine M-II
 
Figure 15, Pharmacophoric comparison among three anticonvulsant drugs and M-II 
 
5.2.4. In vivo anticonvulsant Activity and Sedative Action 
Based on the hypothesis in the last section, these compounds were also investigated for 
their protection against seizure in mice using the maximal electroshock seizure (MES) 
test, subcutaneous metrazole seizure threshold (sc Met) test and toxicity assay at the dose 
of 30 mg/kg. These animal models and the protocols used to identify anticonvulsant 
agents are widely accepted, and the results are tabulated in Table 10. All the 14 
compounds were found to be inactive against seizures induced by electroshock or 
chemical at the dose of 30 mg/kg.  Due to the unexpected toxicity, the higher dose could 
not be applied.  
To our surprise, some of the compounds demonstrated sedative property by Rotorod test, 
which was deemed as one of the side effects of current anticonvulsant drugs. At the dose 
of 30 mg/kg, the compounds having 2’-chloro, 2’-methoxy and 4’-methoxy in the aryl 
ring exhibited sedative property as indicated by the extremely short rotorod time of 
26±12, 65±10 and 86±18 seconds respectively. Except for compounds M-II-01 and M- 
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II-14, the rest of this series exhibited certain sedative effects. It is very likely that this 
sedative property will be a general feature of this class of compounds. 
 
Although neuronal sodium channel blockers found their first major application with the 
discovery of their potential as new treatments for epilepsy, no such anticonvulsant 
activity was demonstrated in this study.  However, since binding of local anesthetic and 
class I antiarrhythmics also resulted in the inhibition of binding of [3H] BTX-B, further 
studies on these disordered animal models is worth trying to identify their in vivo activity. 
Meanwhile, in vivo sedative effect of these compounds has provided leads for further 
investigations into the discovery of therapeutically useful agents as analgesic agents.  
 
Table 10. Screening data on the in vivo anticonvulsant and sedative activity of M-II  
a: Maximal Electroshock Seizure (protection score); 1 = no protection, 2 = tonic extension, 3 = both 
hindlimb extension and tonic flexor stage were abolished, 4 = full protection with no apparent seizure 
activity; d = dead. b: sc MET (Chemical induced seizure) score: 6 = nothing, 5 = jerk, 4 = jumping, 3 
= lying, 2 = full extensor, 1 = death. 
 
 MESa sc Metb Rotorod time Compds  R 
30 mg/kg 30 mg/kg T, s (SEM) 
M-II-1 H 1/d 1 300 (0) 
M-II-2 2’-CH3 1/d 1 222 (12) 
M-II-3 3’-CH3 1/d 1 126 (29) 
M-II-4 4’-CH3 1 1 86 (17) 
M-II-5 2’-OCH3 1/d 1 65 (10) 
M-II-6 3’-OCH3 1 1 267 (20) 
M-II-7 4’-OCH3 1 1 86 (18) 
M-II-8 2’-Cl 1/d 1 26 (13) 
M-II-9 3’-Cl 1 1 300 (0) 
M-II10 4’-Cl 1 1 241 (59) 
M-II-11 2’-Br d 1 249 (26) 
M-II-12 3’-Br 1 1 280 (20) 
M-II-13 4’-Br 1 1 275 (18) 
M-II-14 3’-NO2 1 1 300 (0) 
Phenytoin  4 1 300 (0) 
Phenobarbital   4 5 300 (0) 
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5.3. Conclusion  
A series of 4-amino-6-(substituted anilino)-1,2-dihydro-2,2-dimethyl-1,3,5-triazines (M-
IIs) has been synthesized and characterized in this study. Although these compounds 
showed no inhibitory activity against bovine DHFR and limited antibacterial activity was 
observed in vitro, M-IIs have been demonstrated to exhibit sodium channel blockade 
activity. In particular, compound M-II-12 was ten times more potent than phenytoin in 
blocking sodium channel. No in vivo anticonvulsant activity was observed in this study. 
However, in vivo sedative effect of these compounds has provided leads for further 
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6 4,6-Diamino-1-Benzyl-1,2-Dihydro-2,2-Disubstituted-1,3,5-Triazine (M-III) 
The 4,6-diamino-1,2-dihydro-2,2-dimethyl-1,3,5-triazine antifolates represent a highly 
potent family of DHFR inhibitors. The crystal structure of the ternary complex composed 
of chicken liver DHFR, cofactor NADPH, and 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-
phenyl-1,3,5-triazines has been determined and compared with that of TMP bound to 
DHFRs of E. coli or L. casei.98 It was found that the triazine ring occupied the active site 
similar to that found for the pyrimidine ring of TMP. Also, the heterocyclic rings of both 
inhibitors engage in very similar interactions with the surrounding protein environment.98 
It was noted that the 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-phenyl-1,3,5-triazines 
showed appreciable activity against vertebrate DHFR but were only weakly active 
against the bacterial DHFR.100 There are some reasons as to why the 4,6-diamino-1,2-
dihydro-2,2-dimethyl-1-phenyl-1,3,5-triazines do not bind as well to bacterial DHFR. 
One of the possible reasons is that the phenyl side chain is found to be positioned lower 
in the active site pocket when it binds to E. coli DHFR. However, unlike the 
benzylpyrimidine in TMP, 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-phenyl-1,3,5-
triazines has no side chain torsional freedom in relation to the heterocycle except for 
simple rotation about the single bond connecting the two rings.100 We hypothesized that 
replacing the phenyl ring with a benzyl group at 1 position of the triazine ring resulting in 
new 4,6-diamino-1-benzyl-1,2-dihydro-2,2-dimethyl-1,3,5-triazines, might have better 
interaction with bacterial DHFR, thus would exhibit antibacterial activity. In a 
crystallographic study on M. tuberculosis DHFR, it was elucidated that a glycerol 
molecule was found to bind in a pocket of the M. tuberculosis DHFR: MTX complex 
near the atoms of N1 and N8 of MTX, while this pocket was essentially filled with 
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hydrophobic amino acid residues in human DHFR.106 This position was located near the 
protonated N and dimethyl groups at position C2 of the triazine rings. This data provided 
an opportunity for the designing of new selective inhibitors of M. tuberculosis DHFR. So 
the objective of this study was to synthesize a series of 4,6-diamino-1-benzyl-1,2-
dihydro-2,2-disubstituted-1,3,5-triazines (M-III, Figure 16) with different substitution at 
phenyl ring and various alkyl groups at C2 position and screen them against bovine 
DHFR and various bacteria including M. smegmatis, which is the widely used model 
system for M. tuberculosis.  This study would demonstrate evidence to support possible 
species selectivity between microorganism and mammal. Such species selectivity in 



















Figure 16. Chemical structures of TMP and M-III 
 
6.1. Chemistry 
The three-component method as used in section 5.1.1 could not be applied for the 
synthesis of 1-aliphatic triazines such as benzyltriazines M-III.29 An alternative route to 
synthesize the target compounds using a two-step reaction was therefore devised. This 
reaction proceeded with the synthesis of the benzyl biguanide first and followed by ring 
cyclization to form the 1,3,5-triazine ring was carried out.  
In Modest’s “two-component” method,25 arylbiguanide was formed first by reaction 
between an aromatic amine and cyanoguanidine in the presence of acid before the 
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subsequent reaction with carbonyl compounds. However, aliphatic amines including 
benzylamines reacted very slowly under these conditions. Therefore, alternative synthetic 
method was sought to prepare the benzyl biguanide. There were two methods available 
for the synthesis of aliphatic biguanides. The first synthetic approach involved the 
method used by Curd and Rose (Scheme 44).218 With the excess of free amine dissolved 
in aqueous ethanol, one equivalent of copper sulphate was added with cyanoguanidine, 
and then the biguanide was obtained as a copper complex. The copper complex was then 
destroyed upon the addition of strong acid. After removing the copper by bubbling 
gaseous hydrogen sulfide through the solution, the biguanide could be isolated from the 
aqueous mixture. However the poor yield (30%) and complicated work-up procedures 
discouraged the use of this method. The second synthetic method was developed by 
Shapiro et al. (Scheme 45).219 The preparation of the biguanide hydrochlorides was 
carried out by the reaction of equimolar quantity of the amine hydrochloride and 
cyanoguanidine with the reaction temperature desirably maintained at 130-150oC for 0.5-
2 hours. However, guanidine was frequently formed as a side reaction especially with a 
longer reaction time. In this reaction, biguanides are stronger bases than the aliphatic 
amines, however, the basicity of the related guanidine may be sufficiently high. Thus the 
biguanide product that was formed could conceivably react through intermolecular 
hydrogen-bonded form through hydrogen transfer to yield the guanidine.  By increasing 
the temperature to 180oC at the start of the reaction and shortening the reaction time to 5 
min, the benzylbiguanide was prepared by this method with fewer by-products and higher 
yields of 67%-80% were obtained (Scheme 46).  
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Scheme 46. Synthesis of 4,6-diamino-1-benzyl-1,2-dihydro-2,2-dialkyl-1,3,5-triazine (M-III) 
With the benzylbiguanides, the target compounds M-III were synthesized using the two 
component synthesis. The conditions of the two-component synthesis required the 
presence of more than one equivalent of a strong acid per equivalent of biguanide. The 
solvent for the reaction was alcohol or the carbonyl reagent itself. The reaction time 
varied from one hour to two weeks depending on the temperature employed, the 
homogeneity of the reaction mixture, and the reactivity of the carbonyl reagent. The 
approximate speed of reactivity of the carbony1 reagents employed in the ring cyclization 
step was found to follow this trend: aliphatic aldehydes > aromatic aldehydes > ketones. 
The synthesis was generally carried out under reflux, with stirring, for several hours; 
  RESULTS AND DISCUSSION 
 
 112
although a longer period of time was required if the reactants were poorly soluble. The 
condensation can also be effected at temperatures below the reflux point or at room 
temperature.  
The reaction was best carried out under essentially anhydrous condition because the 
presence of water generally would prevent the condensation from proceeding to 
completion. However, by continuous removal of water using anhydrous calcium sulfate 
in a thimble of a Soxhlet apparatus, Limbardino was able to prepare triazines of this type 
by the “two component” method using a 0.2 mole-equivalent of excess hydrochloride.220 
He was able to achieve yields with aliphatic aldehydes or acetones and biguanides 
ranging from 7-20% yields. It is a well-known art in organic synthesis that in situ 
removal of water from a condensation reaction very often will provide better results since 
the reaction equilibrium will shift to the product side. Dehydration under homogeneous 
conditions using triethyl orthoformate or 2,2-dimethoxypropane as a water scavenger in 
the synthesis of dihydrotriazines has also been reported.26,27 Since triethyl orthoformate 
and 2,2-dimethoxy-propane and their hydrolysis products are volatile, it can be directly 
added to the reaction mixture without interfering with the purification of the product. In 
the synthesis of 4,6-diamino-1-(substituted benzyl)-1,2-dihydro-2,2-dimethyl-1,3,5-
triazine (M-III-01 ~ M-III-07), 2,2-dimethoxypropane was obviously a better choice of 
water scavenger, since when it would react with water to generate acetone which 
incidentally was one of the starting materials. When other ketones and aldehydes were 
used as reactants, triethyl orthoformate was employed as water scavenger instead 
(Scheme 46). 
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An excess of strong inorganic or organic acid was necessary for the success of the 
condensation. Usually, hydrochloric acid is used in this reaction. The successful two-
component synthesis required more than one equivalent of a strong acid per equivalent of 
biguanide free base. The reaction was unsuccessful when equivalent amount of biguanide 
and acid were used. The ratio of equivalents of acid to biguanide free base routinely 
employed is 1.5, or, if the biguanide hydrochloride is used, the proportion is 0.5.  
Aldehydes in general reacted successfully in the two-component synthesis, except for 
highly reactive aldehydes such as formaldehyde, which may undergo copolymerization 
with the arylbiguanide in preference to 1,2-dihydro-1,3,5-triazine ring formation. 
Aromatic aldehydes did not react as rapidly as did aliphatic aldehydes. It should be noted 
that because aliphatic aldehydes could be employed in the three-component synthesis, the 
two-component synthesis was the only route at present to generate the 2-monoalkyl 
substituted 1-benzyl-1,2-dihydro-1,3,5-triazines. 
The whole synthetic route of the target compounds is outlined in Scheme 46 and the 
physicochemical results are listed in Table 11. The two-component synthesis proceeded 
relatively well with acetone, affording yields of 31.9-48.0%, except for the synthesis of 
M-III-07, which was purified using chromatographic column with a yield of 9.3%. This 
reaction also proceeded well with cyclopentanones (yields 25.5-49.7%). In the case of 
higher order of aliphatic ketones, the reaction became progressively less efficient, 
particularly with an increasing steric hindrance of the carbonyl group, the evidence being 
the presence of increasing amount of unreacted biguanide in the reaction mixture. As in 
the three-component synthesis, the striking efficiency of acetone in the two-component 
synthesis at reflux temperature in contrast to the poor performance of the homologous 
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methyl ethyl ketone was evident. When the condensation of benzylbiguanide and methyl 
ethyl ketone was carried out under acid conditions, the products, M-III-08 ~ M-III-10, 
had to be separated from unreacted starting materials through the use of chromatograph 
columns, which made the yields very low (2.4-5.0%). In the case of the two-component 
synthesis from methyl cyclopropyl ketone, it was found not practical to carry out the 
condensation at the reflux point. When this reaction was done at room temperature for 
two weeks, the product M-III-11 was obtained in very low yield (28%) from the mother 
liquor, which had been filtered free of unreacted arylbiguanide; Apart from M-III-11 
from 4’-chlorobenzylbiguanide, other target compounds were not separated from 
unreacted biguanides. Under similar conditions low yields of M-III-16 to M-III-23 were 
obtained from the reaction between the biguanide and the bulky cyclohexanone and 
cycloheptanone. The progress of the reaction was followed by observation of the shifts in 
the ultraviolet absorption spectrum of the reaction mixture or by measurement of the 
disappearance of the biguanide, which was accomplished by means of the colored copper 
complex formed characteristically by biguanides with cuprammonium ion but not formed 
under these conditions by dihydrotriazines. TLC was another method used to monitor the 
reaction, but the solvent system of the mobile phase needed to be very polar (chloroform : 
methanol = 3 : 1).  
 



















C H N C H N 
M-III-01 H CH3 CH3 204-206 38.9 53.11 6.83 25.81 52.89 6.42 25.50 
M-III-02 4’-CH3 CH3 CH3 188-189 31.9 55.41 7.15 24.85 55.40 7.35 24.58 
M-III-03 4’- OCH3 CH3 CH3 193-194 48.0 51.58 6.82 23.24 51.64 6.35 22.98 
M-III-04 4’-F CH3 CH3 183-184 47.7 47.45 6.30 23.05 47.77 6.32 23.10 
M-III-05 4’-Cl CH3 CH3 192-194 43.1 47.69 5.67 23.17 47.22 5.22 22.73 
M-III-06 3’,4’-diCl CH3 CH3 193-194 34.0 41.70 4.96 20.26 42.07 5.28 20.42 
M-III-07 3’,4’,5’-triOMe CH3 CH3 193-194 9.3 50.35 6.76 19.57 50.43 7.11 20.07 
M-III-08 4’-CH3 CH3 C2H5 176-178 5.0 52.67 7.77 21.94 52.87 7.94 22.10 
M-III-09 4’-OCH3 CH3 C2H5 155-157 6.0 51.54 7.29 21.46 51.20 7.47 21.43 
M-III-10 4’-Cl CH3 C2H5 155-157 2.4 47.74 6.23 21.41 47.32 6.29 21.78 
M-III-11 4’-Cl CH3 c-Pr 161-163 28.0 51.23 5.83 21.34 50.80 6.16 21.17 
M-III-12 4’-CH3 -(CH2)4- 200-202 29.0 55.29 7.42 21.49 55.29 7.10 21.51 
M-III-13 4’-OCH3 -(CH2)4- 204-205 48.3 55.63 6.85 21.63 55.71 7.15 21.85 
M-III-14 4’-Cl -(CH2)4- 195-197 25.5 48.56 6.11 20.23 48.62 6.06 20.19 
M-III-15 3’,4’-diCl -(CH2)4- 216-217 49.7 46.36 5.00 19.31 46.57 5.18 19.67 
M-III-16 4’-CH3 -(CH2)5- 216-218 13.8 59.71 7.52 21.76 59.86 7.63 22.24 
M-III-17 4’-OCH3 -(CH2)5- 213-215 11.6 56.88 7.16 20.73 56.78 7.30 20.94 
M-III-18 4’-F -(CH2)5- 211-212 15.0 55.30 6.50 21.49 55.47 6.48 21.60 
M-III-19 4’-Cl -(CH2)5- 213-214 8.0 52.64 6.18 20.46 52.82 5.88 20.64 
M-III-20 3’,4’-diCl -(CH2)5- 210-213 11.7 47.83 5.35 18.59 47.84  5.12 18.82 
M-III-21 3’,4’,5’-triOMe -(CH2)5- 197-199 3.19 59.81 7.53 19.38 59.77 7.77 19.20 
M-III-22 3’,4’-diCl -(CH2)6- 234-236 37.4 49.18 5.68 17.92 49.14 6.02 17.96 
M-III-23 4’-CH3 -(CH2)6- 193-195 5.3 60.79 7.80 20.85 60.29 7.98 21.33 
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6.2.  Biological Evaluation 
6.2.1. Antifolate Activity of Compounds M-III against Bovine DHFR 
Table 12. Bovine DHFR inhibitory activity of M-III 
Compounds R R1 R2 IC50 (µM) 
M-III-01 H CH3 CH3 19.5 
M-III-02 4’-CH3 CH3 CH3 24.6 
M-III-03 4’- OCH3 CH3 CH3 58.8 
M-III-04 4’-F CH3 CH3 21.8 
M-III-05 4’-Cl CH3 CH3 29.9 
M-III-06 3’,4’-diCl CH3 CH3 12.8 
M-III-07 3’,4’,5’-triOMe CH3 CH3 >100 
M-III-08 4’-CH3 CH3 C2H5 >100 
M-III-09 4’-OCH3 CH3 C2H5 >100 
M-III-10 4’-Cl CH3 C2H5 >100 
M-III-11 4’-Cl CH3 c-Pr >100 
M-III-12 4’-CH3 -(CH2)4- >100 
M-III-13 4’-OCH3 -(CH2)4- >100 
M-III-14 4’-Cl -(CH2)4- >100 
M-III-15 3’,4’-diCl -(CH2)4- >100 
M-III-16 4’-CH3 -(CH2)5- >100 
M-III-17 4’-OCH3 -(CH2)5- >100 
M-III-18 4’-F -(CH2)5- >100 
M-III-19 4’-Cl -(CH2)5- >100 
M-III-20 3’,4’-diCl -(CH2)5- >100 
M-III-21 3’,4’,5’-triOMe -(CH2)5- >100 
M-III-22 3’,4’-diCl -(CH2)6- >100 
M-III-23 4’-CH3 -(CH2)6- >100 
TMP   >100 
 
All the compounds were screened against bovine DHFR, the concentration of the 
inhibitor which inhibited 50% of the bovine DHFR activity (IC50) was determined using 
enzyme kinetics assay (Table 12). Seven compounds of this series with dimethyl group at 
position C2 of the 1,2-dihydro-1,3,5-triazine ring showed moderate activity, the IC50 
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values ranging between 12.8 and 55.8 µM. M-III-06 demonstrated the best inhibitory 
activity among all these compounds. This might be ascribed to the dual substitution and 
larger lipophilicity value of the substituents. However, the inhibitory activity against 
bovine DHFR were decreased more than 100 times compared with the 1-phenyl-1,2-
dihydro-1,3,5-triazines I counterparts. The loss of the inhibitory activity may have been 
due to the differences in conformational behavior of the 1-benzyl-1,2-dihydro-1,3,5-
triazines (M-III) from 1-phenyl-1,2-dihydro-1,3,5-triazines (I). The additional rotational 
freedom of the triazine ring round the methylene group is quite different from the simple 
rotation about the single bond between triazine ring and phenyl ring as in 1-phenyl-1,2-
dihydro-1,3,5-triazines. This extended side chains may also interfere the hydrogen bond 
interaction between the enzyme carbonyl of ILe115 and 6-amino group on the triazine 
ring. M-III-07 with similar substitution pattern as in TMP showed no inhibitory activity 
against bovine DHFR. The C2 substituents at the 1-benzyl-1,2-dihydro-1,3,5-triazines 
ring in this series also showed their effects on the inhibitory activity. Using ethyl or 
cyclopropyl group to replace one of the methyl group at C2 position led to the loss of 
activity with IC50 value > 100µM. Spirocyclopentyl or spirocyclohexyl substitutions at 
the C2 position also showed the loss of inhibitory activity. These bulky groups on the 
triazine rings appeared to provide too much steric effect to enable a favorable 
accommodation of the 1-benzyl-1,2-dihydro-1,3,5-triazine at the active site of the 
enzyme. This is consistent with earlier finding on 1-phenyl-1,2-dihydro-1,3,5-triazines 
which suggested that the bulky groups at position C2 is associated with the loss of DHFR 
inhibitory activity.3 The interaction with the active site of DHFR might have been 
interfered by the bulky group around the C2 position of the triazine ring, which forced the 
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phenyl ring to locate their favorite position to contact with the active sites of enzyme. 
This interpretation also gives a plausible explanation for the fact that substitution at C2 
position of the pyrimidines decreased its activity markedly.  
6.2.2. Antimicrobial Activity of M-III 
Table 13. Antibacterial activity of  M-III against S. aureus and M. smegmatis 
a: 100 µg per disc; b: standard drugs for the calculation: S.aureus: cephaloridine 30 
μg, M.smegmatis: Streptomycin 10 μg; “-”= not active. 
Zone Ratiob 
Compda R R1 R2 
S. aureus M.smegmatis 
M-III-01 H CH3 CH3 - - 
M-III-02 4’-CH3 CH3 CH3 0.30 - 
M-III-03 4’- OCH3 CH3 CH3 - - 
M-III-04 4’-F CH3 CH3 - - 
M-III-05 4’-Cl CH3 CH3 0.31 - 
M-III-06 3’,4’-diCl CH3 CH3 0.35 0.5 
M-III-07 3’,4’,5’-triOMe CH3 CH3 - 0.8 
M-III-08 4’-CH3 CH3 C2H5 - - 
M-III-09 4’-OCH3 CH3 C2H5 - - 
M-III-10 4’-Cl CH3 C2H5 0.19 - 
M-III-11 4’-Cl CH3 c-Pr 0.3 0.35 
M-III-12 4’-CH3 -(CH2)4- 0.15 0.17 
M-III-13 4’-OCH3 -(CH2)4- 0.18 0.53 
M-III-14 4’-Cl -(CH2)4- 0.25 0.27 
M-III-15 3’,4’-diCl -(CH2)4- 0.51 0.98 
M-III-16 4’-CH3 -(CH2)5- 0.18 0.45 
M-III-17 4’-OCH3 -(CH2)5- 0.15 0.41 
M-III-18 4’-F -(CH2)5- 0.11 0.24 
M-III-19 4’-Cl -(CH2)5- 0.3 0.67 
M-III-20 3’,4’-diCl -(CH2)5- 0.18 0.56 
M-III-21 3’,4’,5’-triOMe -(CH2)5- - - 
M-III-22 3’,4’-diCl -(CH2)6- 0.43 0.85 
M-III-23 4’-CH3 -(CH2)6- 0.18 0.66 
TMP   1.09 - 
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4,6-Diamino-1-benzyl-1,2-dihydro-2,2-dialkyl-1,3,5-triazine M-III-01~M-III-23 and 
TMP were screened at the compound loading of 100 µg per disc against a panel of 
bacterial and fungi using paper disc diffusion method. The zone ratios which were used 
to express the comparative efficiency are summarized in the Table 13. However, only S. 
aureus, M. smegmatis were sensitive to most of these compounds, and P. aeruginosa, K. 
aerogenes, E. coli, B. subtilis and two fungi C. albicans, A. niger were insensitive to 
these triazines at the loading of 100 µg. In the C2 open chain 1-benzyl-1,2-dihydro-1,3,5-
triazines (M-III), some compounds showed relatively weak activity against Gram 
positive bacterial S. aureus and M. smegmatis. Compounds M-III-02, M-III-05, M-III-
06 and M-III-11 demonstrated about one third of inhibitory zone against S. aureus than 
the positive control, cephaloridine. And none of these compounds showed superiority to 
TMP at the same drug loading (100 µg/ per disc). Some C2 open chain M-III exhibited 
certain activity against M. smegmatis, against which TMP did not exhibit activity. The 
best activity against M. smegmatis was from the 4,6-diamino-1-(3’,4’,5’-
trimethoxybenzyl)-1,2-dihydro-2,2-dimethyl-1,3,5-triazine M-III-6 with the zone ratio of 
0.8. Generally, all the triazaspiroalkanes in this study showed various inhibitory activities 
against S. aureus and M. smegmatis, except M-III-21. But none of these compounds 
exhibited better activity than the controls. M-III-15 was the best among compounds in 
this series with the zone ratio of 0.98, comparable to the positive control.  
Although triazines M-III and TMP have similar benzyl side chain, the antibacterial 
activity of M-III is generally not as good as that of TMP, except for the activity against 
M. smegmatis, which were not sensitive to TMP at 100 µg per disc. Only some of 2,2-
dimethyl substituted M-III derivatives showed moderated DHFR inhibitory activity 
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against bovine DHFR, while most of the M-III were inactive with IC50 values larger than 
100 µM. The inhibitory activity against bacterial DHFR of M-III was not done in this 
study. However, the antibacterial results suggested that the inhibitory activity against 
bacterial DHFR of M-III is not superior to that of TMP. One explanation for these 
activity differences is that the rotational behavior of the triazines around the methylene 
group is quite different from that of TMP. The dimethyl substitutions at the position C2 
may be sterically large enough to force the phenyl ring of the triazines into an orientation 
that disfavored binding to the enzyme. This interpretation gives a plausible explanation 
for the fact that substitution at the position C2 of the pyrimidines decreases its activity 
markedly.221 Such kinds of substitution decrease the stability of the active conformation. 
The above suggestion suggested that the 1-benzyl-2,2-dihydro-1,3,5-triazines having no 
substitution at the C2 position, if chemically stable, may be developed into bacterial 
DHFR inhibitors. However, this series of compounds showed potential activity against M. 
smegmatis. And the bulky spiro cycloalkyl group at position C2 was well tolerated in 
their inhibitory activity. The result supports the findings on pathogenic M. tuberculosis 
that there is a pocket near the C2 position of triazines ring which may contribute the 
affinity of the inhibitors.106  
 
6.3.  Conclusion   
In summary, a series of 4,6-diamino-1-benzyl-1,2-dihydro-2,2-disubstituted-1,3,5-
triazine (M-III) was synthesized and screened against bovine DHFR and microbes.  
Although the inhibition of bovine DHFR is not as good as 4,6-diamino-1-phenyl-1,2-
dihydro-1,3,5-triazine triazines I, the antibacterial activity of the compounds is superior 
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to I. M-III did not show better activity against S. aureus than TMP.  However, M-III 
apparently have better inhibitory activity against M. smegmatis compared to TMP. Based 
on this unique activity, this series of compounds showed potential to develop as an 
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7. 4,6-Diamino-1-Phenalkyloxy-1,2-Dihydro-1,3,5-Triazines (M-IV) 
As discussed in the last chapter, 4,6-diamino-1-benzyl-1,2-dihydro-2,2-dimethyl-1,3,5-
triazines (M-III) exhibited moderate inhibitory activity against bovine DHFR. However, 
replacing the dimethyl group at 2 position of triazine ring with slightly larger groups led 
to the loss of bovine DHFR inhibitory activity, suggesting that steric hindrance may 
affect the binding affinity of the triazine ring with bovine DHFR enzyme. However, 
based on the structure of MTX, where the heterocycle is a fused bicyclic pteridine ring, 
we predict that triazaspiroalkane compounds may also fit in well in the active site. It was 
hypothesized that the size of substitution at position C2 may not be detrimental to the 
binding affinity if there is a flexible structure at position N1 of the triazine ring to reduce 
the steric hindrance; and the substitution at position C2 of 1,2-dihydro-1,3,5-triazines ring 
may serve as a lipophilicity modulator that may facilitate cellular uptake, which is very 
important for the design of non-classical antifolates using as anticancer drugs. Many 
years of SAR study of 1,2-dihydro-2,2-dimethyl-1,3,5-triazines has also demonstrated 
that an additional hydrophobic active site far from the active site cleft, where triazine 
molecule binds, could be reached using a long side chain. For example, as in Figure 17, 
both triazinate (94) and DTBSF (95), which have been evaluated in clinical trials as 
potential anticancer drug candidates, possess long side chains that originate from their 
parent triazine rings. As continuous efforts to develop potent mammalian DHFR 
inhibitors, 1-benzyl-1,2-dihydro-2,2-dimethyl-1,3,5-triazines (M-III) were modified by 
inserting an alkoxy group between the phenyl ring and triazines ring to release steric 
strains and to explore the optimal length of side chain to ensure the maximum  
hydrophobic interaction with the active site hypothesized above.  So the objective of this 
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study was to synthesize a series of phenylalkyloxytriazines with various alkyl or 
cycloalkyl groups introduced at position 2 of 1,2-dihydro-1,3,5-triazine ring and to 
evaluate if different C2 substituents and length of side chain will be able to enhance 

















Triazinate, 94  
Figure 17. Chemical structures of triazinate (94) and DTBSF (95) 
 
7.1. Chemistry 
As illustrated in Scheme 47, the synthesis of 4,6-diamino-1-phenylalkyloxy-1,2-dihydro-
1,3,5-triazines (M-IV) was carried out from O-aminophenylalkyl alcohol hydrochloride 
with various ketones via the well known procedure of “One-Pot Three-Component” 























Scheme 47. Synthesis of 4,6-diamino-1-phenalkyloxy-1,2-dihydro-1,3,5-triazines (M-IV) 
The “One-Pot Three-Component” synthesis was generally carried out at reflux 
temperature as reported by Modest.25 However, this condition worked well only with 
acetone as the reactant in this study. Using the absolute alcohol as solvent, the O-
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aminophenylalkyl alcohol hydrochloride condensed with acetone and cyanoguanidine 
under the reflux condition for 6 hours, followed by crystallization over night at room 
temperature to give M-IV-1 in 53.8% yield. With other hindered ketones or aldehydes, 
the phenylalkoxybiguanide intermediate was the common side product when reflux 
temperature was used during the syntheses. Some products did not precipitate out during 
the reaction and they needed to be kept in the refrigerator for a few days before 
precipitation could occur. The yields of the products were also very poor. In most cases, 
no precipitate was observed even after concentrating the mother liquor. These 
observations suggested that high temperature was not favorable when bulky ketones or 
aldehyde were used. The high temperature might have caused the triazine ring of the 
product to re-open due to the high energy that was supplied, once it was formed. Hence, 
it could be envisaged that the second step of the synthesis might be reversible and ring 
opening might occur to cause the 1,2-dihydro-1,3,5-triazines to revert back to their 
phenylalkyloxybiguanide intermediates. This phenomenon was more predominant in 
bulky and hindered ketones because the triazine ring closure was rather difficult to occur 
due to steric hindrance from the bulky ketone. But triazine ring opening occurred rather 
readily because the phenylalkyloxybiguanide intermediate was the more unhindered 
species. It was less strained and thus thermodynamically more favored and stable than the 
corresponding 1-phenoxy-1,2-dihydro-1,3,5-triazine. Room temperature was finally used 
to perform the reactions. However, the formation of biguanide occurred very slowly at 
room temperature. Based on this concern, the synthesis of these triazines from hindered 
ketones was separated into two steps in one pot. In the fist step, O-aminophenylalkyl 
alcohol hydrochloride was refluxed with cyanoguanidine in absolute alcohol for 3 hours 
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for the formation of biguanides; then in the following step, the ketones or aldehyde and 
conc. HCl were added in the cooled solution of the mixture and the reaction was executed 
at room temperature to synthesize the target compounds. The progress of the reaction was 
monitored by TLC (chloroform : methanol = 3:1 ) or by the measurement of the 
disappearance of the biguanide using the ammoniacal copper complex test. Under room 
temperature, the relative reactive speed of the ketone or aldehyde reagents employed was 
observed in the following trend: cyclohexanone (24h) > cycloheptanone (48 h) > c-propyl 
formaldehyde (120 h) > cyclopentanone (7 days) > cyclobutanone (8 days). Water 
scavenger could not increase the reaction speed; and on the contrary, led to a decrease in 
the reaction yields. The chemical and physicochemical properties of this series of 
compounds are listed in Table 14. 
 
 
Table 14. Chemical structures and physicochemical data of the newly synthesized M-IV 
Elemental Analysis 





C H N C H N 
M-IV-01 CH3 CH3 1 283.76 53.8 208-209 50.79 6.39 24.68 50.31 6.22 24.49 
M-IV-02 CH3 C2H5 1 297.78 51.0 211-215 52.43 6.77 23.52 52.55 6.76 23.68 
M-IV-03 H c-Pr 1 295.77 48.4 201-202 52.79 6.14 23.68 53.01 6.10 23.88 
M-IV-04 -(CH2)3- 1 295.77 43.3 207-208 52.79 6.13 23.68 53.15 6.22 23.74 
M-IV-05 -(CH2)4- 1 309.79 46.8 195-196 54.28 6.51 22.61 53.91 6.58 22.33 
M-IV-06 -(CH2)5- 1 323.82 64.9 216-217 55.64 6.85 21.63 55.93 6.86 21.78 
M-IV-07 -(CH2)6- 1 337.85 60.1 201-203 56.88 7.16 20.73 56.69 7.37 20.63 
M-IV-08 -(CH2)4- 2 360.28 27.1 210-211 50.01 6.43 19.44 50.26 6.17 19.66 
M-IV-09 -(CH2)5- 2 337.85 13.8 225-226 56.88 7.16 20.73 56.50 7.09 20.56 
M-IV-10 -(CH2)4- 3 374.31 27.3 186-188 51.34 6.73 18.71 51.65 6.47 18.83 
M-IV-11 -(CH2)5- 3 360.88 28.0 216-218 56.58 7.54 19.41 56.58 7.30 19.27 
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The key intermediate, O-aminophenylalkyl alcohol hydrochloride was prepared via a 
four-step reaction as illustrated in Scheme 48. Starting from the hydroxyamine 
hydrochloride, potassium benzohydroxamate was prepared by the action of hydroxyl 
amine hydrochloride on ethyl benzoate in the solution of KOH and methanol, producing 
60% yield. Acidifying the potassium benzohydroxamate with acetic acid and 
recrystallization with ethyl acetate gave benzohydroxamic acid in 70% yields. The 
benzohydroxamic acid was reacted with phenylalkyl bromide to form the phenylalkyl 
benzoxamate (68%-72.7%), which was treated with conc. HCl to give O-






















Scheme 48. Synthesis of O-aminophenylalkyl alcohol hydrochloride 
 
7.2 Pharmacological Evaluations 
7.2.1 Antifolate Activity of Compounds M-IV against Bovine DHFR 
All of the 11 compounds were screened against bovine DHFR to obtain the IC50 value 
(Table 15). When the N1 substituent was replaced from a benzyl group to a benzyloxy 
group, the IC50 value of M-IV-01 was decreased by more than 250-fold, to 0.069 μM 
compared to M-III-01 which showed the moderate IC50 value of 19.15 μM. This 
dramatic improvement on the inhibitory activity could be explained by the further relief 
of steric stress caused by C2 dimethyl group and N1 phenyl ring. In addition, the inserted 
oxygen may sever as hydrogen bond acceptor to interact with the hydrogen bond donor of 
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the DHFR enzyme. However, a bulky substituent at C2 position of the triazine ring was 
often detrimental to the inhibitory activity of 1-benzyloxy-1,2-dihydro-1,3,5-triazines. 
With a methyl and an ethyl group disubstitution at the C2 position, the activity of 
compound M-IV-02 was decreased more than two times than that of dimethyl triazine 
M-IV-01. 2-cyclopropyl substituted triazine M-IV-03 also demonstrated weaker activity 
(IC50 = 0.548 µM) than M-IV-01. While the open chain substituted compound at position 
C2 exhibited decreased activity, the C2-spiro substituted compounds with 1-benzyloxy 
substitution also have similar trend on their DHFR inhibitory activity. The activity 
decreased with the size of the spiro rings in the triazaspiroalkanes. The sequences of the 
IC50 values of these compounds were as follows: cyclobutyl < cyclopentyl < cyclohexyl < 
cycloheptyl. The reduction in inhibitory activity when bulky groups were introduced 
similarity were observed in the chemical series M-III, suggesting that C2 position of the 
triazine ring may have interaction with the active site of DHFR, a small substituent like 
dimethyl groups offer better fit. Ethyl, cyclobutyl and cyclopentyl were slightly bigger; it 
might push the phenyl ring to a disfavor conformation. When a cyclohexyl or cycloheptyl 
group was present, it was too big to be able to fit into the enzyme. Hence, the binding 
was very weak or the inhibitor might be displaced from the active site and this resulted in 
a high IC50 value. As the alkoxy chain length was further increased by one methylene 
group, the compounds with the cyclopentyl and cyclohexyl groups at C2 position were 
found to have more potent activity against bovine DHFR, compared their 1-benzyloxy 
counterparts. For example, 1-phenylethyloxy substituted compound M-IV-08 exhibited 
more than 5 times potent bovine DHFR inhibitory activity than 1-benzyloxy compound 
M-IV-05. Compound M-IV-09 showed even more dramatically increased activity with 
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1-phenylethyloxy substitution than M-IV-06 did, when the cyclepentyl group was 
replaced with cyclohexyl groups. Further elongation from inserting one methylene group 
into two methylene group, the inhibitory activity of M-IV-10 and M-IV-11 exhibited 
opposite trends; M-IV-10 showed slightly increased activity over M-IV-08, while M-IV-
11 exhibited three times decreased activity over M-IV-09. However, their activity was 
still substantially much higher than their 1-benzyloxy substituted analogues, respectively. 
M-IV-09 exhibited the lowest IC50 value among this whole series of compounds with the 
IC50 value of 9 nM, which lied in the same inhibitory range of the positive control of 
MTX.  










Compounds n R1 R2 DHFR, IC50 (µM) 
M-IV-01 1 CH3 CH3 0.069 
M-IV-02 1 CH3 C2H5 0.155 
M-IV-03 1 H c-Pr 0.548 
M-IV-04 1 -(CH2)3- 0.134 
M-IV-05 1 -(CH2)4- 0.173 
M-IV-06 1 -(CH2)5- 1.79 
M-IV-07 1 -(CH2)6- 5.33 
M-IV-08 2 -(CH2)4- 0.031 
M-IV-09 2 -(CH2)5- 0.009 
M-IV-10 3 -(CH2)4- 0.020 
M-IV-11 3 -(CH2)5- 0.032 
MTX   0.0034 
 
This simple elongation of the side chain at position N1 brought a dramatic enhancement 
in the inhibitory activity against bovine DHFR.  The trend of elongation on the increase 
of inhibitory activity was observed as follow: 1-phenylethyloxy ≈ 1-phenylpropyl > 1-
benzyloxy > 1-benzyl. This trend suggested that there could be hydrophobic pocket 
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located away from the triazine heterocycle that could accommodate the phenyl ring. The 
interaction between the active site and the phenyl ring, which is 2-4 atoms away from the 
triazine heterocycle, compensates the loss of the original interaction by 1-phenyl ring 
with the active site. This hypothesis on the active site could also be supported by SAR 
study of 1-alkyl and 1-phenylalkyl substituted triazines, in which it was believed in the 
study that the hydrophobic binding region did not start until the third carbon of the side 
chain.222 The 1-oxy atom is also believed to be involved in an interaction with the 
enzyme via hydrogen bond interaction, since the 1-benzyloxy-1,2-dihydro-1,3,5-triazine 
showed greatly increased activity over 1-benzyl-1,2-dihydro-1,3,5-triazines. Bulky 
groups located at C2 may introduce steric effect and caused conformational change that 
reduced the affinity of the inhibitor to the enzyme. However, after as the side chain was 
increased in length, this steric effect was less of an issue to binding affinity of the 
inhibitor. On the contrary, the bulky substitution at position C2 may also increase the 
activity based on new lipophilic interactions. This position could also be served as a 
modulator on the lipophilicity of the triazines, which is an important requirement for non-
classical antifolate to penetrate cells.  
Since these compounds have showed potent inhibitory activity against bovine DHFR, it 
presented potential for the development of these triazines into anticancer agents. The 
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7.2.2. Antiproliferative Activity of Compounds M-IV against the MCF-7 Breast 
Cancer Cell Line 
The potent bovine DHFR inhibitory activity observed in this library of compounds M-IV 
prompted an investigation on their antiproliferative activity against human breast cancer 
cell MCF-7 and human lung fibroblast MRC-5 at the concentration of 20 µM. As a 
preliminary investigation, the antiproliferative activity of the series M-IV was carried out 
using a semiautomated fluorometric microculture cytotoxicity assay (FMCA) and 
percentage of inhibition of compounds at the concentration of 20 µM was determined 
(Table 16).  











Antiproliferative activity  
Inhibition% at 20 µM Compounds n R1 R2 
DHFR, 
IC50, 
(µM) MCF-7 MRC-5 
M-IV-01 1 CH3 CH3 0.069 32.6 25.2 
M-IV-02 1 CH3 C2H5 0.155 30.8 17.5 
M-IV-03 1 H c-Pr 0.548 18.3 15.1 
M-IV-04 1 -(CH2)3- 0.134 33.3 25.1 
M-IV-05 1 -(CH2)4- 0.173 22.9 16.7 
M-IV-06 1 -(CH2)5- 1.79 14.6 17.5 
M-IV-07 1 -(CH2)6- 5.33 5.6 12.8 
M-IV-08 2 -(CH2)4- 0.031 22.9 24.5 
M-IV-09 2 -(CH2)5- 0.009 32.9 16.2 
M-IV-10 3 -(CH2)4- 0.020 30.8 18.0 
M-IV-11 3 -(CH2)5- 0.032 44.8 52.3 
MTX   0.0034 50.5 22.3 
 
Although some compounds in this series showed potent bovine DHFR inhibitory activity, 
however, only moderate antiproliferative activity was observed for the compounds of all 
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this series on MCF-7 as well as MRC-5. Compound M-IV-11 showed the best 
antiproliferative activity against MCF-7, with a 44.8 % inhibition at 20 µM, which was 
comparable to MTX (50.5 %). However, M-IV-11 exhibited marginally higher 
antiproliferative activity against MRC-5, showing that this compound was less selective 
to the normal cell. M-IV-11 was not the most potent DHFR inhibitor among this library, 
but it is the most lipophilic compound. The lipophilicity of this compound may be the 
reason why it turned out to be the most antiproliferative compounds in this library, 




In summary, 1-phenylalkyloxy-1,2-dihydro-1,3,5-triazines (M-IV) with various alkyl or 
cycloalkyl groups at 2 position exhibited potent bovine DHFR inhibitory activity. M-IV-
09 showed the best activity among this series of compounds with the IC50 value of 9 nM, 
which lied in the same inhibitory range of the positive control of MTX. However, some 
antiproliferative activity was observed for this series of compounds on MCF-7 as well as 
MRC-5 cell lines. Among them, M-IV-11 showed reasonably good antiproliferative 
activity against both cells. Further structural optimization is needed to improve their 
DHFR inhibitory activity against bovine DHFR and their potential antiproliferative 
activity. Some of the latest study of this series will be discussed in the next chapter.    
 
 





Among the different side chains inserted at N1 position of the triazine ring that were 
evaluated in the course of this work, 5-(3’-phenyloxypropoxy)-1,3,5-triaza-
spiro[5.5]undeca-1,3-diene-2,4-diamine (M-IV-11) showed potent bovine DHFR 
inhibitory activity, and more importantly, it exhibited antiproliferative activity against the 
human breast cancer cell line MCF-7. This biological activity made it a promising lead 
for the development of a new DHFR inhibitor for cancer chemotherapy. Two notable 
properties on its chemical structure were its phenylpropyloxy side chain and cyclohexyl 
spiro ring at position C2 of the triazine ring. Similar type of side chain was also found in 
the molecule WR99210 (89), which has a trichlorophenoxypropyloxy side chain linking 
to the N1 position of triazine ring. WR99210 was an active inhibitor of Plasmodium 
DHFR-TS.106 WR99210 has been developed for about ten years, and almost all the 
attentions have been focused on the antimalarial applications. Since this compound also 
showed potent activity against mammalian DHFR, there is potential to be developed into 



































Figure 18. Chemical structures of M-IV, WR99210 and M-V 
 
The promising results obtained with M-IV-11 and WR99210 have led us to consider 
synthesizing analogues based on the two lead hits in order to identify the optimal 
structural features for antiproliferative activity (Figure 18). The initial steps in this study 
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included the synthesis of triazines with 1-phenoxyalkyloxy analogues, such as M-V-07 
and M-V-08, which inserted an oxygen atom between phenyl ring and alkoxy group of 
M-IV. Currently at position C2 of triazine ring, there is a complete lack of structure-
activity studies in the literature to date. In the present study, a series of triazines with 
different alkyl and spiroalkyl at position C2 substitutions of triazines ring with 1-
phenoxyalkyloxy side chain was synthesized. Different substitution on the phenyl ring 
was also applied to explore the SAR of their biological activity. 
 
8.1 Chemistry 
Scheme 49 depicts the two general synthetic pathways (Route A and B) used to prepare 
4,6-diamino-1-(phenyloxyalkyloxy)-1,2-dihydro-1,3,5-triazines (M-V). In route A, it 
involved fragment coupling and independent synthesis. The substituted phenyloxyalkyl 
bromides were converted by the reaction of dibromoalkane with substituted phenol. The 
N-hydroxytriazines were prepared by hydrogenation to remove the benzyl group of M-IV. 
Then the target compounds M-V were prepared by alkylation of a substituted 
phenyloxyalkyl bromide with the N-hydroxytriazine. In route B, a linear synthesis 
method has been devised: the target compounds were prepared starting with a selected 
substituted phenol which was converted to a bromo ether. The bromo compound was then 
used to prepare the intermediate amino-oxy compounds. The amino-oxy intermediates 
were converted to the biguanides by reaction with cyanoguanidine. Finally, the target 
triazines were obtained by cyclization of the biguanides with the corresponding ketones. 
Both synthetic routes have their own advantages. Route A can be used to synthesize 
compounds with various side chains. Route B can achieve molecular diversity using 
different ketones in the final step to obtain triazines with different substituents at C2 
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position. However, in chemistry the convergent synthetic route A is a strategy that aims 
to improve the efficiency of multi-step chemical synthesis, and in linear synthesis route B, 
the overall yield quickly drops with each reaction step. In addition, since our main aim of 
study is to explore the impact of different linker and different substitutions of the phenyl 










































































Reagents: (a) PhCONHOH,NaOH, Methanol; (b) Conc HCl, methanol; (c) cyanoguanidine, EtOH, HCl; 
(d).HCl ethanol
 
Scheme 49. Synthetic routes of target compounds M-V 
All the phenols in use are commercially available, except for 4-(aminosulfonyl) phenol 
which was synthesized in 78% yield via a diazotization of the corresponding 
sulphanilamide in an acidic solvent using sodium nitrate, sulfuric acid at 0-5oC followed 
by boiling the solution with aqueous H2SO4.223 1-Aryloxybromoalkanes were synthesized 
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by alkylation of phenols with dibromoalkanes using potassium carbonate or sodium 
hydroxide as the base, and acetonitrile as the solvent. The use of 1-bromo-3-
chloropropane could avoid the danger of dialkylation and usually produced 1-aryloxy-3-
chloropropane as a major product. However, 1-aryloxy-3-chloropropane reacted with N-
hydroxytriazines at a slow pace and the use of higher temperature would generate other 
impurities. The bromo-chloro or iodo-chloro halogens exchange methods was use to 
offset the reactability, however with the inclusion of an addition step in the reaction, it 
increased the complexity of the reaction. Considering all the factors mentioned above, 
dibromoalkane was still the best choice in the synthesis of 1-aryloxybromoalkanes as 
illustrated in Scheme 50 and two procedures have been applied to avoid the formation of 
the disubstituted by-product. Firstly, excess dibromoalkane was used and the optimal 
molecular ratio of phenols to the dibromoalkane in the reaction was found to be 1:3; the 
surplus dibromoalkane was removed after the reaction either by reduced pressure 
distillation or by column chromatography. Secondly, a dropping funnel was used to add 
the dissolved phenols in a controlled rate into the refluxing dibromides in acetonitrile and 
potassium carbonate solution. In this manner, the amount of dibromides in the reaction 
mixture was always in excess and this reduced the formation of disubstituted by-products. 
OH





Scheme 50. Synthesis of 1-aryloxybromoalkanes 
The synthesis of N-hydroxytriazines began with the use of 1-benzyloxy triazines 
(Scheme 51). The synthesis of 1-benzyloxy-1,3,5-triazines has been discussed in Section 
6.1. The benzyl group was removed in many occasions by hydrogenolysis using 10% Pd-
C as the catalyst in this reaction. However, Pd-C cannot be used in this hydrogenolytic 
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debenzylation, because Shatzmiller S. et al. reported that N-O bonds are also readily 
hydrogenolyzed using Pd-C.224 Platinum oxide (Adams’ catalyst) has been used to 
catalyze the hydrogenation and hydrogenolysis of many functional groups. PtO2 is not an 
active catalyst, so no precaution is necessary with the oxide; and this property offers 
another advantage over Pd-C, which need to be stored away from solvents and potential 
poisons such as sulfur- and phosphorous- containing compounds. In the presence of H2, 
the oxide is reduced to Pt black which is the active form of PtO2. A precaution to be 
taken during filtration is that the filter cake must not be allowed to go dry. The benzyl 
group attached to N-oxy-triazines was hydrogenolyzed using 3% PtO2 in the 50% alcohol 















Scheme 51. Synthesis of 1-hydroxy-1,2-dihydro-1,3,5-triazines 
After the synthesis of the two fragments, the target compounds were obtained by 
Williamson etherification as illustrated in Scheme 52. The Williamson ether synthesis 
reaction between an alkoxide or phenoxide anion and a sterically unhindered alkyl halide 
has been extensively studied for 150 years.225 Since N-substituted hydroxyl group of 
triazines have pKa value of 13.9, sodium hydroxide was used to deprotonate the hydroxyl 
group into N-hydroxide anion, rather than use a much stronger base. And sodium 
hydroxide cannot be exceeded in this reaction to limit the side reaction of the elimination 
of phenoxyalkyl bromide. After the deprotonation, methanol was removed and a polar 
aprotic solvent DMF was used for this SN2 substitution. Bromide was added with DMF 
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and mixture was stirred at room temperature to furnish the ether in 44.3-71.4% yields 




















Scheme 52. Synthesis of target compounds M-V 





















(%) C H N C H N 
M-V-01 H CH3 CH3 1 194-195 66.2 47.10 6.44 19.62 47.04 6.23 19.60 
M-V-02 H CH3 CH3 2 190-191 54.0 50.07 7.28 19.46 50.13 6.81 19.37 
M-V-03 H CH3 C2H5 1 175-176 53.3 47.62 6.66 18.51 47.65 6.53 18.30 
M-V-04 H H c-Pr 1 207-208 51.1 50.86 6.71 19.77 50.78 6.39 19.60 
M-V-05 H -(CH2)4- 1 191-192 56.5 51.68 6.78 18.84 52.08 6.76 18.80 
M-V-06 H -(CH2)4- 2 190-191 57.6 53.41 7.28 18.32 53.09 7.13 18.63 
M-V-07 H -(CH2)5- 1 209-210 71.4 52.91 7.31 18.15 52.62 7.49 18.39 
M-V-08 H -(CH2)5- 2 205-206 67.3 55.31 7.48 17.92 55.20 7.69 17.83 
M-V-09 H -(CH2)6- 1 203-205 55.9 54.55 7.53 17.67 54.42 7.15 17.74 
M-V-10 F -(CH2)5- 1 211-212 62.1 52.92 6.53 18.15 52.75 6.56 18.06 
M-V-11 Cl -(CH2)5- 1 219-220 64.8 50.75 6.26 17.41 50.49 6.20 17.57 
M-V-12 NO2 -(CH2)5- 1 212-213 60.5 46.97 5.93 19.33 46.99 5.78 19.12 
M-V-13 Me -(CH2)5- 1 214-215 61.4 56.61 7.39 18.34 56.47 7.45 18.60 
M-V-14 t-Bu -(CH2)5- 1 222-223 47.4 54.78 7.66 15.21 54.82 7.46 15.23 
M-V-15 OMe -(CH2)5- 1 202-203 51.3 51.53 7.30 16.69 51.54 6.97 16.47 
M-V-16 CN -(CH2)5- 1 221-222 53.4 54.53 6.46 21.20 54.60 6.42 21.02 
M-V-17 COCH3 -(CH2)5- 1 206-207 67.1 53.78 7.03 16.50 53.81 6.88 16.62 
M-V-18 SO2NH2 -(CH2)5- 1 198-199 44.3 40.72 6.03 16.76 40.64 5.78 16.66 
M-V-19 F -(CH2)4- 1 182-183 63.6 49.29 6.46 17.96 48.93 5.99 18.19 
M-V-20 Cl -(CH2)4- 1 199-200 67.1 46.44 5.77 16.92 46.37 5.57 16.90 
M-V-21 NO2 -(CH2)4- 1 210-211 62.6 44.90 5.60 19.63 44.82 5.33 19.39 
M-V-22 Me -(CH2)4- 1 192-193 61.3 52.91 7.31 18.15 52.86 7.42 18.53 
M-V-23 t-Bu -(CH2)4- 1 197-198 62.7 56.61 7.98 16.50 56.62 7.85 16.40 
M-V-24 OMe -(CH2)4- 1 187-188 58.0 51.27 6.98 17.58 51.22 6.61 17.61 
M-V-25 CN -(CH2)4- 1 202-203 66.6 51.45 6.35 21.18 51.42 6.02 21.25 
M-V-26 COCH3 -(CH2)4- 1 194-195 66.9 52.23 6.82 16.92 51.87 6.47 16.86 
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8.2. Pharmacological Evaluations 
8.2.1. Antifolate Activity of Compounds M-V against Bovine DHFR 
The 4,6-diamino-l-phenoxyalkyloxy-1,2-dihydro-1,3,5-triazines (M-V) were examined 
for their inhibitory effects on bovine liver DHFR. The results were compared with that of 
MTX (Table 18). M-V-01 showed a ten-fold increase of DHFR-inhibitory activity over 
M-IV-01. The elongation of the N1 side chain from benzyloxy to phenoxypropyloxy at 1 
position resulted in substantial improvement in the inhibitory activity, but the potency of 
this compound did not match that of MTX. The flexibility in the side chain appeared to 
enhance the activity. It may be due to the flexible oxygen bridge found in the compound 
which allows the molecules to adopt suitable confirmations for binding at the active site 
of the enzyme and thus minimizing the steric hindrance presented by the enzyme 
structure. The data suggested that there might be an optimal length for the side chain; 
analogues with 3-carbons between the 2 oxygen atoms exhibited the strongest inhibition, 
while 4-carbon analogues produced a weaker inhibition. For example, M-V-02, which 
has a 4-phenoxy butyloxy side chain on N1 position, was four times weaker than M-V-01. 
Similar activity trend was also observed between M-V-05 and M-V-06, where a bulky 
spiro-cyclopentyl substitution was located at position C2 of 1,2-dihydro-1,3,5-triazine 
ring. Compounds M-V-07, M-V-08 and M-IV-10, all of which have a spiro-cyclohexyl 
substitution at position C2 of triazine ring, showed varied DHFR inhibitory activity. 
Their potencies were ranked according to the different side chains in the following order: 
1-phenoxypropyloxy > 1-phenylpropyloxy > 1-phenoxybutyloxy suggesting the optimal 
length of the side chain. Triazaspiroundecadiene M-V-7 also showed potent inhibitory 
activity with the IC50 of 6.9 nM. With this optimal 1-phenoxypropyloxy side chain, 
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analogues varied by different substituents at position C2 of triazines rings were also 
explored. The overall DHFR inhibitory activity of these compounds with different 
substitutions at position C2 of the 1,2-dihdro-1,3,5-triazine ring was well tolerated. For 
open chain substituted compounds, 2-methyl-2-ethyl compound M-V-03 and 2-
cyclopropyl compound M-V-04 showed similar inhibitory activity against bovine DHFR, 
which are comparable to the 2,2-dimethyl compound M-V-01. For the 2-spiro ring 
substituted compounds, the ring size was found to affect the DHFR inhibitory potency, 
with the larger ring size being less active: cyclopentyl > cyclohexyl > cycloheptyl. M-V-
05 demonstrated the most potent activity among the compounds in this series, with the 
IC50 value of 2.3 nM, which is comparable to MTX (IC50=3.4 nM).  
In order to investigate whether the substitution on phenyl ring has any effect on the 
inhibitory activity, a series of differently substituted phenyl analogues of M-V-05 was 
synthesized and evaluated on the bovine DHFR. For selection of the R groups, the 
parameter plot developed by Craig was used to select the substituents that covered a wide 
range of variation in terms of hydrophobicity (π) and electronic (σ) properties, such that 
electronic effects versus hydrophobicity contributions to biological activity could be 
evaluated. Following the Craig plot, R = F, Cl, NO2 groups (+π, +σ), R = OCH3 (-π, -σ ), 
R = CH3 and t-C(CH3)3 (+π, -σ) and R = CN, SO2NH2 and COCH3 (-π, +σ) were selected 
for this study. As tabulated in Table 19, no increase in inhibitory activity was observed 
with the all 4’-substituted compounds. The inhibitory activity against bovine DHFR was 
also not very well tolerated on the changing of substituents. The bulky substituent 
introduced by C(CH3)3 at 4’-position of phenyl ring led to the loss about ten times of  the 
activity compared to the non-substituted compound M-V-05. Other substituents, no 
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matter electron-withdrawing or electron-donating, did not produce better inhibitory 
activity as compared to the non-substituted compound M-V-05. This observation 
indicated that substitution at 4’-position of the side chain phenyl ring may present 
influence on the active site. 











Compd R R1 R2 n DHFR, IC50 (nM) 
M-V-01 H CH3 CH3 1 5.9 
M-V-02 H CH3 CH3 2 27.1 
M-V-03 H CH3 C2H5 1 7.7 
M-V-04 H H c-Pr 1 7.3 
M-V-05 H -(CH2)4- 1 2.3 
M-V-06 H -(CH2)4- 2 42.2 
M-V-07 H -(CH2)5- 1 6.9 
M-V-08 H -(CH2)5- 2 155.5 
M-V-09 H -(CH2)6- 1 11.3 
M-V-10 F -(CH2)5- 1 15.4 
M-V-11 Cl -(CH2)5- 1 13.8 
M-V-12 NO2 -(CH2)5- 1 14.7 
M-V-13 Me -(CH2)5- 1 17.5 
M-V-14 t-Bu -(CH2)5- 1 21.5 
M-V-15 OMe -(CH2)5- 1 6.1 
M-V-16 CN -(CH2)5- 1 9.7 
M-V-17 COCH3 -(CH2)5- 1 13.3 
M-V-18 SO2NH2 -(CH2)5- 1 5.6 
M-V-19 F -(CH2)4- 1 10.1 
M-V-20 Cl -(CH2)4- 1 7.2 
M-V-21 NO2 -(CH2)4- 1 8.4 
M-V-22 Me -(CH2)4- 1 9.5 
M-V-23 t-Bu -(CH2)4- 1 17.0 
M-V-24 OMe -(CH2)4- 1 11.2 
M-V-25 CN -(CH2)4- 1 7.6 
M-V-26 COCH3 -(CH2)4- 1 9.2 
MTX    3.4 
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In the present study, M-V-07 with a spiro-cyclohexyl group at C2 showed better 
inhibitory activity than one of lead compounds M-IV-11 which have the same spiro-
cyclohexyl substitution. Thus, a series of analogues of M-V-07 with different selected 
substitutions on the phenyl based on Craig plot were also synthesized and evaluated for 
biological activity. On the phenyl ring, all the electron-withdrawing and electron-
donating substituents with +π hydrophobicity showed decreased inhibitory activity; and 
compounds with bulky t-Bu group was the least active compound with IC50 of 21.5 nM. 
All the –π hydrophobicity compounds showed varied activity. Electro-donating 
substituent such as SO2NH2 and electron-withdrawing substituent such as MeO were 
compatible with high activity. And CN substituted compound M-V-16 showed decreased 
activity down to 10~20 nM range.  
The results in this work demonstrated that the three CH2 groups between the two-oxygen 
bridge in the side chain is the critical determinant of the potent DHFR inhibition. It 
suggests that the location of the phenyl ring in M-V and M-IV series may allow it to 
interact optimally with some lipophilic residues in the DHFR active site. Substitution at 
the para position of the phenyl ring also plays an important role on the potency of the 
compounds. However, since their inhibitory activity was not well correlated to the 
electronic and lipophilic effects of the substitution, steric component may also contribute 
to the inhibitory activity against bovine DHFR. The inhibitory potency was well tolerated 
with the variation on the position C2 of the 1,2-dihydro-1,3,5-triazine ring, however, the 
variation may be important in the cellular uptake of the non-classical antifolates since it 
changes the lipophilicity of the compounds. This hypothesis will be proven in the 
following section. 
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8.2.2 Antiproliferative Activity 
The potent inhibitory activity against bovine DHFR of compounds in the M-V library 
suggests that these compounds may exhibit good antiproliferative activity against human 
cancer cells. To this end, the antiproliferative activity of compounds series M-V was 
investigated using a semiautomated fluorometric microculture cytotoxicity assay 
(FMCA). Three human cancer cell lines were used to screen this triazines series, namely 
the MCF-7, MDA-MB-231 and A549 cell line. The MCF-7 cells and MDA-MB-231 cells 
were selected because the properties of these cells are akin to human breast cancer cells 
and they have been used successfully as models to investigate antiproliferative activity 
against estrogen receptor positive (ER(+)) and estrogen receptor negative (ER(-)) breast 
cancer, respectively.227-228 MDA-MB-231 is a breast cancer cell line with a poor capacity 
for polyglutamate synthesis and defective in transporting MTX and thus less sensitive to 
MTX toxicity and is also more aggressive than the ER (+) breast cancer cells.229 A549 
cells are estrogen receptor negative cells which are akin to non-small cell lung carcinoma. 
In comparison with the antiproliferative effects of the test compounds against normal 
cells, human lung fibroblast cell line MRC-5 was chosen as a reference for non-
carcinoma cells. As a preliminary study, three different concentrations (20µM, 2µM and 
0.2 µM) were used in the screening process. The percentage of the inhibition which 
resulted in the reduction of cell growth at different concentrations was compared to the 








Table 19. Antiproliferative activity of M-V and MTX against breast cancer celllines 
MCF-7 and MDA-MB-231 in terms of inhibition percentage 
 
MCF-7, non-viable cells % MDA-MB-231, non-viable cells % Compd 20µM 2 µM 0.2 µM 20µM 2 µM 0.2 µM 
M-V-01 53.7 49.1 32.3 89.4 86.6 48.6 
M-V-02 61.2 50.6 9.8 88.0 83.9 51.8 
M-V-03 63.5 52.8 3.8 89.4 84.4 50.2 
M-V-04 53.8 45.3 8.1 89.3 84.5 41.8 
M-V-05 67.9 52.0 31.9 95.2 88.1 51.2 
M-V-06 68.7 50.1 2.3 97.3 88.0 48.2 
M-V-07 64.9 47.2 14.9 96.9 87.6 42.5 
M-V-08 83.5 34.3 3.5 92.7 79.7 19.8 
M-V-09 73.3 34.8 8.1 96.3 86.5 25.7 
M-V-10 52.0 44.1 5.6 97.4 86.8 49.7 
M-V-11 89.3 40.7 0.0 96.8 87.3 42.2 
M-V-12 53.0 39.5 4.7 91.5 85.6 47.2 
M-V-13 92.6 48.7 7.2 97.1 87.4 52.9 
M-V-14 93.0 24.9 -2.4 97.4 96.8 20.7 
M-V-15 54.4 46.4 5.4 93.9 84.9 54.5 
M-V-16 49.6 38.2 10.2 89.4 85.8 51.2 
M-V-17 61.9 47.2 17.3 87.4 85.7 52.0 
M-V-18 43.9 43.1 9.2 87.0 70.5 0.6 
M-V-19 50.7 43.0 7.2 93.0 83.8 51.1 
M-V-20 90.0 48.4 32.7 95.5 86.3 58.3 
M-V-21 47.0 43.6 4.9 93.0 89.3 44.0 
M-V-22 87.6 47.2 6.4 97.7 89.1 58.8 
M-V-23 92.7 92.4 0.7 97.7 97.2 31.7 
M-V-24 61.9 47.2 17.3 95.1 88.3 48.6 
M-V-25 43.9 43.1 9.2 90.7 87.8 25.4 
M-V-26 50.7 43.0 7.2 88.7 88.0 44.4 
MTX 50.5 52.8 49.9 87.3 63.4 3.8 
 
As shown in Table 19, a wide range of antiproliferative activity of compounds in the M-
V library against MCF-7 was observed at the concentration of 20 µM, and the percentage 
of the inhibition against the MCF-7 varied from 43.9 % to 93.0 %. The overall inhibition 
was obviously more potent than compounds from the M-IV library. Among the 
compounds in M-V, those with lipophilic substitutions on the phenyl ring, such as chloro, 
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methyl and t-butyl, showed more than 80% antiproliferative effects on the MCF-7 cells at 
the concentration of 20 µM. This result could be attributed to higher lipophilicity of these 
compounds which theoretically allowed better penetration across the cell membranes, 
therefore, the concentration of the compound was achieved sufficiently high to bring 
about the biological activity. When the drug concentration was diluted to 2 µM, those 
compounds with lipophilic substitution on the phenyl ring exhibited inhibition lower than 
50 %, indicating their IC50s might fall between 2 µM and 20 µM. There was only one 
exception, compound M-V-23 which has a t-butyl group substituted on the 4’-position of 
the phenyl ring which still showed high antiproliferative activity at 92.4%. However, the 
MTX, a positive control, showed 52.8% inhibition against MCF-7 at 2 µM. when the 
concentration was reduced to 0.2 µM, the inhibitory activity of MTX was stable at the 
49.9%, while the inhibition of M-V-23 dropped to 0.7 %. These results showed that the 
triazine M-V-23 and MTX may have different dose-dependent pattern on MCF-7. A 
dose-response curve of M-V-23 and MTX for MCF-7 are shown in Figure 19. Treatment 
of MCF-7 with different concentrations of M-V (2 µM-20 µM) led to a marked dose 
dependent growth inhibition as determined in the FMCA. However, the dose-response 
properties of MTX for MCF-7 exhibit distinctly different pattern from the M-V 
compounds. A higher concentration (100 µM) of MTX was also used in this study; 
however, the inhibition percentage of MTX was still 50.5 ± 8 %.   It revealed that MTX 
was cytostatic agents on this cell line, and MCF-7 may not be a MTX sensitive cell line, 
although MTX has been found to be used in clinic against breast cancer. MTX showed 
potent bovine DHFR inhibitory activity (IC50 = 3.4 nM) which is higher than M-V-23, 
however, the antifolate activity cannot be mirrored in MCF-7 cancer cell growth. The 
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result suggests that other mechanisms besides antifolate activity may also involve in the 



















Figure 19. Antiproliferative activity of M-V-23 and MTX on MCF-7 cell line dependent on dose of drug exposure  
Three concentrations (20 µM, 2 µM and 0.2 µM) of M-V were also used in the screening 
against MDA-MB-231. The extent of the inhibition as compared with MTX and is 
reported in Table 19. In general, MDA-MB-231 was found to be more sensitive to the 
library of DHFR inhibitors M-V and MTX. All compounds in M-V series at the 
concentration of 20 µM demonstrated very good antiproliferative activity with the 
percentage inhibition ranging from 87.0 to 97.7 %, which turned out to be comparable to 
the control, MTX (87.3%). At the concentration of 2 µM, M-V showed better inhibitory 
activity than MTX. The inhibitory activity was ranged from 70.5 to 97.2 %, of which two 
t-butyl substituted compounds retained more than 90% inhibition. When the 
concentration of the compounds in M-V was further reduced ten times to 0.2 µM, most 
compounds in the M-V series inhibited the cells to the extent of 0.6 % to 58.8%, 
suggesting that a dose-dependent inhibitory pattern was evident in this series of 
compounds. The data indicated that the most of the compounds have their IC50 value 
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located between 0.2 and 2 µM. Positive control MTX nearly lost all the inhibitory 
activity at the concentration of 0.2 µM (inhibition = 3.8 %). The basis of the MTX 
resistance was reported to be due to the lack of expression of the MTX transport protein: 
reduced folate carrier (RFC).229 M-V series is envisioned to be more lipophilic than MTX, 
and they may pass through the tumor cells by passive diffusion without membrane 
transport. This may account for the better inhibitory activity observed for M-V series 
against MDA-MB-231 than the MTX.  
Compared with these two breast cancer cell lines, MDA-MB-231 seems more sensitive to 
the compounds in M-V series at all ranges of screening concentrations, suggesting that 
the antiproliferative effect against ER (+) MCF-7 and ER (-) MDA-MB-231 breast cancer 
cells appears to be independent of the hormone receptor status. Since MCF-7 is not a 
RFC deficient cell line, the different sensitivity between these two cells may also not 
involve different RFC status of these two cells. However, the RFC status and ER status 
are not the only differences between breast cancer cell lines MCF-7 and MDA-MB-231. 
Yu and colleagues demonstrated that these two cell lines differentially express various 
P450 isozymes and, likewise, PCR analyses have shown differential expression of a 
variety of RNA messages in these cell lines.230, 232 Further studies were needed to explore 
how these differences affect their different sensitivities to M-V. 
All of the compounds were also screened against human non-small-cell lung carcinoma 
A549 and human fetal lung fibroblast MRC-5. The antiproliferative activity expressed by 
percentage of inhibition is shown in Table 20. The compounds of M-V series exhibited 
very potent antiproliferative activity at the concentration of 20 µM with inhibition 
percentage ranging from 71.2 to 98.0 %. At the concentration of 2 µM, the 
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antiproliferative effect ranging between 77.1 % and 96.1 % was observed. When the 
screening concentration was further reduced to 0.2 µM, the potency was differentiated 
Table 20. Antiproliferative activity of M-V and MTX against A549 and MRC-5 in terms 
of inhibition percentage 
 
A549, non-viable cells % MRC-5 non-viable cells % 
Compd 
20µM 2µM  0.2µM 20µM  2µM 0.2µM  
M-V-01 87.2 86.7 60.7 27.2 27.0 24.3 
M-V-02 89.4 87.9 58.6 37.0 37.4 16.8 
M-V-03 89.1 87.4 56.8 40. 8 38.0 10.3 
M-V-04 88.9 87.4 56.7 37.5 39.5 23.7 
M-V-05 87.9 85.7 60.1 32.0 30.7 29.8 
M-V-06 85.9 83.4 56.1 36.9 39.7 11.1 
M-V-07 89.7 86.2 60.3 35.9 27.7 29.6 
M-V-08 91.1 87.4 18.2 47.6 32.5 18.7 
M-V-09 90.3 85.9 29.5 33.8 28.5 15.0 
M-V-10 87.1 85.6 62.9 45.7 45.6 6.6 
M-V-11 93.5 85.7 64.2 83.0 44.0 9.0 
M-V-12 85.5 83.5 34.6 43.5 41.4 4.0 
M-V-13 91.9 83.7 65.3 78.6 22.8 4.0 
M-V-14 95.6 83.7 13.6 96.1 11.9 1.1 
M-V-15 84.9 82.8 64.8 21.5 29.9 11.9 
M-V-16 83.8 82.8 46.7 15.4 22.2 3.8 
M-V-17 86.2 84.1 50.5 16.4 17.7 8.7 
M-V-18 84.5 83.3 35.3 17.0 17.8 -1.7 
M-V-19 87.1 86 69.5 23.4 13.7 14.7 
M-V-20 93.3 87.5 73.0 61.4 9.6 5.6 
M-V-21 88.6 87.4 67.8 25.5 30.0 9.6 
M-V-22 93.3 88 66.3 65.4 30.4 22.3 
M-V-23 98.0 96.1 26.1 94.7 62.9 8.3 
M-V-24 88.0 87.8 65.9 28.3 26.6 20.3 
M-V-25 73.1 71.1 62.5 25.2 25.5 8.2 
M-V-26 68.8 71.3 65.2 23.4 18.8 3.2 
MTX 76.3 75.6 69.6 22.7 24.2 11.6 
 
among the compounds in the M-V series. However, most compounds still retained more 
than 50 % inhibition, suggesting their IC50 values were lower than 0.2 µM. M-V also 
exhibited certain inhibitory activity from 17.0 % to 96.1 % against normal cells human 
fibroblast MRC-5 at the concentration of 20 µM. All the compounds except compounds 
M-V-20, M-V-22 and M-V-23 exhibited lower than 50% of inhibition against the MRC-
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5 cells at the concentration of 2 µM, which is comparable to MTX at this concentration. 
There was no obvious antiproliferative activity at the concentration of 0.2 µM of M-V 
and MTX. The results indicated that normal cell was less sensitive than human cancer 
cell line A549, suggesting there was degree of selectivity between the normal cells and 
cancer cells of compounds in M-V series. Among all the three cancer cell lines screened 
in this study, A549 was the most sensitive cell to the triazines in the M-V library. Thus, 
A549 cell line has been selected as the model cell line for the further study on M-V.   
In a preliminary study before the determination of the IC50 values of the M-V series of 
compounds, the influence of time and dose of MTX and M-V-05 were evaluated against 
the A549 cell line. The selection of this compound was because M-V-05 exhibited the 
most potent DHFR inhibitory activity, which was comparable to MTX. The effectiveness 
of both ompounds is expressed as corrected T/Ccorr % or τ % according to the following 
equations: where T (test) and C (control) are the fluorescences in test wells and control 
wells, and C0 the fluorescences of the cells measured immediately before treatment.   
Cytostatic effect: T/Ccorr (%) = (T-C0)/(C-C0) × 100 
Cytocidal effect: τ (%) = (T-C0)/C0 × 100 
As shown in the Figure 20, both compounds showed a concentration dependent reduction 
of cell proliferation during the screening. MTX was slightly more active than M-V-05 
and both of them caused obvious antiproliferative effect at the concentration higher than 
10 nM. However, MTX did not show cytocidal effect at a higher concentration of 500 
µM. On the contrary, cytocidal effect of M-V-05 was observed at the concentration of 
100 µM, suggesting that there could be other mechanism besides DHFR inhibitory effect 
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involved in the antiproliferative activity for M-V-05. During the total 194-hour exposure 
time, both compounds achieved the maximum inhibition at various concentrations 
between 72-96 hours, which is about three doubling time of the proliferation of A549 
cells. In the following study, the incubation time of the assay was fixed at 72 hours. In 
this time-activity curves of MTX and M-V-05, there were no obvious recuperation of the 
tumor cells after the prolonged exposure, suggesting that the development of drug 














































Figure 20. Antiproliferative effects of various concentrations (μM) of MTX and M-V-5 on the A549: 
(upper) M-V-5, (lower) MTX. 




Table 21. IC50 values of antiproliferative activity of M-V against A549 
Compd  R R1 R2 n A549, IC50 (nM) 
M-V-01 H CH3 CH3 1 42.6 
M-V-02 H CH3 CH3 2 48.3 
M-V-03 H CH3 C2H5 1 66.0 
M-V-04 H H c-Pr 1 59.2 
M-V-05 H -(CH2)4- 1 40.2 
M-V-06 H -(CH2)4- 2 87.1 
M-V-07 H -(CH2)5- 1 69.7 
M-V-08 H -(CH2)5- 2 479.0 
M-V-09 H -(CH2)6- 1 318.7 
M-V-10 F -(CH2)5- 1 59.2 
M-V-11 Cl -(CH2)5- 1 49.6 
M-V-12 NO2 -(CH2)5- 1 329.3 
M-V-13 Me -(CH2)5- 1 83.3 
M-V-14 t-Bu -(CH2)5- 1 495.6 
M-V-15 MeO -(CH2)5- 1 51.6 
M-V-16 CN -(CH2)5- 1 116.4 
M-V-17 CH3CO -(CH2)5- 1 144.8 
M-V-18 SO2NH2 -(CH2)5- 1 166.4 
M-V-19 F -(CH2)4- 1 58.8 
M-V-20 Cl -(CH2)4- 1 27.1 
M-V-21 NO2 -(CH2)4- 1 65.8 
M-V-22 Me -(CH2)4- 1 48.1 
M-V-23 t-Bu -(CH2)4- 1 159.9 
M-V-24 MeO -(CH2)4- 1 59.1 
M-V-25 CN -(CH2)4- 1 60.7 
M-V-26 CH3CO -(CH2)4- 1 59.8 
MTX    37.4 
 
The IC50 values of M-V series were determined using FMCA and the results compared 
with MTX are being listed in Table 21. All of the compounds in the M-V series showed 
potent in vitro activity against A459 cells. In general, 1-phenoxypropyloxy substituted 
compounds showed better inhibitory activity against the A549 cells than the 1-
phenoxybutyloxy substituted compounds. Compounds M-V-01 and M-V-02 had similar 
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levels of activity against A549 cells, although 1-phenoxypropyloxy triazine M-V-01 
showed four times more active than 1-phenoxybutyloxy triazine M-V-02 in inhibition of 
DHFR. This suggested that other factors might be also involved in their antiproliferation. 
However, the result did not deny the significant effect of their DHFR inhibitory potency 
on their antiproliferative activity against cancer cell. For example, a dramatic drop in the 
antiproliferative activity was observed in the compound M-V-08 with its IC50 value of 
479.0 nM, while its analog 1-phenoxypropyloxy M-V-07 showed more than seven times 
better in the antiproliferative activity. DHFR inhibitory activity of M-V-07 was showed 
to be over 20 times more potent than that of M-V-08. Similar pattern could also be 
observed from M-V-05 and M-V-06. No matter whether it was the 2,2-disubstituted or 
the 2-spiro substituted compounds, bulky groups were found to be detrimental to the 
antiproliferative activity. For the 2,2-disubstituted compounds, the dimethyl groups 
appeared to be the best for their antiproliferative activity. Among the 2-spiro compounds, 
M-V-05 demonstrated the best antiproliferative activity. M-V-09 showed about eight 
times less in terms of their antiproliferative activity than M-V-05. Compound M-V-06 
which carried a cyclohexyl group on the C2 position also showed decrease activity 
against A549. Attempts have been made to improve the antiproliferative activity of M-V-
06 using different substitution on the 4’-position of the phenyl ring in the side chain. A 
Craig plot was used to select relevant substituents. Improvement in inhibitory activity 
occurred from the first quadrant of Craig’s plot where the lipophilic and electron-
withdrawing groups were present, such as Cl and F. However, one exception was that M-
V-12 which had a NO2 substitution and showed decrease activity. It may be due to 
electronic property of the NO2 group, which is the highly electron-withdrawing, and it 
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has a bulky size. Electron-donating methoxy group was also observed to improve the 
inhibitory activity. Bulky electron-donating and lipophilic t-butyl group reduced the 
antiproliferative activity, suggesting an unfavorable effect of the bulky substitution. 
However, the strong cytocidal effects could be observed during the incubation. All the 
substitution in the fourth quadrant of Craig’s plot led to the decrease in antiproliferative 
effects. Craig’s plot was applied on the modification of M-V-05. 4’-Cl substituted M-V-
20 showed the best antiproliferative activity among the whole series, which was even 
better than the positive control, MTX. But the bulky t-butyl group also gave rise to a 
great decrease in the antiproliferative activity in compound M-V-23.  
 
8.3. Rescue Experiments to Investigate the Mechanism of Inhibition of Cancer Cells 
A549 Growth 
 
The mechanism of action of an antifolate with respect to the affected target enzyme can 
be identified by employing the salvage route for nucleotide synthesis in whole cells. This 
is known as the using rescue experiment where the antifolate effect can be overridden by 
the introduction of the relevant metabolites. These experiments are best done in a cell 
culture setting wherein a compound that can be converted intracellularly into metabolites 
downstream from the toxicity of the drug. The nature of these protection agents provides 
clues about the metabolic pathway affected by the test compounds. Several of these 
affected enzymes are involved in nucleotide biosynthesis metabolic pathway, namely, 
DHFR, thymidylate synthase (TS), glycinamide ribonucleotide formyltransferase 
(GARFT) and aminoimidazole carboxamide ribonucleotide formyltransferase (AICARFT) 
(Scheme 39). In cancer cells, for example, the cytotoxic effect due to inhibition of TS, 
which blocks thymidine monophosphate synthesis, can be alleviated by the supply of 
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thymidine, which is metabolically converted to thymidine monophosphate. Likewise, the 
cytotoxic effect due to inhibition of GARFT or AICARFT can be alleviated by the 
introduction of hypoxanthine, which can be metabolized to inosine monophosphate, the 
end product of the purine biosynthetic pathway. In contrast, DHFR inhibitors which 
affect both thymidylate and purine nucleotide synthesis require the combination of both 
thymidine and hypoxanthine for the revival of the normal metabolism.  
The M-V triazines have been identified as potent inhibitors of bovine DHFR, the 
inhibitory activity of which was comparable to the positive control, MTX. In this study, 
all of the M-V triazines exhibited also antiproliferative activity against 3 selected human 
cancer cell lines. The antiproliferative activity of M-V-20 against non-small cell lung 
carcinoma A549 was even better than that of positive control, MTX. Rescue experiment 
was carried out to investigate their end product protection profile and to gain further 
insight into the mechanism of the action of the M-V triazines.  
The current rescue experiment was designed to investigate the mechanisms of action of 
the newly synthesized DHFR inhibitors M-V-20, in comparison with MTX (which is 
primarily a DHFR inhibitor), and MTA (multi-targeted antifolate against TS, DHFR, 
GARFT and AICARFT).231 The author hypothesized that compounds M-V-20 and MTX 
may have a same mechanism of the action and may an exhibit different mechanism to 
MTA based on rescue experiment. If the main mechanism of the inhibition of the cancer 
cell growth was the inhibition of DHFR, all the cells in the wells that were supplied with 
exogenous hypoxanthine and thymidine should be revived. Hypoxanthine replaced the 
purine and thymidine replaced the thymidylate, which were depleted in the presence of a 
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DHFR inhibitor. If a mechanism other than the inhibition of DHFR was involved, no 
complete reversal of growth would be observed.  
Therefore, the non-small cell lung carcinoma cell line A549 was selected for the 
investigation. To compare the effects of end product rescue and their inhibition, the cells 
were exposed to equitoxic levels of all the compounds, ie, their ten times the respective 
IC50 value. The concentrations used in this study were therefore selected as: 270 nM for 
M-V-20, 370 nM for MTX, and 6.4 µM for MTA. The effect on the growth inhibition of 
A549 in the present of 20 µmol/L thymidine and / or 100 µmol/L hypoxanthine together 
with the test compounds and controls for a exposure of 72-hour was assessed using 
FMCA assay. As indicated in Table 22 and Figure 21, the relative growth control of M-
V-20, MTX and MTA at 10×IC50 were ranged from 11.7 % to 15.2 % with no addition of 
rescue agents. Hypoxanthine (100 µM) was essentially devoid of protective activity with 
all the compounds. Thymidine at the concentration of 20 µM partially protected the cells 
from M-V-20, MTX and MTA. Full protection for M-V-20, MTX and MTA was 
achieved with a combination of thymidine (20 µM) and hypoxanthine (100 µM). 
Table 22. Protection of A549 from the growth inhibitory effects of antifolates by 100µM Hx, 20 µM 
TdR, or the combination of 100 µM Hx + 20 µM TdR 
 
Relative growth (% of the control) 
Compd. 
w/o rescure agent Hx (100 µM) TdR (20 µM) Hx (100 µM)+ TdR(20 µM) 
M-V-20 15.2±1.1 14.3±1.2 68.0±0.8 90.0±4.3 
MTX 14.3±3.0 16.0±0.8 77.3±11.2 96.6±0.8 
MTA 11.7±0.5 12.6±0.0 84.5±2.3 99.3±1.5 




Figure 20. Thymidine and hypoxanthine rescue from antifolates growth inhibition in A549 Cells 
The results indicated that inhibition of the growth of A549 cells of M-V-20 was 
completely reversed by a combination of thymidine (TdR) and of hypoxanthine (Hx). 
Only partial protection was afforded with TdR, and Hx alone was devoid of protection 
for this compound. It would appear that in the absence of hypoxanthine the inhibition of 
purine synthesis is indirect and incomplete. These results are similar to those obtained for 
MTX and MTA that both purine and pyrimidine biosyntheses are inhibited, thus 
implicating DHFR as their primary intracellular target. It also suggests that in A549 cells, 
the action of DHFR inhibitors, including M-V-20, MTX and MTA, has been attributed 
mainly to induction of a thymineless state. However, as shown in the Table 23 and Figure 
20, the protective degree of the protection for M-V-20 (90.0 %) which is slightly lower 
than that of MTX (96.6 %) and MTA (99.3%) suggests that the effect of M-V-20 on cell 
growth could not be due exclusively to purine and thymine depletion; there is other 
mechanism independent of antifolate pathways involved in the cytotoxic effects.  
The concentration of thymidine and hypoxanthine are higher than what is normally found 
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the concentrations in tumors may be greater due to the release of nucleosides from dead 
and dying cells. Moreover, tumor cells in situ will receive continuous supply of 
circulating salvageable nucleotides and bases rather than the finite supply, which is 
consumed during growth inhibition studies in vitro, thus nucleoside and base salvage may 
limit the efficacy of these antifolates in cancer patients. M-V-20 seems to have another 
mechanism to partially block the rescue by thymidine and hypoxanthine. This property 
makes compound M-V-20 more efficacious as antifolates compared with MTX and 
MTA.  
 
8.3.     Conclusion 
This study has demonstrated that the diamino-N1-phenyloxyalkyloxy-triazaspiroalkanes, 
which are analogues of WR 99210, are found to exhibit cytotoxic antitumor activity. 
They showed high antiproliferative activity against MCF-7, MDA-MB-321 and A549 
cancer cells. The mechanism of their antiproliferative activity was believed to be 
dependent on their potent DHFR inhibitory activity, which was proved by rescue 
experiment.  
The study showed that side chain at N1 position of the 1,2-dihydro-1,3,5-triazine rings 
played an essential role to their DHFR inhibitory activity and antiproliferative activity 
against selected cancer cell lines. Although 1-phenylpropyloxy substituted compound M-
IV-11 showed very potent DHFR inhibitory activity, just limited antiproliferative activity 
was observed in the human cancer cell MCF-7 culture. All compounds in M-V series 
exhibited very potent inhibitory activity against both DHFR enzyme and cancer cells, 
with just one modification on M-IV-11 by inserting an oxygen atom between the alkyl 
linker and phenyl ring. It indicates the involvement of more specific processes or 
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mechanism before the triazine molecule targeting the enzyme in the cancer cells. The 
length of the side chain could not be longer than three methylene groups between two 
oxy bridge to ensure the inhibitory activity against enzyme and cancer cells, although 
with longer alkyl linker may increase the lipophilicity of the compounds, which is crucial 
for the drugs uptake via passive diffusion. The substitution in the phenyl ring also played 
a role in the determination of the cytotoxic potency. Based on the Craig plot’s in the 
design, however, there is no very good correlation between the activities against either 
enzyme or cancer cells observed in this study, suggesting steric effects around phenyl 
ring also involved in the potency. M-V-20 demonstrated the best antiproliferative activity 
against A549 cells, which was better than the positive control MTX. The design of 
substitutions at 2 position of 1,2-dihydro-1,3,5-triazines was based on the hypothesis that 
modification on the position may vary inhibitory activity against mammalian DHFR and 
cancer cells as well as the cellular uptake profiles via passive diffusion. Dramatic changes 
with various substitutions on the inhibitory activity against bovine DHFR were not 
observed, indicating that C2 position of triazines is not a crucial factor to influence the 
enzyme inhibitory activity, especially there is a flexible substitution at N1 posiiton of 
triazine. However, substitution at C2 position did have impact on their antiproliferative 
activity against cancer cells. M-V-09 with a bulky 2-spirocycloheptyl substitution, 
showed eight-fold decreased antiproliferative activity to M-V-01 in A549 enlarged their 
differences in their antifolate activity. Although the increased lipophilicity of M-V-09 
may increase the accumulation of the drug in tumor cells if a passive transport through 
the cell membrane occurs. The dramatic decrease antiproliferative activity in cancer cells 
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suggests the steric effect interferes in the uptake of the triazines into tumor cells. With 
smaller 2-substitutent sizes, the antiproliferative potency was well tolerant.  
 
In summary, the result in this dissertation demonstrated that 1-phenoxyalkyloxy side 
chain is critical determinant of potent in vitro biological activity of triazines. A 
combination of the side chain with suitable 2-substitution ensured the antiproliferative 
activity of dihydrotriazines. Compound M-V-20, which showed comparable activity to 
MTX, is worth to exploring further to develop this newly synthesized compound into 
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9.   Concluding Remarks 
The 1,3,5-triazine heterocycle, also known as symmetric or s-triazine, has been known 
for almost 200 years, and it is commonly found in many biologically active chemical 
entities. This dissertation has focused on the synthesis and bioactivity study of the 4,6-
diamino-1,3,5-triazines. Five libraries of 4,6-diamino-1,3,5-triazines and its analogues 
(M-I ~ M-V) were used for this study. The reasons for the selection were derived from 
literature reviews on previous works, from which pharmacological activity of diamino-
1,3,5-triazines against neuronal sodium channels was not demonstrated ever. Gaps from 
previous works in regard to DHFR inhibitory activity and related antimicrobial and 
antiproliferative activity also existed. Particularly, WR99210 has been found to be potent 
antimalarial agents against plasmodial DHFR. However, further structural exploration by 
modifying WR99210 to incorporate spiro ring structure into triazine ring with different 
side chains has never been synthesized nor has their antiproliferative activity been 
investigated before. Therefore, in this study, the five types of 4,6-diamino-1,3,5-triazines 
(Figure 22) have been synthesized and investigated for their sodium channels, 
antimicrobial and bovine DHFR inhibitory activity, and antiproliferative activity against 













































Figure 22. Chemical structures of five different type of diamino-1,3,5-triazines 
 
Aromatic 2-amino-4-(substituted phenylamino)-6-substituted-1,3,5-triazines (M-I) and 4-
amino-6-(substituted anilino)-1,2-dihydro-2,2-dimethyl-1,3,5-triazines (M-II) have the 
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same 2-amino-1,3-diaza structural motif and similar substitution arrangements. But with 
the same phenyl ring substitution, compounds in M-II library exhibited more potent 
sodium channel blockade activity. It may be due to the flexibility of the triazine ring at 
position C2 in M-II. The puckered configuration in M-II with the C2 moving out of the 
planar ring may render this family of sodium channel blockers more adaptable in 
satisfying the steric requirements and hydrogen-bonding directionalities imposed by the 
active site of sodium channels. However, no in vivo anticonvulsant activity was observed 
at the dose of 30 mg/kg for compounds in the M-II library. Some compounds in the M-I 
library exhibited potent antifungal activity against C. albicans and A. niger, and 
compound M-I-07, which carried a 3’-bromo substitution on the phenyl ring and a chloro 
substitution at 6-methyl position of 1,3,5-triazine ring, demonstrated antifungal activity 
better than positive control, chlorhexidine, suggesting the potential to develop this series 
of compounds into antifungal agents or fungicides. Both M-I and M-II were devoid of 
DHFR inhibitory activity, suggesting the importance of the position C2 and the amino 
groups of the 1,3,5-triazines in producing bovine DHFR inhibitory activity. 
1-Benzyl-1,2-dihydro-1,3,5-triazines (M-III) were designed and synthesized based on the 
same benzyl side chain as the TMP. The benzyl side chain may render torsional freedom 
to make the molecules bind to DHFR enzyme more efficiently. Some compounds with 
dimethyl group at position C2 of 1,2-dihydro-1,3,5-triazines in M-III series exhibited 
moderate bovine DHFR inhibitory activity and unexpected antimycobacterial activity 
against M. smegmatis, which TMP did not demonstrate in this study. With 2,2-dialkyl or 
2-spiroalkyl group substituted on 1,2-dihydro-1,3,5-triazine ring, the inhibitory activity of 
the compounds against bovine DHFR disappeared, however, improved antimycobacterial 
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activity against M. smegmatis was observed in some of  these compounds. M-III-15 was 
the best among these series with the zone ratio of 0.98 against M. smegmatis, comparable 
to the positive control. Based on this unique activity, this series of compounds (M-III) 
showed potential to be developed into antimycobacterial agents. 
By inserting an oxygen atom between the benzyl group and 1,2-dihydro-1,3,5-triazine 
ring, a new series of compounds M-IV was synthesized and screened against bovine 
DHFR. A 250-fold of increased inhibitory activity was exhibited by M-IV-1, compared 
to M-III-1. This dramatic improvement on the inhibitory activity could be explained by 
the further relief of steric stress caused by C2 dimethyl group and N1-Ph ring. Although 
the bulky group at 2 position of 1-benzyloxy-1,2-dihydro-1,3,5-triazines was detrimental 
to the inhibitory activity against bovine DHFR, further extension of the side chain can 
compensate the influences by the C2 substitution. M-IV-09 exhibited the lowest IC50 
value among this whole series of compounds against bovine DHFR with the IC50 value of 
9 nM, which lied in the same inhibitory range of the positive control of MTX. Compound 
M-IV-11 showed the best antiproliferative activity against MCF-7, with a 44.8 % 
inhibition at 20 µM, which was comparable to MTX (50.5 %). Both M-IV-09 and M-IV-
11 have a bulky cyclohexyl spiro ring at position C2 of 1,2-dihydro-1,3,5-triazine ring. 
Their potent DHFR inhibitory activity and good antiproliferative activity against cancer 
cell line MCF-7 provided new lead compounds for the design of potent mammalian 
DHFR inhibitors for cancer chemotherapy. 
Based on the structures of the lead compound M-IV-11 and WR99210, a series of 4,6-
diamino-2,2-disubstituted-1-(4’-substitutedphenyloxyalkoxy)-1,2-dihydro-1,3,5-triazines 
(M-V) was synthesized and screened against bovine DHFR and three human cancer cell 
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lines. All the compounds in M-V series were found to be excellent inhibitors of bovine 
DHFR and cancer cell lines A549, with IC50 values in the nanomolar range. And most of 
these compounds also exhibited more than 70 % of growth inhibition against two breast 
cancer cell lines MCF-7 and MDA-MB-231. The results in this study demonstrated that 
the three CH2 groups between the two-oxygen bridge in the side chain is the critical 
determinant of the potent DHFR inhibition and antiproliferative activity. The 2,2-dialky 
or 2-spiro cycloalkyl group may serve as lipophilicity modulator to adjust the optimal 
molecular lipophilicity for cell uptakes. M-V-20 demonstrated the best antiproliferative 
activity against A549 cells, which was better than the positive control MTX. Rescue 
experiments involving the use of hypoxanthine and/or thymidine were performed on M-
V-20 and nearly complete reversal of cancer cell growth was observed. This indicated 
that this series of compounds inhibited cancer cell growth mainly by inhibiting DHFR in 
these cells. 
In conclusion, the five types of 4,6-diamino-1,3,5-triazine and its analogues were 
successfully synthesized and their bioactivity was evaluated. The results revealed that 
triazines in the M-V library were potent inhibitors of DHFR and cancer cell growth. N1-
(4’-substitutedphenyloxypropoxy) side chain and 2-spirocyclopenyl substitution was 
found to be favorable for the DHFR inhibitory and antiproliferative activity. This may be 
due to the ability of the compound to achieve more points of interaction with the bovine 
DHFR enzyme and the ability to penetrate cancer cells to produce DHFR inhibitory 
effects on cells. Some compounds in M-I and M-II series showed potent neuronal 
sodium channel blockade activity, suggesting the importance and validity of the 2-amino-
1,3-diaza structural motif in the development of potent sodium channel blockers. 
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Although M-III possessed the negative/moderate bovine DHFR inhibitory activity, their 
unique antimycobacterial activity suggested that compounds in the M-III library might 
provide leads to the design of new antimycobacterial agents.  
 
10.      Potential Future Developments 
All the compounds in the M-V library showed antiproliferative activity against non-small 
cell lung carcinoma A549 in the nanomolar range, and most of these compounds also 
demonstrated more than 70 % of growth inhibition against two breast cancer cell lines 
MCF-7 and MDA-MB-231. Further evaluation in the full panel of 60 human tumor cell 
lines performed in accordance with the protocol of the Drug Evaluation Branch, National 
Cancer Institute (NCI), Bethesda would be carried out on this whole series of compounds 
to investigate a spectrum of antitumor activities. The panel cell lines used in the NCI 
screen are leukemia lines, non-small cell lung cancer lines, colon cancer lines, central 
nervous system cancer lines, melanoma cell lines, ovarian cancer lines, renal cancer lines, 
prostate cancer lines, and breast cancer lines. A more detailed mechanism exploration 
could be also carried out on the compounds in the M-V library, since the rescue 
experiment suggested that there might be other mechanism involved in the cytotoxicity of 
the M-V library. M-V-20 was found to be very potent inhibitor of DHFR and the most 
potent compound among the whole series on their antiproliferative activity against lung 
cancer cells A549 growth, however, no in vivo test had been performed on the compound 
yet. Lung cancer can be induced in animals and the in vivo activity of those compounds 
can be determined. Detailed elucidation of the mechanism of action, metabolite studies 
and toxicity studies can also be carried out. If in vivo tests and toxicity studies showed 
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promising results, this will suggest the possibility of developing the lead compound into a 
drug candidate. 
As part of the program in structure-activity optimization in our laboratory, continual 
modification on M-V related triazines will be carried out. Introduction of a nitrogen atom 
into the bridge chain of M-V, as seen in natural folic acid and potent DHFR inhibitors 
such as MTX and aminopterin, seems to be a rational modification to elevate the DHFR 
inhibitory potency and increase the antitumor activity. On the other hand, 1,2-dihydro-
1,3,5-triazines belong to traditional nonclassical antifolates, which are not substrates for 
the reduced folate carrier and do not possess intact L-glutamate side chain as required for 
γ-polyglutamate synthetase (FPGS). However, an introduction of a L-glutamate side 
chain may increase the cytotoxicity activity of the triazine M-V, since the polyglutamates 
are supposed to retain the DHFR inhibitory activity and hold longer periods in the cells 
compared to the original compound. Taking these hypotheses into consideration, a series 
of compounds VI is proposed to be synthesized and evaluated for the DHFR inhibitory 








M-V-20, X = O, R = Cl
VI, X=NH, NCH3, R = CO-L-glutamic acid  
Figure 23. Chemical structures of M-V-20 and VI 
In vivo anticonvulsant tests on mice have been carried out on the M-II, however, no in 
vivo anticonvulsant activity was observed in this study, except for some compounds 
having sedative activity. Since binding of local anesthetic and class I antiarrhythmics also 
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resulted in the inhibition of binding of [3H] BTX, further studies on the disorders of the 



























11.1.   Materials and Equipments 
All the chemicals used in the syntheses were purchased from Aldrich Chemical Co. (USA) 
or Tokyo Kasei Organic Chemicals (TCI, Japan). They were used without further 
purification. Melting points were determined on a Gallenkamp Melting Point Apparatus 
and were uncorrected. Infrared spectra (using potassium bromide discs) were recorded 
with a Jasco FT/IR-430 Fourier Transform Infrared Spectrometer and reported in 
reciprocal centimetres (cm-1). The 1H NMR spectra were recorded on a Bruker ACF 300 
MHz NMR Spectrometer. The chemical shift (δ) values are expressed in parts per million 
(ppm) relative to tetramethylsilane as an internal standard: s = singlet, d = doublet, dd = 
double doublet, m = multiplet. Maximum UV absorption wavelengths of the compounds 
were determined on the UV-160A UV-Visible Recording Spectrophotometer. TLC was 
performed on silica gel coated aluminum plates with fluorescent indicator and visualized 
with UV light at 254 nm. Elemental analyses were performed using the Perkin Elmer 
2400 Elemental Analyzer Series II and all the values are within ± 0.4% of calculated 
values. 
 
11.2 Procedures for the Syntheses  
General Procedure for the Synthesis of 2-Amino-4-(Substituted Phenylamino)-6-
Substituted Methyl or Phenyl-1,3,5-Triazines (M-I) 
To a solution of sodium methoxide in methanol (0.23g Na in 30ml methanol) 
corresponding biguanide hydrochloride (0.01 mol) was added and the reaction mixture 
containing the biguanides was stirred at r.t. for 3 h. Then, a chosen substituted acetic acid 
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methyl ester (0.011 mol) was added dropwise. The reaction mixture was stirred for 24 h 
and subsequently heated under reflux for 6 h. After cooling to room temperature, the 
precipitated product was collected by filtration, washed with methanol (1 ml) and water 
and purified by crystallization from methanol. 
2-Amino-4-(4’-chlorophenylamino)-6-methyl-1,3,5-triazine (M-I-01) 
From 1-(4-chlorophenyl) biguanide hydrochloride (2.48 g, 0.01 mol) and ethyl acetate (1 
mL, 0.011 mol), M-I-01 was obtained as a white solid (1.38 g) in 58.5 % yield. mp: 193-
194oC. 1H NMR (DMSO-d6) δ 2.20 (s, 3H, CH3), 7.02 (br s, 2H, NH2, ex), 7.30 (d, 2H, 
aromatic C-H, J = 8.0 Hz), 7.83 (d, 2H, aromatic C-H, J = 8.0 Hz), 9.57 (br s, 1H, NH, 
ex), ESI-MS m/z 236.1 (M+1)+. Anal. calcd for C10H10ClN5: C, 50.96; H, 4.28; N, 29.72. 
Found: C, 50.66; H, 4.14; N, 29.77 
2-Amino-6-chloromethyl-4-(4’-chlorophenylamino)-1,3,5-triazine (M-I-02) 
From 1-(4-chlorophenyl) biguanide hydrochloride (2.48 g, 0.01mol) and ethyl 
chloroacetate (1.2 mL, 0.011 mol), M-I-02 was obtained as a white solid (1.18 g) in 43.5 
% yield. mp: 174-176oC. 1H NMR (DMSO-d6) δ 4.37 (s, 2H, CH2Cl), 7.33 (br s, 2H, NH2, 
ex; d, 2H, aromatic C-H, J = 8.0 Hz), 7.84 (d, 2H, aromatic C-H, J = 8.0 Hz), 9.81 (br s, 
1H, NH, ex). ESI-MS m/z 270.3 (M+1)+. Anal. calculated for C10H9Cl2N5: C, 44.46; H, 
3.36; N, 25.93. Found: C, 44.56; H, 3.23; N, 25.88 
2-Amino-4-(4’-chlorophenylamino)-6-phenyl-1,3,5-triazine (M-I-03)  
From 1-(4-chlorophenyl) biguanide hydrochloride (2.48 g, 0.01mol) and ethyl benzoate 
(1.6 mL, 0.011 mol), M-I-03 was obtained as a white solid (1.10 g) in 36.9 % yield. mp: 
151-152 oC. 1H NMR (DMSO-d6) δ 7.39 (m, 2H, aromatic C-H), 7.59 (m, 2H, aromatic 
C-H,2H, NH2, ex), 7.86 (d, 2H, aromatic C-H, J = 8.0 Hz), 8.32 (d, 2H, aromatic C-H, J = 
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8.0 Hz), 10.12 (br s, 1H, NH, ex). ESI-MS m/z 298.2 (M+1)+. Anal. calculated for 
C15H12ClN5: C, 60.51; H, 4.06; N, 23.52. Found: C, 60.14; H, 4.12; N, 23.67. 
2-Amino-4-(3’-chlorophenylamino)-6-methyl-1,3,5-triazine (M-I-04) 
From 1-(3-chlorophenyl) biguanide hydrochloride (2.48 g, 0.01 mol) and ethyl acetate (1 
mL, 0.011 mol), M-I-04 was obtained as a white solid (1.05 g) in 44.5 % yield. mp: 151-
152oC. 1H NMR (DMSO-d6) δ 2.21 (s, 3H, CH3), 6.99 (d, H, aromatic C-H, J = 8.0 Hz), 
7.07 (br s , 2H, NH2, ex), 7.28 (t, 1H, aromatic C-H, J = 8.0 Hz), 7.73 (d, 1H, aromatic C-
H, J = 8.0 Hz), 7.95 (s, 1H, aromatic C-H), 9.62 (s, 1H, NH, ex). ESI-MS m/z 236.2 
(M+1)+. Anal. calculated for C10H10ClN5: C, 50.96; H, 4.28; N, 29.72. Found: C, 50.88; 
H, 4.45; N, 29.47. 
2-Amino-6-chloromethyl-4-(3’-nitrophenylamino)-1,3,5-triazine (M-I-05) 
From 1-(3-nitrophenyl) biguanide hydrochloride (2.59 g, 0.01mol) and ethyl 
chloroacetate (1.2 mL, 0.011 mol), M-I-05 was obtained as a yellow solid (1.46g) in 
52.1% yield. mp: 196-198oC. 1H NMR (DMSO-d6) δ 4.41 (s, 2H, CH2Cl), 7.36 (br s , 1H, 
NH, ex), 7.45 (br s , 1H, NH, ex), 7.57 (t, 1H, aromatic C-H, J = 8.3 Hz), 7.83 (dd, 1H, 
aromatic C-H, J = 8.3 Hz, J = 0.2), 8.26 (d, 1H, aromatic C-H, J = 8.3 Hz), 8.71 (s, 1H, 
aromatic C-H), 10.15 (s, 1H, NH, ex). ESI-MS m/z 281.2 (M+1)+. Anal. calculated for 
C10H9ClN6O2: C, 42.79; H, 3.23; N, 29.94. Found: C, 42.65; H, 2.98; N, 29.89. 
2-Amino-4-(3’-bromophenylamino)-6-methyl-1,3,5-triazine (M-I-06) 
From 1-(3-bromophenyl) biguanide hydrochloride (2.93g, 0.01 mol) and ethyl acetate (1 
mL, 0.011 mol), M-I-06 was obtained as a yellowish solid (1.68 g) in 61.0 % yield. mp: 
163-164oC. 1H NMR (DMSO-d6) δ 2.20 (s, 3H, CH3), 7.06 (br s , 2H, NH2, ex), 7.13 (d, 
H, aromatic C-H, J = 8.0 Hz), 7.21 (t, 1H, aromatic C-H, J = 8.0 Hz), 7.80 (d, 1H, 
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aromatic C-H, J = 8.0 Hz), 8.05 (s, 1H, aromatic C-H), 9.60 (s, 1H, NH, ex). ESI-MS m/z 
280.2 (M+1)+. Anal. calculated for C10H10BrN5: C, 42.88; H, 3.60; N, 25.00. Found: C, 
43.01; H, 3.87; N, 25.11. 
2-Amino-6-chloromethyl-4-(3’-bromophenylamino)-1,3,5-triazine (M-I-07) 
From 1-(3-bromophenyl) biguanide hydrochloride (2.93g, 0.01mol) and ethyl 
chloroacetate (1.2 mL, 0.011 mol), M-I-07 was obtained as a yellowish solid (1.32g) in 
42.0 % yield. mp: 123-124oC. 1H NMR (DMSO-d6) δ 4.38 (s, 2H, CH2Cl), 7.21 (m, 2H, 
aromatic C-H), 7.37 (br s, 2H, NH2, ex), 7.81 (d, 1H, aromatic C-H, J = 8.0 Hz), 8.07 (s, 
1H, aromatic C-H), 9.83 (s, 1H, NH, ex). ESI-MS m/z 314.1 (M+1)+. Anal. calculated for 
C10H10BrClN5: C, 38.18; H, 2.88; N, 22.26. Found: C, 38.47; H, 2.56; N, 22.19. 
 
General Procedure for Three-component Synthesis of 4,6-Diamino-1,2-Dihydro-2,2-
Dimethyl-1-(Substituted) phenyl -1,3,5-Triazine hydrochlorides (I) 
A mixture of the substituted aniline (0.02 mol), dicyandiamide (0.021 mol), concentrated 
hydrochloric acid (0.024 mol) and acetone (20 ml) was refluxed with stirring until a 
negative biguanide test was obtained (8-18 h). Precipitation of the product occurred either 
during the reaction process, or when the reaction mixture was cool down to room 
temperature. The solid was collected by filtration and washed with acetone and ether. All 
samples were recrystallized from ethanol-water before the further use. 
General Procedure for Synthesis of 4-Amino-6-(Substituted) phenylamino-1,2-
Dihydro-2,2-Dimethyl-1,3,5-Triazine (M-II) by Dimroth rearrangement 
Sodium hydroxide (5N) was added to a solution of 4,6-diamino-1-(substituted) phenyl-
1,2-dihydro-2,2-dimethyl-1,3,5-triazine·HCl (0.01 mol) in 20 ml of 50% aqueous ethanol 
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to pH 11. The solution was refluxed for one hour. After evaporation of the solvent, the 
residue was triturated with water. The solid was collected by filtration and washed with 
water and dried under vacuum. All samples were recrystallized from 95% ethanol before 
analysis. 
4-Amino-6-anilino-1,2-dihydro-2,2-dimethyl-1,3,5-triazine (M-II-01) 
From 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-phenyl-1,3,5-triazine (I-01, 2.5g, 0.01 
mol), M-II-01 was obtained as a white solid (1.86 g) in 85 % yield. mp:  178-180 oC. 1H 
NMR (DMSO-d6) δ 1.27 (s, 6H, 2CH3), 5.59 (br s, 1H, NH, ex), 6.74 (t, 1H, aromatic C-
H, J = 7.9 Hz), 7.11 (t , 2H, aromatic C-H, J = 7.9 Hz), 7.68 (d, 2H, aromatic C-H, J = 7.9 
Hz). ESI-MS m/z 218.2 (M+1) +, λmax (water) = 250.6 nm. Anal. calculated for C11H15N5: 
C, 60.81; H, 6.96; N, 32.23. Found: C, 60.99; H, 6.86; N, 31.98. 
4-Amino-6-(2’-methylanilino)-1,2-dihydro-2,2-dimethyl-1,3,5-triazine (M-II-02) 
From 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-(2’-methylphenyl)-1,3,5-triazine (I-02, 
2.7g, 0.01 mol), M-II-02  was obtained as a white solid (1.37g) in 59.4 % yield. mp:  
200-203 oC. 1H NMR (DMSO-d6) δ 1.34 (s, 6H, 2CH3), 2.17(s, 3H, CH3), 6.92 (t, 1H, 
aromatic C-H, J = 7.5 Hz), 7.10 (m, 2H, aromatic C-H), 7.62 (d, 1H, aromatic C-H, J = 
7.9 Hz). ESI-MS m/z 232.2 (M+1) +, λmax (water) = 243.2 nm. Anal. calculated for 
C11H17N5: C, 62.31; H, 7.41; N, 30.28. Found: C, 62.76; H, 7.21; N, 29.90. 
4-Amino-6-(3’-methylanilino)-1,2-dihydro-2,2-dimethyl-1,3,5-triazine (M-II-03) 
From 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-(3’-methylphenyl)-1,3,5-triazine (I-03, 
2.7g, 0.01 mol),  M-II-03 was obtained as a white solid (1.60 g) in 69.5 % yield. mp: 
178-180 oC. 1H NMR (DMSO-d6) δ 1.29 (s, 6H, 2CH3), 2.21(s, 3H, CH3), 6.63 (d, 1H, 
aromatic C-H, J = 7.9 Hz), 7.03 (t , 1H, aromatic C-H, J = 7.9 Hz), 7.37 (s, 1H, aromatic 
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C-H), 7.55 (d, 2H, aromatic C-H, J = 7.9 Hz). ESI-MS m/z 232.2 (M+1) +, λmax (water) = 
250.0 nm. Anal. calculated for C11H17N5: C, 62.31; H, 7.41; N, 30.28. Found: C, 62.00; H, 
7.32; N, 30.05. 
4-Amino-6-(4’-methylanilino)-1,2-dihydro-2,2-dimethyl-1,3,5-triazine (M-II-04) 
From 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-(4’-methylphenyl)-1,3,5-triazine (I-04, 
2.7g, 0.01 mol),  M-II-04 was obtained as a white solid (1.39g) in 59.9 % yield. mp: 110-
112 oC. 1H NMR (DMSO-d6) δ 1.32 (s, 6H, 2CH3), 2.22(s, 3H, CH3), 7.02 (d, 2H, 
aromatic C-H, J = 7.9 Hz), 7.43 (d, 2H, aromatic C-H, J = 7.9 Hz). ESI-MS m/z 232.2 
(M+1) +, λmax (water) = 249.4 nm. Anal. calculated for C11H17N5: C, 62.31; H, 7.41; N, 
30.28. Found: C, 62.45; H, 7.44; N, 30.56. 
4-Amino-6-(2’-methoxyanilino)-1,2-dihydro-2,2-dimethyl-1,3,5-triazine (M-II-05) 
From 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-(2’-methoxyphenyl)-1,3,5-triazine (I-05, 
2.8g, 0.01 mol),  M-II-05 was obtained as a white solid (0.72g) in 28.4 % yield. mp: 210-
212 oC. 1H NMR (DMSO-d6) δ 1.26 (s, 6H, 2CH3), 3.81 (s, 3H, OCH3), 6.80 (m, 3H, 
aromatic C-H), 8.47 (d, 1H, aromatic C-H, J = 6.8 Hz). ESI-MS m/z 248.2 (M+1) +, λmax 
(water) = 246.6 nm. Anal. calculated for C12H17N5O•0.3H2O: C, 57.04; H, 7.02; N, 27.71. 
Found: C, 57.00; H, 6.83; N, 27.42. 
4-Amino-6-(3’-methoxyanilino)-1,2-dihydro-2,2-dimethyl-1,3,5-triazine (M-II-06) 
From 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-(3’-methoxyphenyl)-1,3,5-triazine (I-06, 
2.8g, 0.01 mol),  M-II-06 was obtained as a white solid (1.50 g) in 60.3 % yield. mp: 
170-171 oC. 1H NMR (DMSO-d6) δ 1.33 (s, 6H, 2CH3), 3.71 (s, 3H, OCH3), 6.49 (d, 1H, 
aromatic C-H, J = 6.8 Hz), 7.09 (m, 2H, aromatic C-H), 7.37 (s, 1H, aromatic C-H). ESI-
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MS m/z 248.2 (M+1) +, λmax (water) = 251.8 nm. Anal. calculated for C12H17N5O: C, 
57.04; H, 7.02; N, 27.71. Found: C, 57.12; H, 7.18; N, 27.25. 
4-Amino-6-(4’-methoxyanilino)-1,2-dihydro-2,2-dimethyl-1,3,5-triazine (M-II-07) 
From 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-(4’-methoxyphenyl)-1,3,5-triazine (I-07, 
2.8g, 0.01 mol),  M-II-07  was obtained as a white solid (1.53g) in 61.7 % yield. mp: 
115-116 oC. 1H NMR (DMSO-d6) δ 1.24 (s, 6H, 2CH3), 3.66 (s, 3H, OCH3), 5.67 (br s, 
1H, N-H, ex), 6.71 (d, 2H, aromatic C-H, J = 9.0 Hz), 7.60 (d, 2H, aromatic C-H, J = 9.0 
Hz). ESI-MS m/z 248.2 (M+1) +, λmax (water) = 247.6 nm. Anal. calculated for 
C12H17N5O: C, 58.28; H, 6.93; N, 28.32. Found: C, 58.02; H, 7.00; N, 28.30.  
4-Amino-6-(2’-chloroanilino)-1,2-dihydro-2,2-dimethyl-1,3,5-triazine (M-II-08) 
From 4,6-diamino-1-(2’-chlorophenyl)-1,2-dihydro-2,2-dimethyl-1,3,5-triazine (I-08, 
2.9g, 0.01 mol),  M-II-08  was obtained as a white solid (1.58g) in 63.0% yield. mp: 196-
198 oC. 1H NMR (DMSO-d6) δ 1.28 (s, 6H, 2CH3), 6.02 (br s, 1H, N-H, ex), 6.80 (t, 1H, 
aromatic C-H, J = 7.5 Hz), 7.14 (t, 1H, aromatic C-H, J = 8.3 Hz), 7.30 (d, 1H, aromatic 
C-H, J = 7.5 Hz), 8.13 (s, 1H, aromatic C-H)  ESI-MS m/z 252.3 (M+1) +, λmax (water) = 
245.2 nm. Anal. calculated for C11H14ClN5: C, 52.49; H, 5.61; N, 27.82. Found: C, 52.25; 
H, 5.54; N, 28.01. 
4-Amino-6-(3’-chloroanilino)-1,2-dihydro-2,2-dimethyl-1,3,5-triazine (M-II-09) 
From 4,6-diamino-1-(3’-chlorophenyl)-1,2-dihydro-2,2-dimethyl-1,3,5-triazine (I-09, 
2.9g, 0.01 mol),  M-II-09   was obtained as a white solid (2.01 g) in 80.4 % yield. mp: 
175-176 oC. 1H NMR (DMSO-d6) δ 1.25 (s, 6H, 2CH3), 5.67 (br s, 1H, N-H, ex), 6.72 
(dd, 1H, aromatic C-H, J = 7.9 Hz, J = 2.3Hz), 7.09 (t, 1H, aromatic C-H, J = 8.3 Hz), 
7.55 (d, 1H, aromatic C-H, J = 8.3 Hz), 7.96 (s, 1H, aromatic C-H)  ESI-MS m/z 252.3 
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(M+1) +, λmax (water) = 252.2 nm. Anal. calculated for C11H14Cl N5: C, 52.49; H, 5.61; N, 
27.82. Found: C, 52.33; H, 5.05; N, 27.42. 
4-Amino-6-(4’-chloroanilino)-1,2-dihydro-2,2-dimethyl-1,3,5-triazine (M-II-10) 
From 4,6-diamino-1-(4’-chlorophenyl)-1,2-dihydro-2,2-dimethyl-1,3,5-triazine (I-10, 
2.9g, 0.01 mol),  M-II-10 was obtained as a white solid (2.11g) in 84.0 % yield. mp:  
132-134 oC. 1H NMR (DMSO-d6) δ 1.41 (s, 6H, 2CH3), 7.32 (d, 2H, aromatic C-H, J = 
9.1 Hz), 7.57 (d, 2H, aromatic C-H, J = 9.1 Hz). ESI-MS m/z 252.3 (M+1) +, λmax (water) 
= 255.0 nm. Anal. calculated for C11H14Cl N5: C, 52.49; H, 5.61; N, 27.82. Found: C, 
52.45; H, 5.55; N, 28.00. 
4-Amino-6-(2’-bromoanilino)-1,2-dihydro-2,2-dimethyl-1,3,5-triazine (M-II-11) 
From 4,6-diamino-1-(2’-bromophenyl)-1,2-dihydro-2,2-dimethyl-1,3,5-triazine (I-11, 
3.3g, 0.01 mol), M-II-11  was obtained as a white solid (2.14g) in 72.5 % yield. mp: 176-
178 oC. 1H NMR (DMSO-d6) δ 1.34 (s, 6H, 2CH3), 7.34 (d, 2H, aromatic C-H, J = 8.7 
Hz), 7.72 (d, 2H, aromatic C-H, J = 8.7 Hz), 9.15 (br s, 1H, N-H, ex). ESI-MS m/z 296.3 
(M+1) +, λmax (water) = 244.8 nm. Anal. calculated for C11H14BrN5: C, 44.61; H, 4.76; N, 
23.65. Found: C, 44.52; H, 4.33; N, 23.43. 
4-Amino-6-(3’-bromoanilino)-1,2-dihydro-2,2-dimethyl-1,3,5-triazine (M-II-12) 
From 4,6-diamino-1-(3’-bromophenyl)-1,2-dihydro-2,2-dimethyl-1,3,5-triazine (I-12, 
3.3g, 0.01 mol),  M-II-12   was obtained as a white solid (2.5 g) in 84.7 % yield. mp: 
180-182 oC. 1H NMR (DMSO-d6) δ 1.27 (s, 6H, 2CH3), 6.88 (m, 1H, aromatic C-H), 7.05 
(t, 1H, aromatic C-H, J = 8.3 Hz), 7.62 (d, 1H, aromatic C-H, J = 8.3 Hz), 8.06(d, 1H, 
aromatic C-H, J = 1.9 Hz)  ESI-MS m/z 296.3 (M+1) +, λmax (water) = 254.4 nm. Anal. 
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calculated for C11H14BrN5: C, 44.61; H, 4.76; N, 23.65. Found: C, 44.53; H, 4.78; N, 
23.26. 
4-Amino-6-(4’-bromoanilino)-1,2-dihydro-2,2-dimethyl-1,3,5-triazine (M-II-13) 
From 4,6-diamino-1-(4’-bromophenyl)-1,2-dihydro-2,2-dimethyl-1,3,5-triazine (I-13, 
3.3g, 0.01 mol),  M-II-13 was obtained as a white solid (2.57g) in 87.0 % yield. mp: 175-
176 oC. 1H NMR (DMSO-d6) δ 1.25 (s, 6H, 2CH3), 5.80 (br s, 1H, N-H, ex), 7. 25 (d, 2H, 
aromatic C-H, J = 9.0 Hz), 7.68 (d, 2H, aromatic C-H, J = 9.0 Hz). ESI-MS m/z 296.3 
(M+1) +, λmax (water) = 256.6nm. Anal. calculated for C11H14BrN5: C, 44.61; H, 4.76; N, 
23.65. Found: C, 44.61; H, 4.72; N, 23.33. 
4-Amino-6-(3’-nitroanilino)-1,2-dihydro-2,2-dimethyl-1,3,5-triazine (M-II-14) 
From 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-(3’-nitrophenyl)-1,3,5-triazine (I-14, 3.0g, 
0.01 mol),  M-II-14 was obtained as a white solid (2.35g) in 90.5 % yield. mp: 138-
139oC. (lit47. 130-132 oC) 1H NMR (DMSO-d6) δ 1.30 (s, 6H, 2CH3), 5.91 (br s,1H, N-H, 
ex ), 7.39 (t, 1H, aromatic C-H, J = 7.9 Hz), 7.59 (d, 1H, aromatic C-H, J = 7.5 Hz), 7.99 
(d, 1H, aromatic C-H, J = 8.3 Hz), 8.75 (s, 1H, aromatic C-H)  ESI-MS m/z 261.3 (M+1) 
+, λmax (water) = 256.8 nm. Anal. calculated for C11H14BrN5: C, 50.38; H, 5.38; N, 32.04. 
Found: C, 50.24; H, 5.22; N, 32.34. 
 
General Procedure for Synthesis of 4,6-Diamino-1-Benzyl-1,2-Dihydro-2,2-
Dimethyl-1,3,5-Triazine Hydrochlorides (M-III) (Method A) 
Commercial (substituted) benzylamines were converted to their hydrochloride with 
hydrogen chloride in ether in 91-96 % yields.  Then the mixture of the benzylamine 
hydrochloride and dicyandiamide was gently heated in an oil bath allowing temperature 
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increase gradually. The mixture began to liquefy at 160-170oC, and was completely 
liquefied at 170-180oC. After heating at 170-180oC for 10 min, the cooled transparent 
mass was triturated with acetone, yield 50-70%. To a suspension of the resulting 
biguanide · HCl (0.01mol) in absolute methanol (25 ml) containing the acetone (5 eq) and 
water scavenger 2,2-dimethoxypropane (0.75 ml) was added conc. HCl (0.42 ml), the 
mixture was refluxed until a negative biguanide test was obtained (12-24 h). After 
evaporation of the solvent, the residue was triturated with acetone. The solid was 
collected by filtration and washed again with ether and dried under oven. If oily residue 
was present, the product had to be separated from unreacted starting materials through the 
use of chromatograph columns (chloroform : methanol = 5 : 1 ). All samples were 
recrystallized from ethanol-water before analysis. 
4,6-Diamino-1-benzyl-1,2-dihydro-2,2-dimethyl-1,3,5-triazine hydrochloride (M-III-
01) 
From 1-benzylbiguanide hydrochloride (2.13g, 0.01mol), M-III-01 was obtained as a 
white solid (1.06g) in 38.9% yield. mp: 204-206oC. 1H NMR (DMSO-d6) δ 1.40 (s, 6H, 
2CH3), 4.74 (s, 2H, CH2), 7.22-7.42 (m, 5H, aromatic C-H), 7.56 (br s, 2H, NH, ex), 8.91 
(br s, 1H, NH, ex), ESI-MS m/z 232.0 (M+1) +. Anal. calculated for C12H18N5Cl·0.2H2O: 
C, 53.11; H, 6.83; N, 25.81. Found: C, 52.89; H, 6.42; N, 25.50. 
4,6-Diamino-1,2-dihydro-2,2-dimethyl-1-(4’-methylbenzyl)-1,3,5-triazine 
hydrochloride (M-III-02) 
From 1-(4-methylbenzyl) biguanide hydrochloride (2.42g, 0.01mol), M-III-02 was 
obtained as a white solid (0.90g) in 31.9 % yield. mp: 188-189oC. 1H NMR (DMSO-d6) δ 
1.40 (s, 6H, 2CH3), 2.28 (s, 3H, CH3), 4.68 (s, 2H, CH2), 7.11 (d, 2H, aromatic C-H, J = 
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8.3 Hz), 7.40 (d, 2H, aromatic C-H, J = 8.3 Hz), 7.54 (br s, 2H, NH, ex), 8.98 (br s , 1H, 
NH, ex) ESI-MS m/z 246.2 (M+1) +. Anal. calculated for C13H20N5Cl·0.2H2O: C, 55.41; 
H, 7.15; N, 24.85. Found: C, 55.40; H, 7.35; N, 24.58. 
4,6-Diamino-1,2-dihydro-2,2-dimethyl-1-(4’-methoxybenzyl)-1,3,5-triazine 
hydrochloride (M-III-03) 
From 1-(4-methoxybenzyl) biguanide hydrochloride (2.58g, 0.01mol), M-III-03 was 
obtained as a white solid (1.43 g) in 48.0 % yield. mp: 193-194oC. 1H NMR (DMSO-d6) 
δ 1.38 (s, 6H, 2CH3), 3.74 (s, 3H, CH3O), 4.62 (s, 2H, CH2), 6.95 (d, 2H, aromatic C-H, J 
= 8.3 Hz), 7.14 (d, 2H, aromatic C-H, J = 8.3 Hz), 7.50 (br s, 2H, NH, ex), 8.69 (br s , 1H, 
NH, ex), ESI-MS m/z 262.1 (M+1)+. Anal. calculated for C13H20N5ClO·0.2H2O: C, 51.58; 
H, 6.82; N, 23.24. Found: C, 51.64; H, 6.35; N, 22.98. 
4,6-Diamino-1-(4’-fluorobenzyl)-1,2-dihydro-2,2-dimethyl-1,3,5-triazine 
hydrochloride (M-III-04) 
From 1-(4-fluorobenzyl) biguanide hydrochloride (2.46g, 0.01mol), M-III-04 was 
obtained as a white solid (1.36 g) in 47.7 % yield. mp: 183-184oC. 1H NMR (DMSO-d6) 
δ 1.39 (s, 6H, 2CH3), 4.69 (s, 2H, CH2), 7.19-7.29 (m, 4H, aromatic C-H), 7.55 (br s, 2H, 
NH, ex), 8.64 (br s , 1H, NH, ex), ESI-MS m/z 250.1 (M+1)+. Anal. calculated for 
C12H17N5ClF·H2O: C, 47.45; H, 6.30; N, 23.05. Found: C, 47.77; H, 6.32; N, 23.10. 
 
4,6-Diamino-1-(4’-chlorobenzyl)-1,2-dihydro-2,2-dimethyl-1,3,5-triazine 
hydrochloride (M-III-05)  
From 1-(4-chlorobenzyl) biguanide hydrochloride (2.62g, 0.01mol), M-III-05 was 
obtained as a white solid (1.30g) in 43.1 % yield. mp: 192-194oC. 1H NMR (DMSO-d6) 
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δ1.39 (s, 6H, 2CH3), 4.73 (s, 2H, CH2), 7.24 (d, 2H, aromatic C-H, J = 8.3 Hz), 7.45 (d, 
2H, aromatic C-H, J = 8.3 Hz), 7.58 (br s, 2H, NH, ex), 8.91 (br s , 1H, NH, ex), ESI-MS 
m/z 266.1 (M+1)+. Anal. calculated for C12H16Cl N5·HCl·H2O: C, 47.69; H, 5.67; N, 
23.17. Found: C, 47.22; H, 5.22; N, 5.22.  
4,6-Diamino-1-(3’,4’-dichlorobenzyl)-1,2-dihydro-2,2-dimethyl-1,3,5-triazine 
hydrochloride (M-III-06) 
From 1-(3,4-dichlorobenzyl) biguanide hydrochloride (2.97g, 0.01mol), M-III-06 was 
obtained as a white solid (1.14 g) in 34.0% yield. mp: 193-194oC. 1H NMR (DMSO-d6) 
δ1.39 (s, 6H, 2CH3), 4.73 (s, 2H, CH2), 7.24 (d, 2H, aromatic C-H, J = 8.3 Hz), 7.45 (d, 
2H, aromatic C-H, J = 8.3 Hz), 7.58 (br s, 2H, NH, ex), 8.91 (br s , 1H, NH, ex), ESI-MS 
m/z 301.1 (M+1)+. Anal. calculated for C12H16N5Cl3·0.5H2O: C, 41.70; H, 4.96; N, 20.26. 
Found: C, 42.07; H, 5.28; N, 20.42. 
4,6-Diamino-1-(3’,4’,5’-trimethoxybenzyl)-1,2-dihydro-2,2-dimethyl-1,3,5-triazine 
hydrochloride (M-III-07) 
From 1-(3,4,5-trimethoxybenzyl) biguanide hydrochloride (3.18g, 0.01mol), M-III-07 
was obtained as a white solid (0.33 g) purified using silica gel column chromatography 
(chloroform : methanol, eluent gradient 5:1 to 3 : 1) in 9.3 % yield. mp: 193 – 194 °C; 
λmax (water): 238.6 nm; IR (KBr disc): 3302 (νN–H), 3103 (νC–H, aromatic), 1650 
(νC=N), 1591 (ν CC−&&& , aromatic), 1492 (C–H, aliphatic) cm-1; 1H NMR (DMSO-d6): δ 
1.41 (s, 6H, 2CH3), 3.65 (s, 3H, OCH3), 3.75 (s, 6H, 2OCH3), 4.65 (s, 2H, CH2), 6.53 (s, 
2H, Ar-H), 7.56 (br s, 2H, NH, ex), 8.99 (br s, 1H, NH, ex) ppm; ESI-MS m/z 321.8 
(M+1)+. Anal. calculated for C15H24N5ClO3: C, 50.35; H, 6.76; N, 19.57. Found: C, 50.43; 
H, 7.11; N, 20.07. 
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General Procedure for the Synthesis of 4,6-Diamino-1-(Substituted)benzyl-1,2-
Dihydro-2,2-Dialkyl or Cycloalkyl-1,3,5-Triazine hydrochloride (Method B)  
The steps for preparation of substituted benzylamine hydrochloride salt and biguanide 
hydrochloride were repeated as of above Method A. For the third step of triazine 
synthesis, amount of ketones used was 1.2 equivalent to biguanide hydrochloride used. 
triethyl orthoformate was employed as water scavenger. The reaction mixture was stirred 
at room temperature and monitored with TLC and biguanide test. The reaction was 
stopped when there was extra spot appeared on the TLC or using a cut off time of 14 days. 
The solid was collected by filtration and washed again with ether and dried under oven. 
When oily product was obtained after the evaporation, the residue was applied onto a 
silica gel column for the purification. All samples were recrystallized from ethanol-water 
before analysis. 
4,6-Diamino-2-ethyl-2-methyl-1, 2-dihydro-1-(4’-methylbenzyl)-1, 3, 5-triazine 
hydrochloride (M-III-08) 
From 1-(4-methylbenzyl) biguanide hydrochloride (2.42g, 0.01mol) and methyl ethyl 
ketone (1.1mL, 0.012 mol), M-III-08 was obtained after purification by a silica gel 
chromatography (chloroform : methanol, eluent gradient 5:1 to 3 : 1) as a white solid 
(0.15 g) in 5.0 % yield; mp: 176-178 oC; λmax (water): 245.0nm; IR (KBr disc): 3312 (vN-
H), 3179 (vC-H, aromatic), 1642 (vC=N), 1598 (vC≈C,aromatic), 1482 (δC-H,,aliphatic) cm-1; 1H NMR 
(DMSO + D2O): δ 1.57 -1.92 (m, 2H, CH2), 0.79 – 0.83 (m, 3H, CH3), 1.37 (s, 3H, CH3), 
2.29 (s, 3H, Ar-CH3) , 4.56 - 4.71 (m, 2H, CH2), 7.10 – 7.21 (m, 4H, Ar-H) ppm; ESI-MS 
m/z 260.7 (M+1)+. Anal. calculated for C14H21N5·HCl·1.3H2O: C, 52.67; H, 7.77; N, 
21.94. Found: C, 52.87; H, 7.94; N, 22.10. 
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4,6-Diamino-2-ethyl-2-methyl-1,2-dihydro-1-(4’-methoxybenzyl)-1, 3, 5-triazine 
hydrochloride (M-III-09) 
From 1-(4-methoxybenzyl) biguanide hydrochloride (2.58g, 0.01mol) and methyl ethyl 
ketone (1.1mL, 0.012 mol), M-III-09 was obtained after purification by a silica gel 
chromatography (chloroform : methanol, eluent gradient 5:1 to 3 : 1) as a white solid 
(0.19 g) in 6.0 % yield; mp: 155-157oC; λmax (water): 262.2 nm; IR (KBr disc): 3311 (vN-
H), 3188 (vC-H, aromatic), 1653 (vC=N), 1602 (vC≈C,aromatic), 1253 (vC-O), 1482 (δC-H,,aliphatic) cm-
1; 1H NMR (DMSO + D2O): δ 1.59 -1.89 (m, 2H, CH2), 0.79 – 0.84 (m, 3H, CH3), 1.38 (s, 
3H, CH3), 3.74 (s, 3H, Ar-OCH3) , 4.54 - 4.70 (m, 2H, CH2), 6.93– 7.17 (m, 4H, Ar-H) 
ppm; ESI-MS m/z 276.7 (M+1)+. Anal. calculated for C14H21N5O·HCl·1.8H2O: C, 51.54; 
H, 7.29; N, 21.46. Found: C, 51.20; H, 7.47; N, 21.43. 
4,6-Diamino-1-(4’-chlorobenzyl) -2-ethyl-2-methyl-1, 2-dihydro-1, 3, 5-triazine 
hydrochloride (M-III-10) 
From 1-(4-chlorobenzyl) biguanide hydrochloride (2.62g, 0.01mol) and methyl ethyl 
ketone (1.1mL, 0.012 mol), M-III-10 was obtained after purification by a silica gel 
chromatography (chloroform : methanol, eluent gradient 5:1 to 3 : 1) as a white solid 
(0.08 g) in 2.4% yield; mp: 155-157oC; λmax (water): 245.6 nm; IR (KBr disc): 3311 (vN-
H), 3176 (vC-H, aromatic), 1642 (vC=N), 1597 (vC≈C,aromatic), 492 (vC-Cl), 1482 (δC-H,,aliphatic) cm-1; 
1H NMR (DMSO + D2O): δ 1.56 -1.92 (m, 2H, CH2), 0.79 – 0.84 (m, 3H, CH3), 1.36 (s, 
3H, CH3), 4.68 (s, 2H, CH2), 7.03– 7.48 (m, 4H, Ar-H) ppm; ESI-MS m/z 280.5 (M+1)+. 
Anal. calculated for C13H18ClN5·HCl·0.6H2O: C, 47.74; H, 6.23; N, 21.41. Found: C, 
47.32; H, 47.32; N, 21.78. 





From 1-(4-chlorobenzyl) biguanide hydrochloride (2.62g, 0.01mol) and methyl c-propyl 
ketone (1.1mL, 0.012 mol), M-III-11 was obtained as a white solid (0.92g) after 
purification by re-crystallization in ethanol-water in 28 % yield; mp: 161-163oC; λmax 
(water): 252.0nm; IR (KBr disc): 3307 (vN-H), 3169 (vC-H, aromatic), 1641 (vC=N), 1564 
(vC≈C,aromatic), 483 (vC-Cl), 1492 (δC-H,,aliphatic) cm-1; 1H NMR (DMSO + D2O): δ 0.29 – 0.61 
(m, 1H, CH), 1.04 -1.09 (m, 4H, 2CH2), 1.43 (s, 3H, CH3), 4.81 (s, 2H, CH2), 7.24– 7.27 
(m, 4H, Ar-H) ppm; ESI-MS m/z 292.5 (M+1)+. Anal. calculated for C14H18Cl N5·HCl: C, 
51.23; H, 5.83; N, 21.34. Found: C, 50.80; H, 6.16; N, 21.17. 
7,9-Diamino-10-(4’-methylbenzyl)-6,8,10-triazaspiro[4.5]deca-6,8-diene 
hydrochloride (M-III-12) 
From 1-(4-methylbenzyl) biguanide hydrochloride (2.42g, 0.01mol) and cyclopentanone 
(1.1mL, 0.012mol), M-III-12 was obtained as a white solid (0.90 g) in 29.0 % yield. mp: 
200 – 202oC ; λmax (water): 244.8 nm ; IR (KBr disc): 3346 (νN-H), 3176 (νC-H, aromatic), 
2967 (νC-H, cyclopentane), 1643 (νC=N), 1556 (νC-C, aromatic), 838 (δopp, C-H, aromatic) ; 1H NMR 
(DMSO-d6): δ 1.70 – 1.94 (dd, 8H, cyclopentyl), 2.29 (s, 3H, CH3), 4.61 (s, 2H, bridge 
CH2), 7.09 – 7.23 (dd, 4H, Ar-H) ppm ; ESI-MS m/z 271.8 (M+1)+ ; Anal. calculated for 
C15H21N5·HCl·H2O: C, 55.63; H, 6.85; N, 21.63. Found: C, 55.71; H, 7.15; N, 21.85. 
7,9-Diamino-10-(4’-methoxybenzyl)-6,8,10-triazaspiro[4.5]deca-6,8-diene 
hydrochloride (M-III-13) 
From 1-(4-methoxybenzyl) biguanide hydrochloride (2.58g, 0.01mol) and 
cyclopentanone (1.1mL, 0.012mol), M-III-13 was obtained as a beige powder (1.56 g) 
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after a recrystallization in 48.3% yield; mp: 204 – 205oC ; λmax (water): 232.6 nm ; IR 
(KBr disc): 3367 (νN-H), 3213 (νC-H, aromatic), 2967 (νC-H, cyclopentane), 1650 (νC=N), 1513 (νC-C, 
aromatic), 1138 (νC-O), 849 (δopp, C-H, aromatic) ; 1H NMR (DMSO-d6): 1.72 – 1.77 (dd, 8H, 
cyclopentyl), 4.40 – 4.42 (d, 2H, bridge CH2), 6.90 – 7.24 (dd, 4H, Ar-H) ppm ; ESI-MS 
m/z 287.8 (M+1)+ ; Anal. calculated for : C15H21N5O·HCl C, 48.56; H, 6.11; N, 20.23. 
Found: C, 48.62; H, 6.06; N, 20.19. 
7,9-Diamino-10-(4’-chlorobenzyl-6,8,10-triazaspiro[4.5]deca-6,8-diene 
hydrochloride (M-III-14) 
From 1-(4-chlorobenzyl) biguanide hydrochloride (2.62g, 0.01mol) and cyclopentanone 
(1.1mL, 0.012mol), M-III-14 was obtained as a white solid (0.84 g) after purification by 
re-crystallization in ethanol-water in 25.5% yield; mp: 195 – 197oC ; λmax (water): 244.6 
nm ; IR (KBr disc): 3347 (νN-H), 3174 (νC-H, aromatic), 2964 (νC-H, cyclopentane), 1670 (νC=N), 
1551 (νC-C, aromatic), 826 (δopp, C-H, aromatic), 409 (νC-Cl ) ; 1H NMR (DMSO-d6): δ 1.68 – 1.92 
(dd, 8H, cyclopentyl), 4.66 (s, 2H, bridge CH2), 7.22 – 7.48 ( dd, 4H, Ar-H) ppm ; ESI-
MS m/z 291.8 (M+1)+ ; Anal. calculated for C14H18N5Cl·HCl·H2O: C, 48.56; H, 6.11; N, 
20.23. Found: C, 48.62; H, 6.06 ; N, 20.19. 
7,9-Diamino-10-(3’,4’-dichlorobenzyl-6,8,10-triazaspiro[4.5]deca-6,8-diene 
hydrochloride (M-III-15) 
From 1-(3,4-dichlorobenzyl) biguanide hydrochloride (2.97g, 0.01mol) and 
cyclopentanone (1.1mL, 0.012mol), M-III-15 was obtained as a white solid (1.80 g) in 
49.7% yield. mp: 216 – 217oC ; λmax (water): 231.2 nm ; IR (KBr disc): 3348 (νN-H), 3102 
(νC-H, aromatic), 2956 (νC-H, cyclopentane), 1670 (νC=N), 1560 (νC-C, aromatic), 865 (δopp, C-H, aromatic), 
409 (νC-Cl ) ; 1H NMR (DMSO-d6): δ 1.72 – 1.81 (m, 8H, cyclopentyl), 4.47 – 4.66 (d, 2H, 
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bridge CH2), 7.18 – 7.42 (m, 3H, Ar-H) ppm ; ESI-MS m/z 325.9 (M+1)+ ; Anal. 




From 1-(4-methylbenzyl) biguanide hydrochloride (2.42g, 0.01mol) and cyclohexanone 
(1.2 mL, 0.012 mol), M-III-16 was obtained as a white solid (0.44 g) in 13.8% yield. mp: 
216 – 218 °C; λmax (water): 243.8 nm; IR (KBr disc): 3301 (νN–H), 3144 (νC–H, aromatic), 
2936 (νC–H, cyclohexane), 1644 (νC=N), 1567 (ν CC−&&& , aromatic) cm
-1; 1H NMR (DMSO-d6): δ 1.50 
– 1.74 (m, 10H, cyclohexyl), 2.28 (s, 3H, CH3), 4.73 (s, 2H, CH2), 7.10 – 7.19 (m, 4H, 
Ar-H), 7.53 (br s, 2H, NH, ex), 8.96 (br s, 1H, NH, ex) ppm; ESI-MS m/z 285.6 (M+1)+. 




From 1-(4-methoxylbenzyl) biguanide hydrochloride (2.58g, 0.01mol) and 
cyclohexanone (1.2 mL, 0.012 mol), M-III-17 was obtained as a white solid (0.39g) in 
11.6% yield; mp: 213 – 215 °C; λmax (water): 240.4 nm; IR (KBr disc): 3276 (νN–H), 
3148 (νC–H, aromatic), 3007 (νC–H, cyclohexane), 1648 (νC=N), 1581 (ν CC−&&& , aromatic) cm
-1; 
1H NMR (DMSO-d6): δ 1.56 – 1.73 (m, 10H, cyclohexyl), 3.73 (s, 3H, OCH3), 4.68 (s, 
2H, CH2), 6.93 – 7.16 (m, 4H, Ar-H), 7.53 (br s, 2H, NH, ex), 8.74 (br s, 1H, NH, ex) 
ppm; ESI-MS m/z 301.6 (M+1)+. Anal. calculated for C16H23N5O·HCl: C, 56.88; H, 7.16; 
N, 20.73. Found: C, 56.78; H, 7.30; N, 20.94. 





From 1-(4-fluorobenzyl) biguanide hydrochloride (2.46g, 0.01mol) and cyclohexanone 
(1.2 mL, 0.012 mol), M-III-18 was obtained as a white solid (0.49 g) in 15.0 % yield; mp: 
211 – 212.5 °C; λmax (water): 243.2 nm; IR (KBr disc): 3305 (νN–H), 3152 (νC–H, aromatic), 
2936 (νC–H, cyclohexane), 1646 (νC=N), 1587 (ν CC−&&& , aromatic) cm
-1; 1H NMR (DMSO-d6): δ 1.57 
– 1.76 (m, 10H, cyclohexyl), 4.76 (s, 2H, CH2), 7.18 – 7.28 (m, 4H, Ar-H), 7.57 (br s, 2H, 
NH, ex), 8.91 (br s, 1H, NH, ex) ppm; ESI-MS m/z 289.9 (M+1)+. Anal. calculated for 
C15H20N5F·HCl: C, 55.30; H, 6.50; N, 21.49. Found: C, 55.47; H, 6.48; N, 21.60. 
2,4-Diamino-5-(4’-chlorophenyl)-1,3,5-triazaspiro[5.5]undeca-1,3-diene 
hydrochloride (M-III-19) 
From 1-(4-chlorobenzyl) biguanide hydrochloride (2.62g, 0.01mol) and cyclohexanone 
(1.2 mL, 0.012 mol), M-III-19 was obtained after purification by a silica gel 
chromatography (chloroform : methanol, eluent gradient 5:1 to 3 : 1) as a white solid 
(0.27 g) in 8.0 % yield; mp: 213 – 214 °C; λmax (water): 242.8 nm; IR (KBr disc): 3306 
(νN–H), 3145 (νC–H, aromatic), 2930 (νC–H, cyclohexane), 1644 (νC=N), 1567 (ν CC−&&& , aromatic) cm
-1; 1H 
NMR (DMSO-d6): δ 1.57 – 1.64 (m, 10H, cyclohexyl), 4.75 (s, 2H, CH2), 7.21 – 7.46 (m, 
4H, Ar-H), 7.57 (br s, 2H, NH, ex), 8.76 (br s, 1H, NH, ex) ppm; ESI-MS m/z 305.4 
(M+1)+. Anal. calculated for C15H20N5Cl·HCl: C, 52.64; H, 6.18; N, 20.46. Found: C, 
52.82; H, 5.88; N, 20.64. 
2,4-Diamino-5-(3’,4’-dichlorophenyl)-1,3,5-triazaspiro[5.5]undeca-1,3-diene 
hydrochloride (M-III-20) 
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From 1-(3,4-dichlorobenzyl) biguanide hydrochloride (2.97g, 0.01mol) and 
cyclohexanone (1.2 mL, 0.012 mol), M-III-20 was obtained as a white solid (0.44 g) in 
11.7 % yield. mp: 210 – 213 °C; λmax (water): 242.6 nm; IR (KBr disc): 3316 (νN–H), 
3088 (νC–H, aromatic), 2949 (νC–H, cyclohexane), 1630 (νC=N), 1591 (ν CC−&&& , aromatic) cm
-1; 1H NMR 
(DMSO-d6): δ 1.58 – 1.74 (m, 10H, cyclohexyl), 4.79 (s, 2H, CH2), 7.18 – 7.67 (m, 3H, 
Ar-H), 8.92 (br s, 1H, NH, ex) ppm; ESI-MS m/z 341.5 (M+1)+. Anal. calculated for 
C15H19N5Cl2·HCl: C, 47.83; H, 5.35; N, 18.59. Found: C, 47.84; H, 5.12; N, 18.82. 
2,4-Diamino-5-(3’,4’,5’-trimethoxyphenyl)-1,3,5-triazaspiro[5.5]undeca-1,3-diene 
hydrochloride (M-III-21) 
From 1-(3,4,5-trimethoxybenzyl) biguanide hydrochloride (3.18g, 0.01mol) and 
cyclohexanone (1.2 mL, 0.012 mol), M-III-21 was obtained after purification by a silica 
gel chromatography (chloroform : methanol, eluent gradient 5:1 to 3 : 1) as a white solid 
(0.13 g) in 3.2 % yield. mp: 197 – 199 °C; λmax (water): 237.0 nm; IR (KBr disc): 3315 
(νN–H), 3142 (νC–H, aromatic), 2934 (νC–H, cyclohexane), 1653 (νC=N), 1593 (ν CC−&&& , aromatic) cm
-1; 1H 
NMR (DMSO-d6): δ 1.58 – 1.75 (m, 10H, cyclohexyl), 3.64 (s, 3H, OCH3), 3.75 (s, 6H, 
2OCH3), 4.67 (s, 2H, CH2), 6.51 (s, 2H, Ar-H), 7.52 (br s, 2H, NH, ex), 8.79 (br s, 1H, 
NH, ex) ppm; ESI-MS m/z 361.9 (M+1)+. Anal. calculated for C18H27N5O3·HCl: C, 
59.81; H, 7.53; N, 19.38. Found: C, 59.77; H, 7.77; N, 19.20. 
2,4-Diamino-5-(3’,4’-dichlorobenzyl)-1,3,5-triazaspiro[5.6]dodeca-1,3-diene 
hydrochloride (M-III-22) 
From 1-(3,4-dichlorobenzyl) biguanide hydrochloride (2.97g, 0.01mol) and 
cycloheptanone (1.5 mL, 0.012 mol), M-III-22 was obtained as a white solid (1.46 g) in 
37.4% yield. mp: 234 – 236oC ; λmax (water): 236.8 nm ; IR (KBr disc): 3335 (νN-H), 3046 
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(νC-H, aromatic), 2933 (νC-H, cycloheptane), 1664 (νC=N), 1563 (νC-C, aromatic), 843 (δopp, C-H, aromatic), 
418 (νC-Cl ) ; 1H NMR (DMSO-d6): 1.53 – 1.83 (d, 12H, cycloheptyl), 4.46 (s, 2H, bridge 
CH2), 7.28 – 7.63 (m, 3H, Ar-H) ppm ; ESI-MS m/z 352.5 (M+1)+; Anal. calculated for 
C16H21N5Cl2·HCl: C, 49.18; H, 5.68; N, 17.92. Found: C, 49.14; H, 6.02; N, 17.96. 
2,4-Diamino-5-(4-Methylbenzyl)-1,3,5-triazaspiro[5.6]dodeca-1,3-diene 
hydrochloride (M-III-23) 
From 1-(4-methylbenzyl) biguanide hydrochloride (2.42g, 0.01mol) and cycloheptanone 
(1.5 mL, 0.012 mol), M-III-23 was obtained after purification by a silica gel 
chromatography (chloroform : methanol, eluent gradient 5:1 to 3 : 1) as a white solid 
(0.18 g) in 5.3 % yield.; mp: 193 – 195oC ; λmax (water): 240.6 nm ; IR (KBr disc): 3300 
(νN-H), 3169 (νC-H, aromatic), 2975 (νC-H, cycloheptane), 1675 (νC=N), 1564 (νC-C, aromatic), 849 (δopp, 
C-H, aromatic) ; 1H NMR (DMSO-d6): 1.52 – 2.01 (m, 12H, cycloheptyl), 2.29 (s, 3H, CH3), 
4.62 (s, 2H, bridge CH2), 7.08 – 7.23 (dd, 4H, Ar-H) ppm ; ESI-MS m/z 298.7 (M+1)+; 
Anal. calculated for C17H25N5·HCl: C, 60.79; H, 7.80; N, 20.85. Found: C, 60.29; H, 7.98; N, 21.33. 
 
Procedure for the Synthesis of 4,6-Diamino-1-Benzyloxy-1,2-Dihydro-2,2-Dimethyl-
1,3,5-Triazines (M-IV-01) 
A mixture of benzoxyamine hydrochloride (12.8g, 0.08mol) and cyanoguanidine (6.8g, 
0.08mol) in 40 ml of EtOH was stirred and refluxed for 3 hours. The reaction solution 
was cooled down and conc. HCl (6.6 mL) and 14.2 mL of acetone were added. The 
solution was then refluxed for another 3 hours and thereafter stirred at room temperature 
overnight. The resultant precipitate was collected on a filter and washed with cold EtOH 
to give white granular crystals 12.2 g. Yield: 53.8 %. mp: 208-209. 1H NMR (DMSO-d6): 
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1.43 (br s, 6H), 4.98 (s, 2H), 7.39-7.55 (m, 5H), 8.01 (br s, 1H, ex), 8.61 (br s, 1H, ex), 
9.16 (br s, 1H, ex); ESI-MS: m/z 247.8 (M+1)+; Anal. calculated for C12H17N5O·HCl: C, 
50.79; H, 6.39; N, 24.68. Found: C, 50.31; H, 6.22; N, 24.49. 
 
General Procedure for the Synthesis of 4,6-Damino-1-Phenylalkoxy-1,2-Dihydro-
2,2-Dialkyl or Spiroalkyl-1,3,5-Triazines 
After the solution of phenylalkoxyamine hydrochloride (0.08mol) and cyanoguanidine 
(6.8g, 0.08mol) in 40 mL of EtOH was refluxed for 3 hours, conc. HCl (6.6mL) and 
ketone or aldehyde (0.1mol) were added. The solution was stirred at room temperature 
for several days. The resultant precipitate was collected on a filter and washed with cold 
EtOH. Recrystallization of the collected solid from 90% EtOH gave analytical pure 




From benzoxyamine hydrochloride and methyl ethyl ketone, M-IV-02 was obtained as a 
white solid in 51.0% yield. mp: 211-215 oC; 1H NMR (DMSO-d6): δ 0.90 (br s, 3H), 
1.44 (br s, 3H), 1.74 (br s, 2H), 4.97 (br s, 2H), 7.20 (br s, 1H, ex), 7.40-7.45 (m, 3H), 
7.65 (br s, 1H, ex), 7.98 (s, 1H, ex), 8.57 (s, 1H, ex), 9.24 (s, 1H, ex); ESI-MS: m/z 
(M+1)+ Anal. calculated for C13H19N5O·HCl: C, 52.43; H, 6.77; N, 23.52. Found: C, 
52.55; H, 6.76; N, 23.68. 
4,6-Damino-1-benzoxy-2-cyclopropyl-1,2-dihydro-1,3,5-triazines (M-IV-03) 
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From benzoxyamine hydrochloride and cyclopropyl aldehyde, M-IV-03 was obtained as 
a white solid in 48.4% yield. mp: 201-202 oC; 1H NMR (DMSO-d6): ESI-MS: δ 0.26-
0.31 (m, 1H), 0.44-0.54 (m, 2H), 0.61-0.67 (m, 1H), 1.17-1.22 (m, 1H), 4.25-4.28 (q, 1H, 
J1=7.92, J2=2.6), 4.96-4.98 (d, 2H, J=6.0Hz), 7.41-7.44 (m, 3H), 7.57-7.54 (m, 2H), 8.02 
(s, 1H, ex), 8.46 (s, 1H, ex), 8.82, (s, 1H, ex); m/z (M+1)+ 260.1. Anal. calculated for 
C13H19N5O·HCl: C, 52.79; H, 6.14; N, 23.68. Found: C, 53.01; H, 6.10; N, 23.88. 
6,8-Diamino-9-benzyloxy-5,7,9-triaza-spiro[3.5]nona-5,7-diene hydrochloride (M-
IV-04) 
From benzoxyamine hydrochloride and cyclobutanone, M-IV-04 was obtained as a white 
solid in 43.3% yield. mp: 207-208 oC; 1H NMR (DMSO-d6): δ 1.61-1.81 (m, 2H), 2.09-
2.12 (t, 2H, J=4.9Hz), 5.00 (s, 2H), 7.23 (br s, 1H, ex), 7.41-7.45 (m, 3H), 7.55-7.58 (m, 
2H), 7.83 (br s, 1H, ex), 8.12 (s, 1H, ex), 8.67 (s, 1H, ex), 10.11 (s, 1H, ex). ESI-MS: m/z 
(M+1)+ Anal. calculated for C13H18N5O·HCl: C, 52.79; H, 6.13; N, 23.68. Found: C, 
53.15; H, 6.22; N, 23.74. 
7,9-Diamino-10-benzoxy-6,8,10-triazaspiro[4.5]deca-6,8-diene hydrochloride (M-IV-
05) 
From benzoxyamine hydrochloride and cyclopentanone, M-IV-05 was obtained as a 
white solid in 46.8% yield. mp: 195-196 oC; 1H NMR (DMSO-d6): δ 1.65-1.74 (m, 6H), 
1.95 (br s, 2H), 4.97 (s, 2H), 7.16 (br s, 1H, ex), 7.39-7.53 (m, 5H), 7.77 (br s, 1H, ex), 
8.06 (br s, 1H, ex), 8.65 (br s, 1H, ex), 9.54 (br s, 1H, ex); ESI-MS: m/z = 274.1 (M+1)+ 
Anal. calculated for C14H19N5O·HCl: C, 54.28; H, 6.51; N, 22.61. Found: C, 53.91; H, 
6.58; N, 22.33. 
 





From benzyloxyamine hydrochloride and cyclohexanone, M-IV-06 was obtained as a 
white solid in 64.9% yield. mp: 216-217 oC; 1H NMR (DMSO-d6): δ 1.06-1.11 (m, 1H), 
1.47-1.76 (m, 9H), 4.96 (s, 2H), 7.39-7.55 (m, 5H), 7.62 (br s, 1H, ex), 7.80 (br s, 1H, ex), 
7.97 (br s, 1H, ex), 8.59 (br s, 1H, ex), 9.52 (br s, 1H, ex); ESI-MS: m/z = 288.0 (M+1)+ 
Anal. calculated for C15H21N5O·HCl: C, 55.64; H, 6.85; N, 21.63. Found: C, 55.93; H, 
6.86; N, 21.78. 
2,4-Diamino-5-benzyloxy-1,3,5-triazaspiro[5.6]dodeca-1,3-diene hydrochloride (M-
IV-07) 
From benzyloxyamine hydrochloride and cycloheptanone, M-IV-07 was obtained as a 
white solid in 60.1% yield. mp: 201-203 oC; 1H NMR (DMSO-d6): δ 1.51 (br s, 8H), 
1.80-1.85 (br s, 2H), 2.06 (br s, 2H), 4.97 (s, 2H), 7.15 (br s, 1H, ex), 7.40-7.45 (m, 3H), 
7.51-7.56 (m, 2H), 7.92 (s, 1H, ex), 8.61 (s, 1H, ex), 9.35 (br s, 1H, ex); ESI-MS: m/z = 
302.0 (M+1)+ Anal. calculated for C16H23N5O·HCl: C, 56.88; H, 7.16; N, 20.73. Found: 
C, 56.69; H, 7.37; N, 20.63. 
7,9-Diamino-10-phenylethyloxy-6,8,10-triazaspiro[4.5]deca-6,8-diene hydrochloride 
(M-IV-08) 
From phenylethyloxyamine hydrochloride and cyclopentanone, M-IV-08 was obtained as 
a white solid in 27.1% yield. mp: 210-211 oC; 1H NMR (DMSO-d6): δ 1.37-1.74 (br m, 
9H), 2.97-3.01 (t, 2H), 4.10 (br s, 2H), 7.21-7.34 (m, 6H), 8.10 (s, 1H, ex), 8.64 (s, 1H, 
ex), 9.60 (br s, 1H, ex); ESI-MS: m/z = 288.2 (M+1)+ Anal. calculated for 
C15H21N5O·2HCl: C, 50.01; H, 6.43; N, 19.44. Found: C, 50.26; H, 6.17; N, 19.66. 





From phenylethyloxyamine hydrochloride and cyclohexanone, M-IV-09 was obtained as 
a white solid in 13.8% yield. mp: 225-226 oC; 1H NMR (DMSO-d6): δ 0.78 (br s, 1H), 
1.24-1.68 (m, 9H), 2.96-3.00 (t, 2H) 4.06 (s, 2H), 7.22-7.36 (m, 5H), 8.07 (br s, 1H, ex), 
8.59 (br s, 1H, ex), 9.10 (br s, 1H, ex); ESI-MS: m/z = 302.0 (M+1)+ Anal. calculated for 
C16H23N5O·HCl: C, 56.88; H, 7.16; N, 20.73. Found: C, 56.50; H, 7.09; N, 20.56. 
7,9-Diamino-10-phenylpropyloxy-6,8,10-triazaspiro[4.5]deca-6,8-diene 
hydrochloride (M-IV-10) 
From phenylpropyloxyamine hydrochloride and cyclopentanone, M-IV-10 was obtained 
as a white solid in 27.3% yield. mp: 186-188 oC; 1H NMR (DMSO-d6): δ 1.70 (br s, 6H), 
2.62-2.67 (t, 4H), 3.91-3.95 (t, 2H), 7.17-7.76 (m, 6H), 8.03 (s, 1H, ex), 8.61 (s, 1H, ex), 
9.48 (s, 1H, ex); ESI-MS: m/z = 302.3 (M+1)+ Anal. calculated for C16H23N5O·2HCl: C, 
51.34; H, 6.73; N, 18.71. Found: C, 51.65; H, 6.47; N, 18.83. 
2,4-Diamino-5-phenylpropyloxy-1,3,5-triazaspiro[5.5]undeca-1,3-diene 
hydrochloride (M-IV-11) 
From phenylpropyloxyamine hydrochloride and cyclohexanone, M-IV-11 was obtained 
as a white solid in 28.0 % yield. mp: 216-218 oC; 1H NMR (DMSO-d6): δ 1.12 (br s, 1H), 
1.57-1.69 (m, 7H), 2.00-2.05 (br t, 2H), 2.63-2.69 (t, 2H), 3.90 (s, 2H), 7.17-7.32 (m, 5H), 
7.96 (br s, 1H, ex), 8.56 (br s, 1H, ex), 9.37 (br s, 1H, ex); ESI-MS: m/z = 316.2 (M+1)+ 
Anal. calculated for C16H23N5O·H2O·HCl: C, 56.58; H, 7.54; N, 19.41. Found: C, 56.58; 
H, 7.30; N, 19.27. 
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General Procedure for the Synthesis of M-V series 
1-hydro-1,2-dihydro-1,3,5-triazine (1 g) was dissolved in 20 mL of methanol, 1 molar 
equivalent of NaOH was added into the solution and reflux was carried out for 30 min. 
After being cooled to room temperature, the solvent was evaporated using vacuum. The 
dry white precipitate was dissolved in 5 ml of DMF and to this solution, 1.2 molar 
equivalent of 3-aryloxypropyl bromide was added. The mixture was stirred at room 
temperature and TLC was used to monitor the reaction. After the reaction was completed, 
the solution was adjusted to pH 1 using concentrated HCl, followed by evaporating of 
DMF at room temperature to dryness. The residue was filtered and washed using water, 




From 4,6-diamino-1,2-dihydro-1-hydroxy-2,2-dimethyl-1,3,5-triazine hydrochloride 
(1.0g, 5.2 mM) and phenoxypropyl bromide (1.3 g, 6.2 mM), M-V-01 was obtained as a 
white solid (1.1 g) in 66.2 % yield. mp: 194-195 oC; 1H NMR (DMSO-d6): δ 1.40 (br s, 
6H), 2.17 (br s, 2H,), 4.07 (t, 4H), 6.93-7.32 (m, 5H), 8.07 (s, 1H, ex), 8.62 (s, 1H, ex), 
9.20 (s, 1H, ex); ESI-MS: m/z = 292.0 (M+1)+ Anal. calculated for C14H21N5O2·1.8HCl: 
C, 47.10; H, 6.44; N, 19.62. Found: C, 47.04; H, 6.23; N, 19.60. 
 4,6-Diamino-1,2-dihydro-2,2-dimethyl-1-(4’-phenoxybutyloxy)-1,3,5-triazines (M-
V-02) 
From 4,6-diamino-1,2-dihydro-1-hydroxy-2,2-dimethyl-1,3,5-triazine hydrochloride (1g, 
5.2 mM) and phenoxybutyl bromide (1.4, 6.2 mM), M-V-02 was obtained as a white 
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solid (1.0 g) in 54.0 % yield. mp: 194-195 oC; 1H NMR (DMSO-d6) 0.77 (br m, 1H), 
1.36-1.48 (br m, 9H), 2.16 (br s, 2H), 4.06 (m, 4H), 6.74 (br s, 1H, ex), 6.93 (t, 3H), 7.27-
7.32 (m, 2H), 7.87 (br s, 1H, ex), 8.11(s, 1H, ex), 8.61 (s, 1H, ex). ESI-MS: m/z = 331.9 
(M+1)+ Anal. calculated for C15H23N5O2·HCl·H2O: C, 50.07; H, 7.28; N, 19.46. Found: C, 
50.13; H, 6.81; N, 19.37. 
4,6-Diamino-2-ethyl-1,2-dihydro-2-methyl-1-(3’-phenoxyproyloxy)-1,3,5-triazines 
(M-V-03) 
From 4,6-diamino-2-ethyl-1,2-dihydro-1-hydroxy-2-methyl-1,3,5-triazine hydrochloride 
(1g, 4.8 mM) and phenoxypropyl bromide (1.2 g, 5.8 mM), M-V-03 was obtained as a 
white solid (0.97 g) in 53.3 % yield. mp: 175-176 oC; 1H NMR (DMSO-d6): δ 0.86 (br s, 
3H), 1.40 (br s, 3H), 1.62-1.72 (m, 2H), 2.15 (br s, 2H), 4.07 (m, 4H), 6.93 (q, 3H), 7.30 
(t, 2H, J=8.3Hz) 7.68 (br s, 1H, ex), 8.03 (s, 1H, ex), 8.56 (s, 1H, ex), 8.88 (s, 1H, ex); 
ESI-MS: m/z = 306.2 (M+1)+ Anal. calculated for C15H23N5O2·2HCl: C, 47.62; H, 6.66; 
N, 18.51. Found: C, 47.65; H, 6.53; N, 18.30. 
4,6-Diamino-2-cyclopropyl-1,2-dihydro-1-(3’-phenoxyproyloxy)-1,3,5-triazines (M-
V-04) 
From 4,6-diamino-2-cyclopropyl-1,2-dihydro-1-hydroxy-1,3,5-triazine hydrochloride (1g, 
4.9 mM) and phenoxypropyl bromide (1.2g, 5.8 mM), M-V-04 was obtained as a white 
solid (0.88 g) in 51.1 % yield. mp: 207-208 oC; 1H NMR (DMSO-d6): δ 0.27-0.64 (m,4H), 
1.13-1.21 (m, 1H), 2.15 (t, 2H, J=6.4 Hz), 4.05-4.17 (m, 4H), 4.30 (d, 1H, J=7.2Hz), 6.94 
(t, 3H, J=4.9Hz), 7.30 (t, 2H, J=7.9Hz), 7.73 (br s, 1H, ex), 8.07 (s, 1H, ex), 8.51 (s, 1H, 
ex), 8.90 (s, 1H, ex); ESI-MS: m/z = 304.3 (M+1)+ Anal. calculated for 
C15H21N5O2·HCl·0.8H2O: C, 50.86; H, 6.71; N, 19.77. Found: C, 50.78; H, 6.39; N, 19.60. 





From 7,9-diamino-6,8,10-triaza-spiro[4.5]deca-7,9-dien-6-ol hydrochloride (1g, 4.6 mM) 
and phenoxypropyl bromide (1.2g, 5.5 mM), M-V-05 was obtained as a white solid 
(0.97g) in 56.5 % yield. mp: 191-192 oC 1H NMR (DMSO-d6): δ 1.54-1.73 (br m, 6H), 
1.97 (br s, 2H), 2.15 (t, 2H, J=5.6Hz), 4.07 (m, 4H), 6.93 (t, 3H), 7.30 (m, 2H), 7. 70 (br s, 
1H, ex), 8.12(s, 1H, ex), 8.64 (s, 1H, ex), 9.36 (s, 1H, ex); ESI-MS: m/z = 318.2 (M+1)+ 
Anal. calculated for C16H23N5O2·HCl·H2O: C, 51.68; H, 6.78; N, 18.84. Found: C, 52.08; 
H, 6.76; N, 18.80. 
7,9-Diamino-10-(4’-phenoxybutyloxy)-6,8,10-triazaspiro[4.5]deca-6,8-diene 
hydrochloride (M-V-06)  
From 7,9-diamino-6,8,10-triaza-spiro[4.5]deca-7,9-dien-6-ol hydrochloride (1g, 4.6 mM) 
and phenoxybutyl bromide (1.3g, 5.5 mM), M-V-06 was obtained as a white solid (1.0g) 
in 57.6 % yield. mp: 190-191oC; 1H NMR (DMSO-d6): δ 1.71 (br s, 6H), 1.77-1.84 (br m, 
4H), 1.99 (br s, 2H), 3.96-4.00 (t, 4H, J=5.6Hz), 6.91-6.94 (t, 3H), 7.12 (br s, 1H, ex), 
7.26-7.31 (t, 2H, J=7.9Hz), 7.77 (br s, 1H, ex), 8.06 (s, 1H, ex), 8.62 (s, 1H, ex), 9.51 (s, 
1H, ex); ESI-MS: m/z = 332.2 (M+1)+ Anal. calculated for C17H25N5O2·HCl·0.8H2O: C, 
53.41; H, 7.28; N, 18.32. Found: C, 53.09; H, 7.13; N, 18.63. 
2,4-Diamino-5-(3’-phenoxypropyloxy)-1,3,5-triazaspiro[5.5]undeca-1,3-diene 
hydrochloride (M-V-07)  
From 2,4-diamino-1,3,5-triaza-spiro[5.5]undeca-2,4-dien-1-ol hydrochloride (1g, 4.3 mM) 
and phenoxypropyl bromide (1.1g, 5.1 mM), M-V-07 was obtained as a white solid (1.2g) 
in 71.4 % yield. mp: 209-210oC; 1H NMR (DMSO-d6): δ 0.77 (br m, 1H), 1.36-1.48 (br 
  MATERIALS AND METHODS 
 
 194
m, 9H), 2.16 (br s, 2H), 4.06 (m, 4H), 6.74 (br s, 1H, ex), 6.93 (t, 3H), 7.27-7.32 (m, 2H), 
7.87 (br s, 1H, ex), 8.11(s, 1H, ex), 8.61 (s, 1H, ex); ESI-MS: m/z = 331.9 (M+1)+ Anal. 
calculated for C17H25N5O2·HCl·H2O: C, 52.91; H, 7.31; N, 18.15. Found: C, 52.62; H, 
7.49; N, 18.39. 
2,4-Diamino-5-(4’-phenoxy-butyloxy)-1,3,5-triazaspiro[5.5]undeca-1,3-diene 
hydrochloride (M-V-08)  
From 2,4-diamino-1,3,5-triaza-spiro[5.5]undeca-2,4-dien-1-ol hydrochloride (1g, 4.3 mM) 
and phenoxybutyl bromide (1.2g, 5.1 mM), M-V-08 was obtained as a white solid (1.1g) 
in 67.3 % yield. mp: 205-206 oC; 1H NMR (DMSO-d6): 1.10 (br m, 1H), 1.58-1.80 (br m, 
9H), 1.79 (br s, 4H), 3.99 (t, 4H, J=5.3Hz, J=6.0Hz), 6.92 (q, 3H), 7.28 (t, 2H), 7.80 (br s, 
1H, ex), 8.00 (s, 1H, ex), 8.57 (s, 1H, ex), 9.19 (s, 1H, ex). ESI-MS: m/z = 346.3 (M+1)+ 
Anal. calculated for C18H27N5O2·HCl·0.5H2O: C, 55.31; H, 7.48; N, 17.92. Found: C, 
55.20; H, 7.69; N, 17.83. 
2,4-Diamino-5-(3’-phenoxypropyloxy)-1,3,5-triazaspiro[5.6]dodeca-1,3-diene 
hydrochloride (M-V-09) 
From 5-hydroxy-1,3,5-triazaspiro[5.6]dodeca-1,3-diene-2,4-diamine hydrochloride (1g, 
4.0 mM) and phenoxypropyl bromide (1.0 g, 4.8 mM), M-V-09 was obtained as a white 
solid (1.1g) in 55.9 % yield. mp: 203-205 oC; 1H NMR (DMSO-d6): δ 1.29-1.49 (br d, 
8H), 1.80-2.17 (br s, 4H), 2.17 (br s, 2H), 4.08 (m, 4H), 6.94 (t, 3H), 7.29 (t, 2H), 7.75 
(br s, 1H, ex), 8.01(s, 1H, ex), 8.60 (s, 1H, ex), 9.34 (s, 1H, ex); ESI-MS: m/z = 346.2 
(M+1)+; Anal. calculated for C18H27N5O2·HCl·0.8H2O: C, 54.55; H, 7.53; N, 17.67. 
Found: C, 54.42; H, 7.15; N, 17.74. 




diene hydrochloride (M-V-10)  
From 5-hydroxy-1,3,5-triazaspiro[5.5]undeca-1,3-diene-2,4-diamine hydrochloride (1g, 
4.3 mM) and 3’-(p-fluorophenoxy) propyl bromide (1.2g, 5.1 mM), M-V-10 was 
obtained as a white solid (1.0g) in 62.1 % yield. mp: 211-212 oC; 1H NMR (DMSO-d6): δ 
0.77 (br s, 1H), 1.48-1.69 (br d, 9H), 2.14 (br s, 2H), 4.04-4.07 (m, 4H), 6.93-6.99 (m, 
2H), 7.09-7.16 (d, 2H), 7.40 (br s, 1H, ex), 7.81 (br s, 1H, ex), 8.08(s, 1H, ex), 8.60 (s, 
1H, ex), 9.28 (s, 1H, ex); ESI-MS: m/z = 350.3 (M+1)+; Anal. calculated for 
C17H24FN5O2·HCl: C, 52.92; H, 6.53; N, 18.15. Found: C, 52.75; H, 6.56; N, 18.06. 
2,4-Diamino-5-(3’-(4’’-chlorophenoxy)-propyloxy)-1,3,5-triazaspiro[5.5]undeca-1,3-
diene hydrochloride (M-V-11)  
From 2,4-diamino-1,3,5-triaza-spiro[5.5]undeca-2,4-dien-1-ol hydrochloride (1g, 4.3 mM) 
and 3’-(p-chlorophenoxy) propyl bromide (1.2g, 5.1 mM), M-V-11 was obtained as a 
white solid (1.1g) in 64.8 % yield. mp: 219-220 oC; 1H NMR (DMSO-d6): δ 0.79 (br s, 
1H), 1.48-1.68 (br d, 9H), 2.16 (br s, 2H), 4.08 (m, 4H), 6.99 (d, 2H, J=8.6Hz), 7.34 (d, 
2H, J=8.7Hz), 7.37 (br s, 1H, ex), 7.81 (br s, 1H, ex), 8.08(s, 1H, ex), 8.60 (s, 1H, ex), 
9.28 (s, 1H, ex); ESI-MS: m/z = 366.1 (M+1)+; Anal. calculated for C17H24ClN5O2·HCl: 
C, 50.75; H, 6.26; N, 17.41. Found: C, 50.49; H, 6.20; N, 17.57. 
2,4-Diamino-5-(3’-(4’’-nitrophenoxy)-propyloxy)-1,3,5-triazaspiro[5.5]undeca-1,3-
diene hydrochloride (M-V-12)  
 From 2,4-diamino-1,3,5-triaza-spiro[5.5]undeca-2,4-dien-1-ol hydrochloride (1g, 4.3 
mM) and 1-(3-bromo-propyloxy)-4-nitro-benzene (1.3g, 5.1 mM), M-V-12 was obtained 
as a yellowish solid (1.1g) in 60.5 % yield. mp: 212-213 oC; 1H NMR (DMSO-d6): δ 0.79 
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(br s, 1H), 1.45-1.70 (br d, 9H), 2.22 (br s, 2H), 4.06 (br s, 2H), 4.25 (m, 2H, J=6.0Hz), 
7.17 (br s, 1H, ex), 7.19 (d, 2H, J=9.4Hz), 7.83 (br s, 1H, ex), 8.11 (s, 1H, ex), 8.24 (d, 
2H, J=9.0Hz), 8.62 (s, 1H, ex), 8.99 (s, 1H, ex). ESI-MS: m/z = 377.2 (M+1)+; Anal. 
calculated for C17H24N6O4·1.6HCl: C, 46.97; H, 5.93; N, 19.33. Found: C, 46.99; H, 5.78; 
N, 19.12. 
2,4-Diamino-5-(3’-(4’’-tolyloxy)-propyloxy)-1,3,5-triaza-spiro[5.5]undeca-1,3-diene 
hydrochloride (M-V-13)  
 From 2,4-diamino-1,3,5-triaza-spiro[5.5]undeca-2,4-dien-1-ol hydrochloride (1g, 4.3 
mM) and 1-(3-bromo-propyloxy)-4-methyl-benzene (1.2g, 5.1mM), M-V-13 was 
obtained as a white solid (1.0g) in 61.4 % yield. mp: 214-215oC; 1H NMR (DMSO-d6): δ 
0.80 (br s, 1H), 1.44-1.69 (br t, 9H), 2.14 (br s, 2H), 2.23 (s, 3H), 4.04 (m, 4H), 6.84 (d, 
2H, J=8.7Hz), 7.09 (d, 2H, J=8.3Hz), 7.33 (br s, 1H, ex), 7.81 (br s, 1H, ex), 8.06 (s, 1H, 
ex), 8.59 (s, 1H, ex), 9.21 (s, 1H, ex); ESI-MS: m/z = 346.3 (M+1)+; Anal. calculated for 
C18H27N5O2·HCl : C, 56.61; H, 7.39; N, 18.34. Found: C, 56.47; H, 7.45; N, 18.60. 
2,4-Diamino-5-(3’-(4’’-tert-butylphenoxy)-propyloxy)-1,3,5-triazaspiro[5.5]undeca-
1,3-diene hydrochloride (M-V-14) 
From 2,4-diamino-1,3,5-triaza-spiro[5.5]undeca-2,4-dien-1-ol hydrochloride (1g, 4.3 mM) 
and 1-(3-bromo-propyloxy)-4-tert-butyl-benzene (1.4g, 5.1mM), M-V-14 was obtained 
as a white solid (0.94g) in 47.4 % yield. mp: 222-223oC; 1H NMR (DMSO-d6): δ 0.74 (br 
s, 1H), 1.35 (s, 9H), 1.39-1.68 (br t, 9H), 2.15 (br s, 2H), 4.05 (t, 4H, J=5.3Hz, J=5.7Hz), 
6.87 (d, 2H, J=8.6Hz), 7.14 (br s, 1H, ex), 7.29 (d, 2H, J=8.7Hz), 7.84 (br s, 1H, ex), 
8.08(s, 1H, ex), 8.60 (s, 1H, ex), 8.88 (s, 1H, ex).; ESI-MS: m/z =388.3 (M+1)+; Anal. 
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calculated for C21H33N5O2·2HCl: C, 54.78; H, 7.66; N, 15.21. Found: C, 54.82; H, 7.46; 
N, 15.23. 
2,4-Diamino-5-(3’-(4’’-methoxyphenoxy)-propyloxy)-1,3,5-triazaspiro[5.5]undeca-
1,3-diene hydrochloride (M-V-15) 
From 2,4-diamino-1,3,5-triaza-spiro[5.5]undeca-2,4-dien-1-ol hydrochloride (1g, 4.3 mM) 
and 3’-(p-methoxyphenoxy) propyl bromide (1.3g, 5.1mM), M-V-15 was obtained as a 
white solid (0.93g) in 51.3 % yield. mp: 202-203oC; 1H NMR (DMSO-d6): δ 0.80 (br s, 
1H), 1.45-1.70 (br t, 9H), 2.13 (br s, 2H), 3.69 (s, 3H), 3.99-4.07 (m, 4H), 6.84-6.91 (m, 
4H), 7.12 (br s, 1H, ex), 7.84 (br s, 1H, ex), 8.08(s, 1H, ex), 8.61 (s, 1H, ex), 8.95 (s, 1H, 
ex); ESI-MS: m/z =362.3 (M+1)+; Anal. calculated for C18H27N5O2·HCl·1.2H2O: C, 
51.53; H, 7.30; N, 16.69. Found: C, 51.54; H, 6.97; N, 16.47. 
4’’-(3’-(2,4-Diamino-1,3,5-triaza-spiro[5.5]undeca-2,4-dien-1-yloxy)-propyloxy)-
benzonitrile hydrochloride (M-V-16) 
From 2,4-diamino-1,3,5-triaza-spiro[5.5]undeca-2,4-dien-1-ol hydrochloride (1g, 4.3 mM) 
and p-(3-bromo-propyloxy)-benzonitrile (1.2g, 5.1mM), M-V-16 was obtained as a white 
solid (0.91g) in 53.4 % yield. mp: 221-222 oC; 1H NMR (DMSO-d6): δ 0.76 (br s, 1H), 
1.48-1.69 (br d, 9H), 2.20 (br s, 2H), 4.05 (br s, 2H), 4.19 (t, 2H, J=5.6Hz, J=6.0Hz), 7.15 
(d, 2H, J=9.0Hz), 7.44 (br s, 1H, ex), 7.79 (d, 2H, J=9.1Hz), 7.79 (br s, 1H, ex), 8.09(s, 
1H, ex), 8.60 (s, 1H, ex), 9.32 (s, 1H, ex). ESI-MS: m/z =357.2 (M+1)+; Anal. calculated 
for C18H24N6O2·HCl·0.2H2O: C, 54.53; H, 6.46; N, 21.20. Found: C, 54.60; H, 6.42; N, 
21.02. 
1-(4’’-(3’-(2,4-Diamino-1,3,5-triaza-spiro[5.5]undeca-2,4-dien-1-yloxy)-propyloxy)-
phenyl)-ethanone hydrochloride (M-V-17) 
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From 2,4-diamino-1,3,5-triaza-spiro[5.5]undeca-2,4-dien-1-ol hydrochloride (1g, 4.3 mM) 
and 1-[4-(3-bromo-propyloxy)-phenyl]-ethanone (1.3g, 5.1mM), M-V-17 was obtained 
as a white solid (1.2 g) in 67.1% yield. mp: 206-207 oC; 1H NMR (DMSO-d6): δ 0.77 (br 
s, 1H), 1.47-1.69 (br t, 9H), 2.19 (br s, 2H), 2.54 (s, 3H), 4.05 (t, 2H, J=5.6Hz, J=4.5Hz), 
4.19 (t, 2H, J=5.6Hz, J=6.0Hz),  7.07 (d, 2H, J=8.6 Hz), 7.33 (br s, 1H, ex), 7.80 (br s, 1H, 
ex), 7.94 (d, 2H, J=8.7Hz), 8.09(s, 1H, ex), 8.60 (s, 1H, ex), 8.85 (s, 1H, ex), 9.21 (s, 1H, 
ex); ESI-MS: m/z =374.2 (M+1)+; Anal. calculated for C19H27N5O3·HCl·H2O: C, 53.78; 
H, 7.03; N, 16.50. Found: C, 53.81; H, 6.88; N, 16.62. 
4’’-(3’-(2,4-Diamino-1,3,5-triaza-spiro[5.5]undeca-2,4-dien-1-yloxy)-propyloxy)-
benzenesulfonamide hydrochloride (M-V-18) 
From 2,4-diamino-1,3,5-triaza-spiro[5.5]undeca-2,4-dien-1-ol hydrochloride (1g, 4.3 mM) 
and 4-(3-bromo-propyloxy)-benzenesulfonamide (1.5g, 5.1mM), M-V-18 was obtained 
as a white solid (0.96g) in 44.3% yield. mp: 198-199 oC; 1H NMR (DMSO-d6): δ 0.79-
0.83 (br d, 1H, J=12.1 Hz), 1.40-1.72 (br t, 9H), 2.20 (br s, 2H), 4.07 (br s, 2H), 4.16-4.20 
(t, 2H, J=6.0Hz), 7.00 (br s, 1H, ex), 7.11-7.14 (d, 2H, J=9.0 Hz), 7.23 (s, 2H), 7.76-7.79 
(d, 2H, J=8.6 Hz), 7.80 (br s, 1H, ex), 8.12(s, 1H, ex), 8.70 (br s, 2H, ex); ESI-MS: m/z 
=410.6 (M+1)+; Anal. calculated for C17H26N6O4S·2HCl·H2O: C, 40.72; H, 6.03; N, 
16.76. Found: C, 40.64; H, 5.78; N, 16.66. 
7,9-Diamino-10-(3’-(4’’-fluoro-phenoxy)-propyloxy)-6,8,10-triaza-spiro[4.5]deca-
6,8-diene (M-V-19) 
From 7,9-diamino-6,8,10-triaza-spiro[4.5]deca-7,9-dien-6-ol hydrochloride (1g, 4.6 mM) 
and 1-(3-bromo-propyloxy)-4-fluoro-benzene (1.3g, 5.5mM), M-V-19 was obtained as a 
white solid (1.1g) in 63.6 % yield. mp: 182-183 oC; 1H NMR (DMSO-d6): δ 1.51-1.73 (br 
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m, 6H), 1.97 (br s, 2H), 2.15 (m, 2H, J=5.6Hz), 4.02-4.10 (m, 4H), 6.83-6.99 (m, 2H), 
6.09-7.18 (m, 2H), 7.81 (br s, 1H, ex), 8.14 (s, 1H, ex), 8.66 (s, 1H, ex), 9.47 (s, 1H, ex); 
ESI-MS: m/z =336.2 (M+1)+; Anal. calculated for C16H22FN5O2·HCl: C, 49.29; H, 6.46; 
N, 17.96. Found: C, 48.93; H, 5.99; N, 18.19. 
7,9-Diamino-10-(3’-(4’’-chloro-phenoxy)-propyloxy)-6,8,10-triaza-spiro[4.5]deca-
6,8-diene (M-V-20) 
From 7,9-diamino-6,8,10-triaza-spiro[4.5]deca-7,9-dien-6-ol hydrochloride (1g, 4.6 mM) 
and 1-(3-bromo-propyloxy)-4-chloro-benzene (1.4g, 5.5mM), M-V-20 was obtained as a 
white solid (1.3g) in 67.1 % yield. mp: 199-200 oC; 1H NMR (DMSO-d6): δ 1.53-1.74 (br 
m, 6H), 1.97 (br s, 2H), 2.15 (m, 2H, J=5.7Hz), 4.06 (m, 4H), 6.96-6.99 (d, 2H, J=9.0Hz), 
7.32-7.35 (m, 2H, J=9.0Hz), 7.79 (br s, 1H, ex), 8.13 (s, 1H, ex), 8.66 (s, 1H, ex), 9.36 (s, 
1H, ex); ESI-MS: m/z =352.2 (M+1)+; Anal. calculated for C16H22ClN5O2·1.7HCl: C, 
46.44; H, 5.77; N, 16.92. Found: C, 46.37; H, 5.57; N, 16.90. 
7,9-Diamino-10-(3’-(4’’-nitro-phenoxy)-propyloxy)-6,8,10-triaza-spiro[4.5]deca-6,8-
diene (M-V-21) 
From 7,9-diamino-6,8,10-triaza-spiro[4.5]deca-7,9-dien-6-ol hydrochloride (1g, 4.6 mM) 
and 1-(3-Bromo-propyloxy)-4-nitro-benzene (1.4g, 5.5mM), M-V-21 was obtained as a 
white solid (1.2 g) in 62.6% yield. mp: 210-211 oC; 1H NMR (DMSO-d6): δ 1.54-1.75 (br 
m, 6H), 1.97 (br s, 2H), 2.21 (m, 2H, J=5.7Hz), 4.10 (t, 2H, J=5.7Hz), 4.23 (t, 2H, 
J=5.7Hz), 7.00 (br s, 1H, ex) 7.16-7.19 (d, 2H, J=9.0Hz), 7.81 (br s, 1H, ex), 8.15 (s, 1H, 
ex), 8.20-8.25 (d, 2H, J=9.0Hz), 8.67 (s, 1H, ex), 9.22 (s, 1H, ex); ESI-MS: m/z =363.2 
(M+1)+; Anal. calculated for C16H22N6O2·1.8HCl: C, 44.90; H, 5.60; N, 19.63. Found: C, 
44.82; H, 5.33; N, 19.39. 





From 7,9-diamino-6,8,10-triaza-spiro[4.5]deca-7,9-dien-6-ol hydrochloride (1g, 4.6 mM) 
and 1-(3-bromo-propyloxy)-4-methyl-benzene (1.3g, 5.5mM), M-V-22 was obtained as a 
white solid (1.0 g) in 61.3% yield. mp: 192-193 oC; 1H NMR (DMSO-d6): δ 1.54-1.73 (br 
m, 6H), 2.11 (br s, 2H), 2.13 (t, 2H, J=6.0), 2.23 (s, 3H), 4.00-4.09 (m, 4H), 6.83 (d, 2H, 
J=8.7Hz), 7.09 (d, 2H, J=8.7Hz), 7.13 (br s, 1H, ex), 7.79 (br s, 1H, ex), 8.12 (s, 1H, ex), 
8.65 (s, 1H, ex), 9.47 (s, 1H, ex); ESI-MS: m/z =332.2 (M+1)+; Anal. calculated for 
C16H22N6O2·HCl: C, 52.91; H, 7.31; N, 18.15. Found: C, 52.86; H, 7.42; N, 18.53. 
7,9-diamino-10-(3’-(4’’-tert-butyl-phenoxy)-propyloxy)-6,8,10-triaza-spiro[4.5]deca-
6,8-diene (M-V-23) 
From 7,9-diamino-6,8,10-triaza-spiro[4.5]deca-7,9-dien-6-ol hydrochloride (1g, 4.6 mM) 
and 1-(3-bromo-propyloxy)-4-tert-butyl-benzene (1.5g, 5.5mM), M-V-23 was obtained 
as a white solid (1.2g) in 62.7 % yield. mp: 197-198 oC; 1H NMR (DMSO-d6): δ 1.25 (s, 
9H), 1.51-1.72 (br m, 6H), 1.96 (br s, 2H), 2.14 (m, 2H), 4.01-4.09 (m, 4H), 6.85 (d, 2H, 
J=8.6Hz), 7.13 (br s, 1H, ex), 7.29 (d, 2H, J=8.6Hz), 7.79 (br s, 1H, ex), 8.12 (s, 1H, ex), 
8.65 (s, 1H, ex), 9.53 (s, 1H, ex); ESI-MS: m/z =374.3 (M+1)+; Anal. calculated for 
C20H31N5O2·HCl·0.8H2O: C, 56.61; H, 7.98; N, 16.50. Found: C, 56.62; H, 7.85; N, 16.40. 
7,9-diamino-10-(3’-(4’’-methoxy-phenoxy)-propyloxy)-6,8,10-triaza-spiro[4.5]deca-
6,8-diene (M-V-24) 
From 7,9-diamino-6,8,10-triaza-spiro[4.5]deca-7,9-dien-6-ol hydrochloride (1g, 4.6 mM) 
and 1-(3-bromo-propyloxy)-4-methoxy-benzene (1.3g, 5.5mM), M-V-24 was obtained as 
a white solid (1.1g) in 58.0 % yield. mp: 187-188 oC; 1H NMR (DMSO-d6): δ 1.54-1.73 
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(br m, 6H), 1.98 (br s, 2H), 2.12 (m, 2H, J=5.6Hz), 3.69 (s, 3H), 3.99 (t, 2H, J=6.0Hz), 
4.07 (t, 2H, J=6.0Hz), 6.87 (s, 4H), 7.10 (br s, 1H, ex), 7.64 (br s, 1H, ex), 8.12 (s, 1H, 
ex), 8.65 (s, 1H, ex), 9.44 (s, 1H, ex); ESI-MS: m/z=348.2 (M+1)+; Anal. calculated for 
C17H25N5O3·HCl·0.8H2O: C, 51.27; H, 6.98; N, 17.58. Found: C, 51.22; H, 6.61; N, 17.61. 
4’’-(3’-(7,9-Diamino-6,8,10-triaza-spiro[4.5]deca-7,9-dien-6-yloxy)-propyloxy)-
benzonitrile (M-V-25) 
From 7,9-diamino-6,8,10-triaza-spiro[4.5]deca-7,9-dien-6-ol hydrochloride (1g, 4.6 mM) 
and 4-(3-bromo-propyloxy)-benzonitrile (1.3g, 5.5mM), M-V-25 was obtained as a white 
solid (1.2g) in 66.6 % yield. mp: 202-203 oC; 1H NMR (DMSO-d6): δ 1.49-1.73 (br m, 
6H), 1.95 (br s, 2H), 2.18 (m, 2H, J=5.6Hz), 2.52 (s, 3H), 4.05 (t, 2H, J=6.0Hz), 4.09 (t, 
2H, J=6.0Hz), 7.13 (q, 2H, J=7.1Hz, J=2.3Hz), 7.79 (d, 2H, J=7.1Hz, J=2.3Hz ), 8.13 (s, 
1H, ex), 8.65 (s, 1H, ex), 9.53 (s, 1H, ex); ESI-MS: m/z=343.2 (M+1)+; Anal. calculated 




From 7,9-diamino-6,8,10-triaza-spiro[4.5]deca-7,9-dien-6-ol hydrochloride (1g, 4.6 mM) 
and 1-[4-(3-bromo-propyloxy)-phenyl]-ethanone (1.4 g, 5.5mM), M-V-26 was obtained 
as a white solid (1.3 g) in 66.9 % yield. mp: 194-195 oC; 1H NMR (DMSO-d6): δ 1.54-
1.73 (br m, 6H), 1.97 (br s, 2H), 2.19 (m, 2H, J=5.6Hz), 2.52 (s, 3H), 4.09 (t, 2H, 
J=6.0Hz), 4.16 (t, 2H, J=6.0Hz), 7.05 (d, 2H, J=5.8Hz), 7.93 (d, 2H, J=5.8Hz), 8.14 (s, 
1H, ex), 8.65 (s, 1H, ex), 9.36 (s, 1H, ex). ESI-MS: m/z=360.2 (M+1)+; Anal. calculated 
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for C18H25N5O3·HCl·H2O: C, 52.23; H, 6.82; N, 16.92. Found: C, 51.87; H, 6.47; N, 
16.86. 
 
12. Biological Evaluations 
12.1. DHFR Enzyme Assay 
Phosphate buffer (0.15 M, pH 7) was used for all the DHFR assays and was prepared by 
dissolving potassium dihydrogen orthophosphate (10.21 g) in milli-Q water (300 mL), 
adjusting the solution to pH 7 with potassium hydroxide (5 M) and diluting to 500 mL 
with milli-Q water. The buffer was kept at 4oC and discarded after 7 days. 2-
mercaptoethanol solution (0.25 M) was prepared by dissolving 2-mercaptoethanol (1.75 
mL) in milli-Q water (to 100 mL). The solution was stored in a tinted bottle at 4oC prior 
to use. An aqueous solution of NADPH (2 mg/mL, 2 mM) was prepared immediately 
prior to use and incubated in an ice bath. A solution of dihydrofolate (DHF) (1 mg/mL, 2 
mM) was prepared immediately before use by suspending DHF in the 2-mercaptoethanol 
solution (0.25 M) and adding sodium hydroxide (2 M) solution dropwise, with vigorous 
agitation, until dissolution had occurred. A solution of DHFR (0.25 U/ml) was prepared 
by dissolving DHFR (5 unit) in buffer (20ml). The solution was incubated in an ice bath 
before use. 
The assay was performed at 37oC in a Hewlett Packard 8453 Diode Array UV-visible 
Spectrophotometer with HP 89090A Peltier Temperature Controller at a detection 
wavelength of 340 nm and full scale deflection of 4.0 absorbance units. The assay was 
carried out over 6 minutes with absorbance readings taken every 5 seconds. A graph of 
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absorbance readings versus time was plotted and the gradient over the linear range from 
60 to 300 seconds was taken to be the rate of the reaction.  
The assay was conducted by mixing the appropriate volumes of phosphate buffer, 
NADPH, DHF, partially purified bovine liver DHFR and inhibitor in the cuvette (Table 
25). The rate of consumption of NADPH at 340 nm during the conversion of dihydrofolic 
acid to tetrahydrofolic acid was monitored. The reduction in absorbance over 6 minutes 
in the absence of the inhibitor was taken as the control. Total inhibition of DHFR was 
indicated by an insignificant change in the rate of consumption of NADPH and no 
inhibition would be seen when the rate of consumption of NADPH was equal to that of 
the control. The percentage activity of each inhibitor was calculated by the following 
formulae:- 
 (i)  Activity =   Slope of inhibited enzyme      x 100%       
    Slope of uninhibited enzyme   
(ii) Inhibition = 100% - Activity 
A graph of percentage inhibition against the logarithmic concentration (μM) was plotted 
for each pot and the IC50 value was taken to be the concentration (μM) at which 50% 
















Control I 0.1 0.2 - 2.7 - 3.0 
Control II 0.1 - 0.1 2.8 - 3.0 
Uninhibited 
Enzyme 
0.1 0.2 0.1 2.6 - 3.0 
Inhibited 
Enzyme 
0.1 0.2 0.1 2.5 0.1 3.0 
 
Table 23 Volume of reagents, enzyme and inhibitors used in the DHFR enzyme assay 
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12.2. Antiproliferative Assay 
1. Cryopreservation and Storage of Cell Lines 
The human cancer cells were stored under liquid nitrogen when not in use. Cells that 
were removed from liquid nitrogen storage were rapidly defrosted at 37oC and then 
transferred into centrifuge tube, containing 10 mL of medium. The cells were centrifuged 
at 1000 g for five minute before the medium was replaced with fresh medium. The 
resuspended cells were transferred into culture flask and incubation for 48 hours. The 
cells were then routinely passaged two to three times before performing the FMCA 
assays to ensure adequate recovery. The extra flask of cells would be cryopreserved for 
long-term storage to maintain the cell line. For cryopreservation, the medium was 
aspirated from a flask of confluent cells and 2 mL of 1% trypsin/EDTA solution was 
added to the flask and then removed. The cells were then incubated at 37oC for 5 minutes 
to enable the cells to detach and then resuspended in 1 to 2 mL of freezing cryoprotectant. 
The most commonly used cryoprotectant is DMSO at a final concentration of 10% in 
FBS. The cells were frozen immediately at a rate of –1ºC to –3ºC per minute for 24 hours, 
after which the samples were transferred to liquid nitrogen for their long-term storage. 
2. Cells and Cell culture 
The cell lines used in our experiment were three human cancer cell lines (MCF-7, MDA-
MB-231, A 549) and one human fetal lung fibroblast MRC-5. The human breast cancer 
cell line MCF-7 was obtained from the American Type Culture Collection (ATCC). 
Three cell lines MDA-MB-231, A549 and MRC-5 were kindly supplied by Collaboration 
Labs in Department of Pharmacy, NUS. The MCF-7 cells were maintained in L-
glutamine containing Eagle’s MEM (Sigma) supplemented with NaHCO3 (1.5 g/L), non-
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essential amino acids (0.1 mM), bovine insulin (0.01 mg/ml), sodium pyruvate (110 
mg/L), 1% penicillin/streptomycin and 10 % fetal bovine serum (HyClone Laboratories, 
Logan, Utah) at 37 oC in a humidified atmosphere containing 5 % CO2. The MDA-MB-
231, A549 and MRC-5 were grown in Dulbecco’s modified Eagle’s medium (DMEM), 
supplemented with 1 % penicillin/streptomycin and 10 % fetal bovine serum under the 
same condition. The cell lines were passaged weekly after previous treatment with 
trypsin (0.05%) / ethylenediaminetetraacetic acid (0.02 %). Cell viability of the stock 
cultures used for subsequent experiments was always above 95 % as assessed by trypan 
blue solution.  
3. Drug and Reagents 
Stock solution were prepared by dissolving new synthesized compounds using 5% 
DMSO in phosphate-buffered saline (PBS) at a concentration of 1.0 mmol/L and stored at 
-20 oC. MTX was obtained from Department of Pharmacy, NUH as solution of 25 
mg/2mL. MTA was kindly supplied by Pharmacy of Oncology and Hematology 
department of NUH. The test compounds were diluted to the working concentration with 
culture medium before use. A stock solution of fluorescein diacetate (FDA) was prepared 
in 10 mg/mL concentration in DMSO, kept frozen (-20 oC) and protected from light. 
4. Fluorometric microculture cytotoxicity assay  
The FMCA is based on measurement of fluorescence generated from hydrolysis of 
fluorescein diacetate (FDA) to fluorescein by cells with intact plasma membranes and has 
been described in detail previously.1,2 The drug cytotoxicity and cell proliferation were 
determined using the previously described FMCA, exponential cell growth is guaranteed 
during the whole time of incubation. Briefly, by utilization of 96 well microtiter plates, 
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200 µL of a cell suspension were plated into each well (A549, 1000 cells per well, MDA-
MB-231, 3000 cells per wells, MCF-7, 5000 cells per well). The plates were incubated at 
37 oC for 24 hours in a humidified atmosphere (50%, CO2) to allow the cells to adhere to 
the bottom. The medium of the plates was then replaced with 200µL of medium 
containing the test compounds. Twelve wells without compounds were served as controls 
and twelve wells containing culture medium only served as blanks. After an incubation 
period of 72 hours, the medium was removed by multichannel pippet. After one wash 
with PBS, 200 µL/well PBS containing FDA (2 µg/mL) was added. Subsequently, the 
plates were incubated for 45 min at 37° C and the fluorescence generated from each well 
was then read at an excitation wavelength of 485 nm and an emission wavelength of 535 
nm by a scanning fluorometer. In a preliminary study, the fluorescence was found to be 
proportional to the number of viable cells in the well. Quality criteria for a technically 
successful assay included a proportion of 70% cells in control wells after 72 h of 
incubation, a fluorescence signal in control wells of greater than or equal to five times the 
mean blank value, and a mean coefficient of variation in control wells of <30%. The 
results are presented as survival index (SI), defined as fluorescence in test 
wells/fluorescence in control wells (blank values subtracted) ×100. Thus, a low numerical 
value indicates high sensitivity to the cytotoxic effect of the drug. IC50 value was defined 
as the concentration giving a SI 50 % of the control SI. Compounds were tested in 
triplicate and the results are expressed as means ± SEM for the data combined from 
separate experiments.  
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5. Rescue Experiment  
FMCA assays were carried out using the method stated above. Investigations of the effect 
of rescue agents were conducted using a fixed concentration of antifolates and new 
synthesized triazines at the 10 ×IC50 concentration determined as above for A549. Cells 
in 200 μL of medium were seeded in each well of 96-well plates. After 24 hours of 
incubation, the medium was replaced with medium containing 10 ×IC50 concentration of 
compounds in the absence of protection, or with the same concentration of drug plus 20 
µM dThd, 100 µM Hx, 20 µM dThd and 100 µM Hx in the medium. Twelve wells were 
used for each test solution and for the control, which contained the corresponding amount 
of solvents for dissolving compounds. After the incubation of 72 h, the medium was 
removed with multichannel pippet. After one wash with PBS, 200 µL/well PBS 
containing FDA (2 µg/mL) was added. Subsequently, the plates were incubated for 45 
min at 37° C and the fluorescence generated from each well was then read at an 
excitation wavelength of 485 nm and an emission wavelength of 535 nm by a scanning 
fluorometer. The effectiveness of the compounds at 10×IC50 is expressed as corrected % 
T/Ccorr or % τ values according to the following equations: where T (test) and C (control) 
are the fluorescences in test wells and control wells, and C0 the fluorescences of the cells 
measured immediately before treatment.   
Cytostatic effect: T/Ccorr (%) = (T-C0)/(C-C0) × 100 
Cytocidal effect: τ (%) = (T-C0)/C0 × 100 
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12.3 Antimicrobial Assay 
1. Test compounds 
Test compounds were weighted, dissolved in the DMSO and loaded on the sterile paper 
disc (diameter 5 mm, Whatman No. 1 filter paper). After drying in the vacuum oven at 60 
oC overnight, the paper discs were re-weighted to ensure 100 µg compounds was loaded. 
All the discs were stored in sealed container under the -20 oC. For the cup diffusion assay, 
the test compounds were dissolved using 10 % DMSO to concentration of 10 mg/ml and 
then diluted using sterilized distilled water into different concentrations for determination 
of the critical concentration.  
2. Microorganisms  
Five bacteria (Staphylococcus aureus ATCC 6538P, Pseudomonas aeruginosa ATCC 
9027, Mycobacterium smegmatis ATCC 607, Bacillus subtilis ATCC 6633, Klebsiella 
aerogenes ATCC 9621, Escherichia coli ATCC 25922) and two fungus (Candida 
albicans ATCC 10231 and Aspergillus niger ATCC 16404) were used for the screening. 
Bacteria were maintained on nutrient agar. The inoculum suspension were adjusted to a 
turbidity equivalent to McFarland No. 0.5 (108 cells / ml) and diluted to 1×106 cells/ml 
subsequently. The diluted inoculum was stored in the fridge (4 oC) to be used within 2 
weeks. The fungi were maintained on Sabouraud sextrose agar. The suspension of 
conidia of Aspergillus niger was prepared, counted using Neubaucer chanber to adjust to 
obtain a count of 5-10 organisms per square (2-4 ×107 cells/ml). As the suspension of 
Candida albicans, it was prepared in a similar way as bacteria to obtain 1×106 cells/ml. 
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3. Paper Disc Agar Diffusion Assay 
Agar diffusion tests with agents in paper discs are still the most widely used methods. 20 
mL of Mueller Hinton agar and Nutrient agar for assay on bacteria (Sabouraud dextrose 
agar for fungus) was sterilized by autoclave. 100 µL of the diluted bacteria inoculum was 
overlaid on the surface of agar. 200 µL of the diluted bacteria inoculum was used for M. 
smegmatis to compensate the difficulty encountered in sampling sufficient number of 
cells. Paper discs with sample loaded were then applied on the surface of the agar. Plates 
were kept at room temperature for one hour to allow for pre-diffusion. Plates were then 
incubated at 37 oC for 18-24 hours before the zone sizes were read. For fungus, the plates 
were kept in the fridge for pre-diffusion and placed in room temperature for incubation. 
3-5 days of incubation period was required before zone size were read. All the tests were 
done in triplicate. Various standard antibiotic discs were used as reference for the 
respective susceptible microorganisms. the diameters (mm) of the zones of inhibition 
were measured and the diameters of the paper discs were subtracted. Two measurements 
which perpendicular to each other were made, and the average value was recorded and 
divided by 2 to obtain ZIB (mm). Zone ratio was used to express the comparative 
efficiency to compensate for the interassay fluctuation, calculated from the following 
formula: ZR = mean zones of inhibition for disc loaded with test compounds/mean zones 
of the inhibition of standard antibiotics disc.  
4. Agar cup diffusion assay 
Cup diffusion method was performed subsequently to determine the critical concentration 
of inhibition for the most potential compounds identified though the screening. Test 
compounds were dissolved using respective solvents and prepared into different 
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concentration. Preliminary test had been carried out to rule out the bactericidal or 
bacteriostatic effect of the respective solvents.  
20 ml of the sterile molten Mueller Hinton agar, Nutrient agar and Sabouraud dextrose 
agar was equilibrated to 45 oC. 100 µL of the diluted culture was inoculated into this 
molten agar, mixed homogenously and pour into the Petri dish. 200 µL was used for S. 
aureus and M. smegmatis to compensate the difficulty encountered in sampling sufficient 
number of cells.  Cups or wells (diameter 10 mm) were bored with sterile cork borer. 
Different concentration of the test compounds was delivered to the separate cup. One 
hour of prediffusion was allowed and incubated at 37 oC later. Zone size of inhibition was 
measured after 18-24 hours, in the same way as paper disc method. For fungus, the plates 
were kept in the fridge for pre-diffusion and placed in room temperature for incubation 
and read after 3-5 days. 
 
12.4  Sodium Channels Assay  
[3H] BTX Radioligand Assay. The details for the sodium channel-binding assay were 
reported in a previous paper. Synaptoneurosomes were prepared from rat cerebral cortex 
as follows. The cerebral cortex (gray matter) was obtained by removing the white matter 
and other subcortical structures. An incubation buffer was prepared which contained 130 
mM choline chloride, 50 mM HEPES, 5.5 mM glucose, 0.8 mM MgSO4, and 5.4 mM 
KCl, adjusted to pH 7.4 using Tris base. The tissue was then homogenized in 10 mL of 
incubation buffer using 10 full strokes of a glass-glass homogenizer. The tissue 
preparation was transferred to a centrifuge tube, the homogenizer was rinsed with 3 mL 
of the incubation buffer, and the rinse was combined with the preparation. The 
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preparation was then centrifuged at 1000g for 15 min at 4 oC. The pellet was resuspended 
in a total volume of 20 mL of the incubation buffer and transferred to a 50-mL 
homogenizer. Three full strokes were used to homogenize the tissue. The suspension was 
gently filtered through three layers of 160-µm nylon mesh, then through a Whatman No. 
4 filter paper using the house vacuum. The filtrate was centrifuged at 1000g for 30 min at 
4 oC. The pellet was resuspended with 5 mL of isotonic sucrose solution, which contained 
10 mM NaH2PO4 and 0.32 mM sucrose at pH 7.4 (Tris base). The isotonic suspension 
was stored in a freezer for up to 3 months at -80 oC until needed.  
Prior to the binding assay, the tissue was thawed, the suspension was centrifuged at 
1000g for 30 min at 4 oC, and the pellet was resuspended in the incubation buffer (using 
the same volume as the isotonic buffer used to store the tissue). For the sodium channel 
binding assay, synaptoneurosomes (1 mg of protein) from rat cerebral cortex were 
incubated for 30 min at 25 oC with the test compound (seven different concentrations 
spanning the IC50) in a total volume of 300 µL containing 10 nM [3H] BTX-B (specific 
activity of 30 Ci/mol) and 50 µg/mL of scorpion venom. Incubations were terminated by 
dilution with ice-cold buffer and filtration through a Whatman GF/C filter paper, and the 
filters were washed four times with ice-cold buffer. Filters were counted in a Beckmann 
scintillation counter. Specific binding was determined by subtracting the nonspecific 
binding, which was measured in the presence of 300 µM veratridine, from the total 
binding of [3H] BTX-B. Each data point used for generating the IC50 curve was the mean 
of triplicate experiments. The IC50 values were determined from a Prism Graphpad 
analysis of the dose-response curve and excluded doses producing <10% or >90% 
inhibition. 
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12.5 Rotorod Test 
The rotorod test was conducted using the UGO BASILE accelerating Rota-Rod (Jones 
and Roberts) 7605. Adult male Swiss albino mice (20-25 g) were employed as animals. 
Animals of the same sex, age and weight were used to minimize biological variability. 
Prior to commencement of the anticonvulsant tests, the mice were subjected to rotorod 
screening. A plastic rod, 3 cm in diameter, 30 cm long, with non-slippery surface,15 cm 
over the base was used. This Rod was divided into 5 equal sections by six discs, thus 
enabling 5 mices to walk on the rod at the same time. The speed of the rotating rod was 
accelerating which was allowed to accelerate from 4 to 40 rpm over 5 min. Mice which 
were able to stay on the rotating rod for at least 5 min were subsequently used for further 
test. Compounds were dissolved in DMSO before administration. The solutions were 
injected intreperitoneally at 5 ml/kg body weight of mice. The compounds were screened 
at the dose of 30 mg/kg. 15 min after injection, the mice were subjected to rotorod test 
again. The measurements were reported as the times (in seconds) at which the mice fell 
from the rotating rod, with the cut-off time of 300 s. 
 
12.6 Anticonvulsant Assay   
The in vivo anticonvulsant activity of triazines was evaluated using the maximal 
electroshock seizure (MES) test. Maximal electroshock induced seizure is an established 
model for the generalized tonic-clonic seizures. Swiss albino male mice (25-30 g) were 
used for the tests. The mice were housed in an environmentally controlled room for 12 h 
light and dark cycles with proper food and water before testing. Prior to drug 
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administration, the mice were subjected to the rotorod test, and those that could pass this 
test by staying on the rotating rod for the full 5 min of the testing period were used for the 
MES assay. The test compounds were dissolved in DMSO and injected into the mice 
intraperitoneally at an initial dose of 30 mg/kg. Depending on the test scores from this 
initial dose, subsequent doses used were gradated higher or lower to obtain a complete 
dose-activity profile. At 30 min after drug administration, the mice were subjected to a 
current of 45 mA (100 MHz) using a UGO BASILE ECT unit 7801 instrument for 0.2 s 
via auricular electrodes to elicit maximal electroshock seizures. This amount of current 
was approximately 6 times the threshold and reveals the ability of the compound to 
prevent seizure spread. The anticonvulsant activity of each compound on the mice was 
assessed by an arbitrary scoring system (1, 2, 3, and 4) at various stages of seizure. A 
score of 1 or 4 indicates no protection or full protection of seizure, respectively. At each 
dose level, the average MES score given for a test sample of five to six mice was 
recorded.  
For the chemically induced convulsion test, pentylenetetrazol (PTZ) was dissolved in 
0.9% sodium chloride solution, and subcutaneously injected to mice in volumes of 0.01 
mL/g of body weight. Five min after the rotorod test, each mouse was injected 
subcutaneously with pentylenetetrazol (90 mg/kg). The occurrence of clonic generalized 
convulsion was noted for at least 30 min period. The anticonvulsant activity of each 
compound on the mice was assessed by scoring system (1, 2, 3, 4, 5, 6) at various 
occurrences of seizure (nothing (6), jerk (5), jumping (4), lying (3), full extensor (2), 
death (1), and a score of 1 or 6 indicates no protection or full protection of seizure, 
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